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There have been many advancements in the field of tissue engineering for the repair or 
regeneration of single tissues. However, orthopedic injuries often occur at the interface between 
soft tissues and bone. The tendon-bone junction (TBJ) is a classic example of such an interface, 
containing overlapping patterns of growth factors, extracellular matrix (ECM) proteins and 
structure, and mineral content that serve to dissipate stress concentrations and effectively transfer 
force between contracting muscles and bone for locomotion. Current clinical strategies to treat 
common TBJ injuries, such as in the rotator cuff, prioritize mechanical reattachment, forsaking 
biological reintegration and recapitulation of the native structure. As a result, TBJ repairs are 
plagued by high failure rates, and new tissue engineering solutions are necessary for improved 
patient outcomes. Modern efforts in tissue engineering have focused on the design of new 
instructive biomaterials that present combinations of compositional, microstructural, mechanical, 
and biochemical cues, with the potential to control stem cell fate decisions and promote enhanced 
tissue regeneration. This thesis describes a series of studies undertaken to better comprehend the 
impact of biomaterial cues and mechanical stimulation on cell bioactivity and the application of 
this knowledge to the design of spatially-graded biomaterials and culture techniques for 
engineering the TBJ. The studies herein utilize collagen-glycosaminoglycan (CG) scaffolds, a set 
of regulatory compliant analogs of the native ECM that have been previously applied to the 
regeneration of dermis, peripheral nerves, and osteochondral tissues. Here, we show how scaffold 
microstructure and mechanical properties are critical regulators of the maintenance of tenocyte 
phenotype and bioactivity in in vitro culture. We also describe the design and fabrication of a 
custom cyclic tensile strain (CTS) bioreactor system for the examination of the effects of 
mechanical stimulation on cell-material interactions and stem cell differentiation for tendon 
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regeneration.  The knowledge gained in this study was then applied to a spatially graded scaffold 
to selectively bias stem cell differentiation for TBJ applications. These results represent the first 
application of CTS across a spatially graded material with variations in microstructural alignment, 
mineral content, and mechanical properties. Finally, we adapt the CG scaffold system to 
selectively sequester and display growth factor content through the promotion of guest-host 
interactions. The growth factors presented by the scaffolds are sufficient to drive enhanced stem 
cell responses. Together, these studies present the framework for designing instructive 
biomaterials to regulate stem cell fate in a spatially-dependent manner in the context of 
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CHAPTER 1: INTRODUCTION AND BACKGROUND: BIOMATERIAL STRATEGIES 
TO ENGINEER MULTI-TISSUE JUNCTIONS AND REGULATE STEM CELL FATE1 
1.1 Thesis overview 
This chapter will introduce the concept of biomaterials as regenerative templates for tissue 
engineering applications and review the latest work in the field of tendon-bone junction (TBJ) 
engineering and stem cell fate regulation through the controlled presentation of material and 
biological cues. The remainder of the thesis will focus on the development of a collagen-GAG 
(CG) scaffold material system for TBJ engineering, including the influences of local scaffold 
microstructure, supplemental mechanical stimulation, and biomolecule presentation on spatially-
defined lineage specification of mesenchymal stem cells (MSCs).  Some of the materials used in 
this thesis were initially developed as part of separate projects, including a geometrically 
anisotropic CG scaffold that mimics the microstructure of native tendon (Caliari and Harley 2011) 
as well as a multi-compartment CG scaffold with distinct, but continuous, regions of structural 
anisotropy and mineral content as seen in the native TBJ (Caliari, Weisgerber et al. 2015). For 
more information of these fundamental studies, please reference the cited manuscripts.  
In this thesis, Chapter 2 will describe the influence of scaffold pore structure, as determined by 
freezing temperature, and scaffold stiffness, as a function of covalent crosslinking density, on the 
maintenance of a tendon phenotype in equine tenocytes. Chapter 3 introduces the design and use 
of a custom cyclic tensile strain (CTS) bioreactor system to promote the robust tenogenic 
differentiation of human MSCs on aligned CG scaffolds. Chapter 4 expands on the use of the 
bioreactor system to evaluate the effects of CTS on multi-compartment CG scaffolds designed for 
                                                 
 
1 This chapter has been adapted from the following publication: 
Grier, W.K. and B. A. C. Harley (in preparation). "Biomaterial strategies to engineer multi-tissue junctions and 
regulate stem cell fate."  
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TBJ regeneration and the resultant compartment-specifics effects of mechanical stimulation on 
MSC differentiation. Chapter 5 explores the next generation of instructive biomaterials, 
incorporating β-cyclodextrin into CG scaffolds, as a means to sequester and control the 
presentation of selected growth factors, for the preferential differentiation of MSCs. Finally, 
Chapter 6 will then conclude this thesis with a summary of the findings and recommendations for 
ongoing and future work. 
1.2 Chapter overview 
To date, the bulk of tissue engineering research has focused on the repair of individual tissues. 
This has led to many advances in the field, with a number of products being successfully 
introduced into clinical settings. Despite these advances, many orthopedic injuries often occur at 
tissue interfaces, such as the tendon-bone junction. The nature of these interfacial tissues motivates 
new approaches to expand current, regenerative strategies to address unique challenges associated 
with such multi-tissue structures. The current clinical approaches to repair these interfaces are 
generally inadequate and prioritize simple surgical reattachment over biological reintegration of 
the tissues. As a result, the intricate patterns of extracellular matrix structure and composition at 
these interfaces are rarely recapitulated, leading to a loss of function. In this review, we will 
highlight emerging technologies to develop spatially stratified biomaterials for the regulation of 
stem cell fate for the regeneration of complex multi-tissue structures. We will first introduce the 
unique challenges inherent in engineering the interface between tendon and bone and the 
regulation of stem cell fate in a spatially-dependent manner. We will summarize the current 
strategies available for the development of spatially-stratified biomaterial systems for multi-tissue 
repair applications.  We will then review approaches to leverage the applications of mechanical 
stimulation and biochemical supplementation in cell culture, specifically for the regeneration of 
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the tendon-bone junction. Lastly, we will conclude with a perspective on how to potentially 
integrate the knowledge gleaned from new understandings of native tissue development for the 
design of next-generation tissue engineering systems.  
1.3 Introduction 
The fields of tissue engineering and regenerative medicine have seen major advancements over 
the last 25 years (Langer and Vacanti 1993). Early biomaterial systems focused on passive 
materials which permitted and supported biological responses. Normally, the adult wound healing 
process results in the formation of hypertrophic scar tissue that is characterized by a disorganized, 
mechanically-inferior extracellular matrix (ECM) and general loss of function (Rhett, Ghatnekar 
et al. 2008).  Evidence has shown that the use of biomaterials to aid in wound healing can 
fundamentally alter this process. Materials specifically designed to block the initial wound 
contraction have already been successfully introduced into the clinic for dermal and peripheral 
nerve applications (Yannas, Lee et al. 1989; Soller, Tzeranis et al. 2012). By blocking the initial 
contraction of the wound site and providing a base material to support new tissue growth, these 
biomaterials can promote the enhanced regeneration of the natural tissue over simple wound 
closure.   
More recently, there has been an increased focus on the development of instructive biomaterials 
that have the ability to facilitate and guide tissue repair or regeneration through microstructural, 
mechanical, and biochemical means. Cells naturally exist within locally-defined regions of ECM 
which display complex and tissue-specific properties. All tissues display a unique combination of 
characteristics based on their composition, microstructural organization, mechanical properties, 
and biomolecule content/availability.  It has been shown that these local cues are critical to promote 
early tissue development and regeneration in vivo (Blitz, Viukov et al. 2009; Pryce, Watson et al. 
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2009; Schweitzer, Zelzer et al. 2010), and that mechanical cues, such as substrate stiffness, are 
sufficient to control MSC differentiation in vitro (Engler, Bacakova et al. 2004; Allen, Cooke et 
al. 2012). The incorporation of these instructive cues that are specific to the tissue of interest is a 
critical component of new biomaterial systems.  
While designing materials for the regeneration of a single tissue type is already a daunting task, 
many injuries occur at the interface between two dissimilar tissue types, particularly in 
orthopedics. These multi-tissue structures commonly contain distinct regions or specific 
architectural, mechanical, and compositional cues that, together, are critical in order to maintain 
tissue and organ integrity and function. Therefore, any biomaterial strategy to regenerate these 
multi-tissue structures must at least be able to incorporate the prominent features of these disparate 
tissues. 
This review will focus on the development of biomaterial systems and supplementation strategies 
specifically for the regeneration of tendon-bone, or osteotendinous, junctions (TBJ). While a 
number of reviews have focused on material systems to engineer orthopedic interfaces (Lu and 
Thomopoulos 2013; Lee, Robinson et al. 2016), or specific strategies to regenerate either tendon 
(Voleti, Buckley et al. 2012) or bone (Porter, Ruckh et al. 2009), this review will serve as a bridge 
between those two communities while focusing on applications for osteotendinous repair. This 
review will begin with an overview of the tendon-bone junction organization and biology in an 
effort to understand critical components to be considered for biomaterial design. It will continue 
with a discussion of the various biomaterial strategies that have recently been employed in this 
field. We will then discuss various mechanical stimulation and biochemical supplementation 
strategies to control stem cell differentiation and tissue development. Finally, we will conclude 
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with a perspective on how the combination of biomaterial design, stem cell biology, and external 
factors can be used to pursue optimal regenerative strategies for the TBJ moving forward.  
1.4 Tendon-bone junction organization and biology 
The tendon joins muscle to bone, allowing for force generated in muscle fibers to be translated 
into motion (Wang 2006). Tendons are hierarchical, and mechanically and geometrically 
anisotropic tissues composed primarily of type I collagen fiber bundles. These fiber bundles show 
a characteristic crimp pattern that helps the tissue adapt to normal loading. Collagen fiber bundles 
are bound together by the endotenon, which in turn is integrated with the peritenon, surrounding 
the whole tissue (Gross and Hoffmann 2013). The peritenon is composed of an inner layer called 
the epitenon and an outer layer called the paratenon. Some tendons, especially in the hands and 
feet, are enclosed by synovial sheaths to enable smooth gliding during movement (Gross and 
Hoffmann 2013). Tendons can be up to an order of magnitude stiffer in the plane longitudinal to 
collagen fiber alignment compared to the transverse plane (Quapp and Weiss 1998). Tendon tissue 
is 70% water, with collagen comprising 75-85% of the dry weight, of which 95% is type I with the 
remainder being types III and V (Wang 2006). Elastin composes less than 3%  of the tendon tissue  
and proteoglycans constitute about 2%, although this amount varies widely and is typically higher 
in tendons that must withstand significant compressive stress (Martin, Burr et al. 1998). Type III 
collagen is typically localized to the endotenon and epitenon, although it can also appear in 
mechanically dynamic regions such as the supraspinatus (Duance, Restall et al. 1977). Tendons 
are populated primarily by fibroblastic cells, called tenocytes, which are interspersed throughout 
the collagen fibers in the tissue (James, Kesturu et al. 2008).  
The junction between tendon and bone, or the enthesis, is where the tendon inserts into subchondral 
bone through a fibrocartilage insertion region. This tissue interface is structurally continuous but 
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consists of compositionally and microstructurally distinct regions of tendon, non-mineralized 
fibrocartilage, mineralized fibrocartilage, and bone (Blevins, Djurasovic et al. 1997; Genin, Kent 
et al. 2009; Genin and Thomopoulos 2017). The transition zone between tendon and bone tissues 
is fairly well conserved between different joints and generally span a total distance between 250-
800 μm, with approximately half of that span consisting of calcified fibrocartilage (Lee, Robinson 
et al. 2016). The TBJ is an emerging tissue engineering target as injuries frequently occur right at 
this interface due to the high stress concentrations that develop between the two mechanically 
mismatched tissues (Saadat, Deymier et al. 2016). Rotator cuff injuries for example, account for 
more than 4.5 million physician visits and 250,000 repair surgeries each year in the United States 
(Galatz, Sandell et al. 2006; Colvin, Egorova et al. 2012). These rotator cuff injuries commonly 
present at the supraspinatus-humerus junction. Current clinical repair strategies typically involve 
mechanical fixation of tendon to the bone, but tendon detachment remains a primary cause for 
surgical failure. Rotator cuff repairs generally fail at a rate of 27% within 2 years of surgery with 
rates as high as 94% in older demographics (Lorbach, Baums et al. 2015). Poor surgical outcomes 
are attributed to the very poor innate healing response and general inability to recapitulate the 
native complexities of the interface (Lorbach, Baums et al. 2015). 
In order to facilitate the design of adequate solutions for regeneration of the tendon enthesis, many 
groups have looked to inspiration from the embryonic development of the tendon (Okech and Kuo 
2016). In vertebrates, the tendon enthesis begins to develop when a subset of mesenchymal cells 
amass and begin to form a cartilaginous template for the future bone. However, unlike primary 
cartilage, where progenitor cells only express SOX9, the progenitor cells at the sites of the tendon 
enthesis co-express SOX9 and the tendon marker scleraxis (SCX) (Blitz, Sharir et al. 2013). SCX 
is a transcription factor that is highly expressed throughout both progenitor and mature tendinous 
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tissues and is known to regulate differentiation (Schweitzer, Chyung et al. 2001). Currently, there 
are two lines of thought how the final connection between bone, fibrocartilage, and tendon is 
formed. The connection may form following differentiation, which would require signaling to 
direct the tendon to the correct insertion site, or the tissues may be derived from a common pool 
of progenitors that undergo divergent differentiation (Zelzer, Blitz et al. 2014). The use of a 
common pool of progenitors, in combination with directed differentiation, is attractive for tissue 
engineering applications as it would require just a single cell isolation to regenerate this spatially-
defined tissue structure. A single cell source would also reduce the number of specific cell 
isolations required and associated donor site morbidity, as well as issues associated with the 
difficulty of culturing and maintaining terminally-differentiated primary cells, like tenocytes, in 
vitro (Yao, Bestwick et al. 2006). 
The maturation of the TBJ is primarily regulated by a combination of TGF-β and BMP-4 signaling 
(Blitz, Sharir et al. 2013). Ablation of the TGF-β type II receptor in mouse embryos results in the 
complete loss of all tendon tissue (Pryce, Watson et al. 2009) and is suggested to regulate the 
development of both cartilage and bone in limb development (Lorda-Diez, Montero et al. 2009). 
As the tendon matures, a gradient of mineral gradually moves into the developing transition zone 
of the TBJ and begins to mineralize the fibrocartilaginous progenitors, through a process known 
as endochondral ossification (Schwartz, Pasteris et al. 2012). Mechanical loading is also known to 
play an important role in TBJ development. Once the tendon is sufficiently anchored into the bone, 
muscle forces can be transmitted across the interface and have been linked to the regulation of 
growth and mineralization (Thomopoulos, Kim et al. 2007; Schwartz, Lipner et al. 2013; Song, 
Jiang et al. 2017). Altogether, the combination of cells, local microstructural cues, biochemical 
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signals, and mechanical force are crucial for the development of the TBJ, and these relationships 
must be taken into consideration when designing regenerative medicine solutions. 
1.5 Technologies for fabricating multi-phase biomaterials 
The majority of materials designed for TBJ regeneration fall into two categories, stratified 
scaffolds with distinct regions of specific biomimetic cues and gradient materials that are able to 
recapture some of the organization of native transitional zones (Lee, Robinson et al. 2016).  
An attractive method to try and mimic the natural biomimetic cues of the TBJ is to use spatially 
stratified materials with regions of distinct characteristics. One of the first stratified constructs 
designed specifically for tendon-bone regenerations, Xie et al. fabricated PLGA nanofiber 
scaffolds with discrete areas of randomly distributed and highly aligned fibers (Xie, Li et al. 2010). 
Mechanical testing showed significantly higher tensile modulus and ultimate stress in mats 
composed of the aligned fibers compared to randomly oriented fibers. When seeded with tendon 
fibroblasts, the aligned region of the scaffolds promoted increased cell elongation and alignment 
and upregulated expression of collagen type I. Font Tellado et al. has recently produced a silk 
fibroin scaffold with separate regions of aligned and isotropic porosity which were suitable to 
induce spatial patterns in tenogenic and chondrogenic gene expression (Font Tellado, Bonani et 
al. 2017). Dickerson et al. produced a biphasic scaffold by demineralizing a portion of a cancellous 
bone explant (Dickerson, Misk et al. 2013). When implanted into an ovine rotator cuff wound 
model, the groups treated with scaffolds showed better tissue integration and histological evidence 
of a preliminary fibrocartilaginous interface development when compared to standard suture 
repair. Our lab has also previously developed a bi-phasic collagen-GAG scaffold with distinct, but 
continuous, regions of microstructural alignment and mineral content by combining a directional 
solidification approach with liquid-phase co-synthesis (Caliari, Weisgerber et al. 2015).   
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Another class of biomaterials developed for the tendon-bone junction repair are those containing 
explicit gradient properties. Phillips et al. produced collagen scaffolds with a gradient of retroviral 
vectors encoding the osteogenic transcription factor RUNX2 (Phillips, Burns et al. 2008). Primary 
fibroblasts seeded onto the materials showed a graded response with regards to osteogenic 
differentiation and mineral deposition. There have also been a number of studies on materials with 
gradients of mineral content. Li et al. produced a gradient of calcium phosphate on an electrospun 
PLGA mats. This gradient of mineral content resulted in spatially-graded stiffening of the material 
and variations in the adhesion and proliferation of murine preosteoblast cells (Li, Xie et al. 2009). 
Similar scaffold materials were later used by Lipner et al. and implanted into a rat rotator cuff 
model along with adipose-derived stem cells that had been engineered to overexpress BMP-2 
(Lipner, Liu et al. 2014; Lipner, Shen et al. 2015). In this case, it was noted that the scaffold alone, 
and groups seeded with cells, resulted in delayed healing and inferior mechanical properties when 
compared to standard suture repair. Zou et al. developed a similar electrospun scaffold composed 
of poly(DL-lactide) with gradients of hydroxyapatite and plasmid DNA which resulted in gradients 
of cellular proliferation, osteogenic differentiation, and collagen deposition (Zou, Liu et al. 2012). 
Recently, Liu et al. used an ultrasound treatment to develop decellularized tendon matrix scaffolds 
with gradients in structural alignment for a ligament-to-bone junction application (Liu, Yang et 
al.). These scaffolds demonstrated increased chondrogenic and osteogenic differentiation of MSCs 
on the randomly-oriented regions of the scaffold and improved bone and fibrocartilage formation 
at the interface in an in vivo model.  
These studies have demonstrated that biomaterials that mimic the natural characteristics of the TBJ 
with spatially distributed mineral content, composition, and microstructural alignment are crucial 
for the reestablishment of the fibrocartilaginous interface. Most of this previous work has focused 
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on the development of gradients of biomimicry of a single factor (i.e mineralization or anisotropy). 
This presents an emerging need to develop multi-functional biomaterial strategies which resemble 
the compositional and structural heterogeneity that makes up the native TBJ. 
1.6 Targeted mechanical stimulation for tendon-bone junction engineering 
As previously discussed in section 1.4, biomechanical loading is a crucial factor during the 
development and maturation of the tendon and enthesis (Thomopoulos, Kim et al. 2007; Killian, 
Cavinatto et al. 2012; Schwartz, Lipner et al. 2013; Song, Jiang et al. 2017).  Additionally, 
variations in tension and compressive loading paradigms have been shown to play a role in the 
differentiation of MSCs towards a fibrocartilage or tendon-like phenotype (Connelly, Vanderploeg 
et al. 2010; Thomopoulos, Das et al. 2011). Thus, it will be critical to design mechanical loading 
paradigms and systems to impart physiologically relevant loads onto materials for TBJ 
regeneration. This would potentially include applications and materials which experience spatially 
graded strain profiles as are normally seen in mechanically mismatched tissues like orthopedic 
interfaces.  
Early work evaluating the effect of tensile strain on tendon regeneration was performed in 2D 
systems, such as the Tissue Train culture plate in conjuction with the Flexcell Loading Station 
(Flexcell international, Hillsborough, NC). In these systems, a vacuum is used to stretch a flexible 
membrane over a loading post, exposing any cells or materials on the membrane to tensile strain. 
Kuo et al. seeded MSCs into a collagen gel on a Flexcell membrane to show that cyclic stretching 
at 1 Hz and 1% elongation for 30 minutes per day was required to maintain the expression of the 
tendon-marker SCX over the course of a 7 day study (Kuo and Tuan 2008). More recent work has 
involved the use of custom bioreactor systems to impart a defined tensile strain onto 3D 
biomaterials. These systems generally consist of either loading posts, which string-like materials 
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can be tied to (Qiu, Lei et al. 2014) or clamps to grip the ends of the biomaterial (Burk, Plenge et 
al. 2016).  
While the systems mentioned above have been used successfully to demonstrate that MSCs can 
differentiate towards a fibroblast or tendon-like state on a variety of compatible materials, such as 
electrospun mats (Xu, Wang et al. 2015), decellularized tendon matrix (Burk, Plenge et al. 2016) 
or collagen fiber bundles (Qiu, Lei et al. 2014), there has been a demonstrated need to develop 
systems to apply strain to alternative materials such as porous scaffolds or hydrogels, which are 
not amenable to these attachment methods. In order to address this issue, Doroski et al. and 
Connelly et al. developed a system in which fibrin gels could be formed between two solid end 
blocks, which could be hooked onto loading posts within a bioreactor system (Connelly, 
Vanderploeg et al. 2010; Doroski, Levenston et al. 2010). Paxton et al used a similar method by 
forming a fibrin gel between two brushite anchors in order to optimize loading paradigms designed 
to promote increased collagen production (Paxton, Hagerty et al. 2012). We have also recently 
expanded on this method by embedding the ends of porous collagen-GAG scaffolds into hollow 
end blocks (Grier, Moy et al. 2017).  
Cells sense various mechanical stimuli via a network of mechanotransduction pathways. These 
pathways, activated through microstructural cues and applied mechanical stimulation, can 
influence stem cell activation and differentiation. Substrate alignment and stiffness have been 
shown to activate canonical RhoA/ROCK1 and FAK pathways to promote MSC differentiation 
towards musculoskeletal lineages (Sarasa-Renedo, Tunç-Civelek et al. 2006; Xu, Song et al. 2011; 
Allen, Cooke et al. 2012; Xu, Song et al. 2012; Andalib, Lee et al. 2013; Kanazawa, Furumatsu et 
al. 2014). The application of cyclic tensile strain can also promote the phosphorylation of ERK 1/2 
via RhoA activation (Laboureau, Dubertret et al. 2004), and the upregulation of procollagen 
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mRNA (Papakrivopoulou, Lindahl et al. 2004). As a result, some studies have focused on 
identifying strain profiles to prolong ERK 1/2 activation to promote cell-mediated ECM 
biosynthesis (Paxton, Hagerty et al. 2012). The p38 mitogen-activated protein kinase pathway is 
known to inhibit ERK 1/2 activation (Papakrivopoulou, Lindahl et al. 2004; Weinbaum, Schmidt 
et al. 2013), suggesting an alternate target for promoting ECM biosynthesis. A better 
understanding of how mechanical stimulation and resultant mechanotransduction signaling affect 
stem cell differentiation would help to identify more robust tissue engineering culture systems.   
One thing that must be noted is that the overwhelming majority of published work has been limited 
to the application of cyclic tensile strain for the development of just tendon or fibroblastic tissues 
(Govoni, Muscari et al. 2016). Despite evidence that loading is crucial for the development and 
healing the of TBJ (Thomopoulos, Kim et al. 2007; Schwartz, Lipner et al. 2013; Song, Jiang et 
al. 2017), there has yet to be any comprehensive study on the application of loading on spatially-
graded materials designed for TBJ applications. 
1.7 Biochemical strategies for tendon-bone junction engineering 
Another key area to consider for tendon enthesis regeneration is the use of biologics, such as 
growth factors, that are known to play a role during tissue development. The primary growth 
factors involved in tendon and enthesis development interact with cells via TGF-β signaling 
(Pryce, Watson et al. 2009). There are two main sub-groups within the TGF-β superfamily, the 
TGF-β and bone morphogenic protein (BMP) subfamilies, which activate the Smad 2/3 and Smad 
1/5/8 intracellular pathways, respectively. In general, BMP signaling and Smad 1/5/8 activation is 
associated with osteogenic differentiation while TGF-β signaling, and Smad 2/3 activation is 
associated with the development of connective tissues, such as tendon, ligament, and cartilage 
(Towler and Gelberman 2006; Maeda, Sakabe et al. 2011; Shen, Gelberman et al. 2013). Smad 3 
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has been shown to interact directly with the transcription factor SCX and regulate tendon matrix 
organization (Berthet, Chen et al. 2013). However, BMP-12, BMP-13, and BMP-14 (also known 
as GDF-7, GDF-6, and GDF-5, respectively) are also shown to be expressed in developing tendons 
and ligaments and have been used to promote tendon healing (Wolfman, Hattersley et al. 1997; 
Shen, Gelberman et al. 2013). While critical for development of the tendon enthesis, TGF-β 
treatment for tendon repair has generally been unsuccessful, leading to increased collagen 
production, but also fibrosis and scar formation (Beredjiklian, Favata et al. 2003).  
In addition to TGF-β, there are several other growth factors that have demonstrated efficacy, 
particularly in tendon healing. Basic fibroblast growth factor (bFGF) and platelet-derived growth 
factor-BB (PDGF-BB) have been used to promote accelerated wound closure and matrix synthesis 
(Chan, Chan et al. 1997; Thomopoulos, Das et al. 2010). Fibrin gels designed for the sustained 
release of active bFGF were used in a canine model to promote neovascularization and cell 
proliferation but failed to produce improvements in functional or mechanical properties. Instead, 
the increased cellular activity resulted in increased scar formation and reduced range of motion 
(Thomopoulos, Kim et al. 2010). In a comparable manner to the bFGF work, fibrin or heparin-
based delivery systems of PDGF-BB were able to improve collagen remodeling and cell 
proliferation but also resulted in improved range of motion (Thomopoulos, Zaegel et al. 2007; 
Thomopoulos, Das et al. 2009; Manning, Schwartz et al. 2013). More recently, the use of 
connective tissue growth factor (CTGF) has shown promising results in the ability to induce 
tenogenic, fibroblastic, and chondrogenic differentiation of MSCs (Fukunaga, Yamashiro et al. 
2003; Lee, Shah et al. 2010; Liu, Tao et al. 2015). In a similar manner to BMP-12, CTGF increased 
the expression of tenocyte lineage markers, like SCX, in vitro (Liu, Tao et al. 2015).  
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A few select studies have examined the patterned display of growth factors to control cellular 
responses in a spatially-dependent manner. Inkjet printing has been used to establish gradients of 
BMP-2 and FGF onto 2D fibrin surfaces to preferentially drive osteogenic differentiation of 
C2C12 myogenic precursor cells (Miller, Phillippi et al. 2009). Ker et al. has investigated a similar 
method to print FGF and BMP-2 onto both fibrin-coated substrates and polymer fiber mats, 
showing spatially localized differentiation of C2C12 cells with myogenic differentiation on 
unprinted regions and tenogenic and osteogenic differentiation in regions patterned with FGF and 
BMP-2, respectively (Baselga, Rothenberg et al. 2008; Ker, Chu et al. 2011; Ker, Nain et al. 2011). 
Benzophenone photochemistry has also been used to selectively pattern CG substrates of varying 
stiffness with BMP-2 and PDGF-BB to regulate adipose-derived stem cell bioactivity and, 
proliferations, and gene expression (Banks, Mozdzen et al. 2014). 
In addition to growth factors, some groups have started to use materials derived from native tendon 
to provide many of the innate cues for enthesis development (Schulze-Tanzil, Al-Sadi et al. 2012). 
The deceulluarized tendon matrix matches the biomechanical and structural properties of the 
native tendon and can include growth factors entrapped within the ECM (Hoganson, O’Doherty et 
al. 2010).  Zhang et al. used a decellularized tendon matrix coating on tissue culture plastic to 
promote the maintenance of tendon stem cells in vitro and then implanted a tendon stem cell and 
matrix composite into rat models where the combination led to increased tendon-like tissue 
formation (Zhang, Li et al. 2011). ECM derived from tendon tissue was also shown to induce TGF-
β dependent differentiation of adipose-derived stem cells (Yang, Rothrauff et al. 2016). When 
looking across the full TBJ, Schulze-Tanzil et al. implanted a decellularized tendon-bone graft into 
a rat model and found that animals treated with the composite graft showed increased mechanical 
properties with a more organized matrix structure after 12 weeks (Farnebo, Woon et al. 2014). 
 15 
While the use of native EMC can provide many of the necessary cues to influence stem cells and 
regenerate these complex tissues, decellularized tissues face many obstacles in reaching the clinic. 
It can be difficult to adequately characterize explants and ensure uniformity from one graft to the 
next. Additionally, there are always limitations based on limited donor availability and potential 
disease transmission or immunogenic responses. Thus, ideal tissue engineering solutions should 
be fabricated from commercially available materials.  
1.8 Overall summary and future perspective 
The fields of tissue engineering and regenerative medicine have grown substantially over the last 
two decades. Current research has expanded to focus on the design of spatially organized materials 
to regenerate complex multi-tissue structures, like the tendon-bone junction and other common 
injury sites in orthopedics. In parallel, a great amount of work has focused on the fundamental 
understanding of the microstructural, mechanical, and biochemical cues that drive stem cell 
differentiation, looking to developmental biology as a guide. Moving forward, the integration of 
these two areas of study is likely to yield new breakthroughs in clinical applications to repair 
tissues. 
Many of the materials outlined in this review have focused on spatial distributions of singular 
components of the native TBJ, primarily mineral content or structural alignment. Additionally, 
gradient materials have only been developed at non-physiological scales on the order of 
centimeters, while the native enthesis is normally less than 1 millimeter in length (Lee, Robinson 
et al. 2016). Disparate spatially-stratified materials may appear to mimic the overall scale of the 
TBJ, but the hard interfaces used in their fabrication can lead to issues, such as excess shear and 
inadequate transport and cellular crosstalk at the interface. The use of decellularized tissues, that 
match the native structure, overcomes many of these issues; however, there remains complications 
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due to donor availability and potential host immune response. The previous work from our lab 
(Caliari, Weisgerber et al. 2015), along with the work presented here, aims to address this need by 
the fabrication of a continuous natural ECM material with distinct regions of structural anisotropy 
and mineral content.  
In addition to heterogenous material systems, a variety of supplemental factors, such as mechanical 
stimulation or growth factor supplementation have been shown to play crucial roles in the 
regeneration of the tendon enthesis. However, for the most part their use has so far been limited to 
singular applications of growth factor supplementation or mechanical stimulation. Comprehensive  
studies of the combined influence of growth factors with mechanical stimulation and the combined 
influence of material properties are still lacking, despite evidence of the importance of these 
interactions in musculoskeletal development (Mei, Nguyen et al. 2013; Rys, Monteiro et al. 2016). 
To conclude, the future of multi-tissue engineering is exciting. Substantial advancements have 
been made in the development of intricate material systems and supplementation strategies to 
regulate stem cell fate. This provides realistic opportunities for multi-disciplinary approaches to 




CHAPTER 2: THE INFLUENCE OF PORE SIZE AND STIFFNESS ON TENOCYTE 
BIOACTIVITY AND TRANSCRIPTOMIC STABILITY IN COLLAGEN-GAG 
SCAFFOLDS2 
 
2.1 Chapter overview 
The focus of this chapter will be on the evaluation of CG scaffold microstructural properties on 
the phenotypic maintenance in equine tenocytes. The scaffold pore size and strut stiffness were 
independently by controlling freezing temperatures during lyophilization and crosslinking density. 
The effects of scaffold microstructure on cell-mediated scaffold contraction and resultant tenocyte 
bioactivity, viability, and gene expression were assessed in an effort to inform the design of 
biomaterials for tendon repair. 
 
2.2 Introduction 
The field of tissue engineering faces a unique set of challenges with geometrically and 
mechanically anisotropic tissues. The functional capacity of tendon derives from its extracellular 
matrix (ECM) composed of type I collagen that is arranged in highly aligned cross-linked fibrils 
(Towler and Gelberman 2006; James, Kesturu et al. 2008; Liu, Ramanath et al. 2008). The cellular 
component of tendon is primarily composed of tendon fibroblasts, or tenocytes, distributed 
throughout a hierarchical organization of aligned type I collagen fibers (James, Kesturu et al. 2008; 
Liu, Ramanath et al. 2008). Tendon and ligament injuries plague individuals from all walks of life, 
from elite athletes to the elderly, with more than 32 million occurrences every year in the US alone 
(James, Kesturu et al. 2008; Liu, Ramanath et al. 2008; Xu and Murrell 2008; Breidenbach, Gilday 
et al. 2013). While small tendon injuries heal spontaneously via regeneration, larger defects 
                                                 
 
2 This chapter has been adapted from the following publication: 
Grier, W.K. E.M. Iyoha, et al. (2017). "The influence of pore size and stiffness on tenocyte bioactivity and 
transcriptomic stability in collagen-GAG scaffolds.” J. Mech. Behav. Biomed. Mater 65: 295-305. 
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undergo a repair-mediated process generating fibrocartilagenous scar tissue with inferior structural 
and biomechanical properties. The resulting misaligned ECM leads to losses in range of motion 
and strength along with high rates of injury recurrence (James, Kesturu et al. 2008; Liu, Ramanath 
et al. 2008; Xu and Murrell 2008). Inadequate healing after surgical repair remains a primary 
clinical challenge. Because the musculoskeletal system depends on a balance of contributions from 
multiple tissues to maintain joint patency, ineffective tendon repair has both short-term (i.e. slowed 
rehabilitation) and long-term (i.e. chronic, degenerative joint pathologies) consequences (Butler, 
Juncosa-Melvin et al. 2008; Liu, Ramanath et al. 2008). Due to an ageing US population with 
increasing rates of underlying chronic conditions (i.e. obesity, diabetes), injury volume and 
complexity are only expected to increase (Fox, Bedi et al. 2011).  
A primary challenge to improving tendon regeneration is poor understanding of how tenocytes 
respond to the dynamic structural microenvironment within the tendon. Tendon fibroblasts, or 
tenocytes (TCs) are responsible for tendon homeostasis, remodeling, and repair. However, 
tenocytes exhibit rapid de-differentiation when cultured in 2D or within hydrogels (Clegg, 
Strassburg et al. 2007; Taylor, Vaughan-Thomas et al. 2009). While tensile loading and aligned 
topographical cues on two-dimensional substrates can partially abrogate this effect (Caporali, 
Kapoor et al. 2009; Maeda, Shelton et al. 2009; Paxton, Hagerty et al. 2011), 3D platforms for 
stable expansion of tenocytes represent an important advance for the field. A crucial effort in the 
development of tissue engineering and regenerative medicine approaches for a range of tissues is 
the design of an appropriate biomaterial platform. Often these approaches are inspired by the native 
extracellular matrix (ECM) in order to provide an environment to speed healing or regeneration 
(Yannas, Lee et al. 1989; Spilker, Asano et al. 2001; Yannas 2001).  
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Collagen-glycosaminoglycan (CG) scaffolds have been used in a wide variety of in vivo 
applications for skin, peripheral nerve, and cartilage tissue engineering, as well as 3D 
environments for in vitro studies of cell-matrix interaction (cell, migration and contraction) 
behaviors (Yannas, Lee et al. 1989; Schulz Torres, M. Freyman et al. 2000; Harley, Spilker et al. 
2004; O'Brien, Harley et al. 2005; Farrell, O'Brien et al. 2006; Harley, Freyman et al. 2007; Harley, 
Kim et al. 2008). The vast majority of past efforts using CG scaffolds have primarily been focused 
on the regeneration of soft tissues. However, those scaffold variants were unsuitable for tendon 
repair applications due to their inability to withstand TC-mediated contraction (Schulz Torres, M. 
Freyman et al. 2000; Caliari and Harley 2011) leading to rapid tenocyte de-differentiation. We 
have recently developed a fabrication method to produce anisotropic CG scaffolds composed of 
an aligned ellipsoidal pore structure (Caliari and Harley 2011). This anisotropic scaffold geometry 
promotes preferential tenocyte alignment along the long axis of the ellipsoidal pores.  Surprisingly, 
increasing the scaffold relative density while maintaining the aligned pore geometry was shown to 
reduce TC-mediated scaffold contraction, maintain an aligned morphology, and reduce TC de-
differentiation (Caliari and Harley 2011; Caliari, Ramirez et al. 2011; Caliari, Weisgerber et al. 
2012). The potential to tailor scaffold anisotropy and its resistance to adverse (contraction-based) 
remodeling events offers an exciting platform to control long-term maintenance of tenocyte 
bioactivity. Here, we look at two different means to alter the local scaffold environment 
experienced by individual tenocytes: pore size and crosslinking density. For a low-density, open-
cell foam such as the CG scaffold, changing scaffold pore size does not affect the macro-scale 
mechanical properties, such as scaffold elastic modulus (Harley, Leung et al. 2007; Gibson, Ashby 
et al. 2010). However, changing the pore size for a series of scaffolds with constant relative density 
does alter the length and thickness (hence, flexural rigidity) of individual struts which define the 
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pore structure of the scaffold (Harley, Freyman et al. 2007). Alternatively, increasing scaffold 
crosslinking density via either dehydrothermal (DHT) (Olde Damink, Dijkstra et al. 1996; Schulz 
Torres, M. Freyman et al. 2000; Harley, Leung et al. 2007; Gibson, Ashby et al. 2010) or chemical 
(1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride, EDC; N-
hydroxysulfosuccinimide, NHS) (Olde Damink, Dijkstra et al. 1996) means can increase scaffold 
and individual strut stiffness, independent of pore size. Both modifications alter the local strut 
properties but via different means, opening the door to questions exploring how strut stiffness 
versus pore size affects TC-mediated contraction and resultant maintenance of TC-phenotype.  
The work presented here seeks to describe the relationship between scaffold pore size and 
crosslinking with scaffold mechanical properties and its ability to resist TC-mediated contraction. 
We hypothesized that a scaffold’s ability to resist TC-mediated contraction would increase with 
increasing crosslinking density and decreasing pore size. Moreover, more mechanically robust 
scaffolds with smaller pore sizes and higher crosslinking densities were hypothesized to be more 
supportive of the maintenance of a tendon-like phenotype through the resistance to TC-mediated 
contraction and preservation of a permeable open-cell pore structure that allows for efficient 
nutrient transport and cell spreading. While our group and others have investigated the impact of 
initial scaffold pore size and crosslinking on cell attachment and tenocyte contraction (Schulz 
Torres, M. Freyman et al. 2000; Caliari and Harley 2011; Caliari, Weisgerber et al. 2012), this 
previous work did not examine long-term cell-mediated contraction of the scaffold network, nor 
the effect of  EDC crosslinking density on scaffold pore size and TC-mediated contraction and 
subsequent bioactivity.  
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2.3 Materials and Methods 
Preparation of CG suspension 
Type I microfibrillar collagen from bovine tendon (Sigma-Aldrich, St. Louis, MO) and 
chondroitin-4,6-sulfate from shark cartilage (Sigma-Aldrich, St. Louis, MO) were homogenized 
in 0.05M acetic acid. The concentration of the collagen suspension made was 1.0%, and the ratio 
of the collagen to glycosaminoglycan was kept at 11.25:1 (Yannas, Lee et al. 1989; O'Brien, Harley 
et al. 2004; Caliari and Harley 2011). 
Aligned CG scaffold fabrication 
The scaffolds were fabricated through directional solidification as previously described (Caliari 
and Harley 2011). Degassed CG suspension was pipetted into a polytetrafluoroethylene (PTFE) - 
copper mold (8mm diameter, 15mm deep), and placed on a pre-cooled freeze-dryer shelf (VirTis, 
Gardner, NY). The mismatch in thermal conductivity between the PTFE body and copper base of 
the mold promotes unidirectional heat transfer through the more conductive copper, resulting in 
anisotropic ice crystal formation when cooled (Caliari and Harley 2011). In order to control pore 
size, the CG suspension was frozen at three different temperatures (Tf): -10°C, -40°C, and -60°C. 
These freezing temperatures have been previously shown to produce scaffolds with aligned pore 
geometries of 243, 152, and 55 µm diameters respectively (Caliari and Harley 2011). The CG 
suspensions were frozen for 2 hours, and then sublimated at 0°C and 200mTorr to remove the ice 
crystals, resulting in a dry, porous scaffold. 
Aligned CG scaffold crosslinking 
Following lyophilization, the scaffolds were DHT crosslinked in a vacuum oven (Welch, Niles, 
IL) (105°C, <25 torr) for 24 hours, and then stored in a desiccator until use. Before use, scaffolds 
were immersed in 200-proof ethanol for 6 hours, followed by washing with phosphate-buffered 
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saline (PBS) overnight. Solutions of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (Sigma-Aldrich, St. Louis, MO) and N-hydroxysulfosuccinimide (Sigma-Aldrich) 
were used to further crosslink each of the three scaffolds groups at three different molar ratios: 
1:1:5 (low), 5:2:5 (medium), and 5:2:1 (high) EDC:NHS:COOH that correspond with increasing 
collagen strut and overall scaffold stiffness (Olde Damink, Dijkstra et al. 1996; Harley, Leung et 
al. 2007). 
Equine tenocyte isolation and culture 
Equine tenocytes were isolated as previously described (Caliari and Harley 2011) from horses, 
aged 2–3 years, euthanized for reasons not related to tendinopathy, and in a manner consistent with 
protocols approved by the University of Illinois IACUC. Digital flexor tendons were extracted, 
diced, and incubated in a collagenase solution at 37◦C, under constant shaking. Digest solution 
was filtered (40 μm pore size) to isolate tenocytes (Kapoor, Caporali et al. 2010). Tenocytes were 
plated at a density of 1x104 cells/cm2, and cultured in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Fisher, Pittsburgh, PA) with 1% L-glutamine (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA), 1% amphotericin-B (MP Biomedical, Solon, 
OH), and 25µg/mL ascorbic acid (Wako, Richmond, VA) (Caliari and Harley 2011). The tenocytes 
were cultured at 37°C and 5% CO2, and fed every 3 days. Cells were used at passage 3. 
Scaffold seeding 
Each cylindrical CG scaffold (8mm diameter, 15mm length) was cut into ~5mm long plugs (8mm 
dia.) and placed in ultra-low attachment, 6-well plates (Corning Life Sciences, Lowell, MA). 
Confluent tenocytes were trypsinized and resuspended at a concentration of 5x105 cells/20μL 
media. Scaffolds were seeded, with tenocytes using a previously validated static seeding method 
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(O'Brien, Harley et al. 2005; Caliari and Harley 2011), with 10μL of cell suspension (2.5x105 cells) 
pipetted directly onto each scaffold. The scaffolds were then incubated at 37°C for 15 minutes, 
turned over, and seeded with an additional 10 μL of cell suspension, for a total of 5x105 cells 
seeded per scaffold. The cell-seeded scaffolds were then incubated at 37°C with 5% CO2 and fed 
complete DMEM every 3 days (Caliari and Harley 2011). 
Quantification of cell metabolic activity 
The mitochondrial metabolic activity of the tenocytes within each scaffold was determined through 
the use of non-destructive AlamarBlue® assay as previously described (Caliari and Harley 2011). 
Healthy, viable cells continuously convert the active ingredient in AlamarBlue® (resazurin) to a 
fluorescent byproduct (resorufin), allowing comparison of the gross metabolic activity of each 
cell-seeded construct. Cell-seeded scaffolds were incubated at 37◦C in AlamarBlue (Invitrogen, 
Carlsbad, CA) solution with gentle shaking for 2 hours (Tierney, Jaasma et al. 2009). Resorufin 
fluorescence was measured (excitation: 540 nm, emission: 590 nm) via a fluorescent 
spectrophotometer (Tecan, Switzerland). Relative cell metabolic activity was determined from a 
standard curve generated from known cell numbers prior to seeding the scaffolds and reported as 
a percentage of the total number of seeded cells. 
Measurement of cell-mediated scaffold contraction 
At days 1, 4, 7, and 14, the diameter of each scaffold disk was measured using a standard drafting 
template. The measurements were then normalized against the diameter of each scaffold at day 0 
to determine cell-mediated contraction of each scaffold disk (Spilker, Asano et al. 2001; Caliari, 
Weisgerber et al. 2012). 
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Quantification of cell number 
The total number of cells on each scaffold was assayed via DNA quantification (Caliari and Harley 
2011). Scaffolds were rinsed in PBS and placed in a papain solution (Sigma-Aldrich, St. Louis, 
MO) (60°C, 24 hours) to digest the scaffolds and lyse the cells. Hoechst 33258 dye (Invitrogen, 
Carlsbad, CA) was used to fluorescently label double-stranded DNA (Kim, Sah et al. 1988). 
Fluorescence was read (excitation: 360nm; emission: 465nm) via a fluorescent spectrophotometer 
(Tecan, Switzerland). Experimental readings were normalized to the scaffolds with crosslinking 
density of 5:2:1 and Tf of -10°C in order to serve as a comparison to previous work (Kim, Sah et 
al. 1988). 
RNA isolation and real-time PCR 
RNA from the tenocytes in the scaffolds was extracted at days 1, 4, 7 ,and 14, using an RNeasy 
Plant Mini kit (Qiagen, Valencia, CA) and was then reverse transcribed to cDNA in a Bio-Rad 
S1000 thermal cycler using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA), as 
previously described (Caliari and Harley 2011). Real-time PCR reactions were carried out in 
triplicate, using 10ng of cDNA and QuantiTect SYBR Green PCR kits (Qiagen, Valencia, CA) in 
a 7900HT Fast Real-Time PCR system (Carlsbad, CA). The primers used were consistent with 
previous studies (Table 2.1; collagen type I alpha 2; collagen type III alpha 1; cartilage oligomeric 
matrix protein; decorin; scleraxis; tenascin-c, C; matrix metalloproteinases 1, 3, and 13; 
glyceraldehyde 3-phosphate dehydrogenase, housekeeping) (Caliari and Harley 2011; Caliari, 
Weisgerber et al. 2012), and were synthesized by Integrated DNA Technologies (Coralville, IA). 
Results were generated using the ΔΔCt method, and all results were expressed as fold changes 
normalized to the expression levels of cells on the -10°C/5:2:1 scaffold group at day 1 for 
comparison to previous studies (Caliari and Harley 2011; Caliari, Ramirez et al. 2011; Caliari, 
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Weisgerber et al. 2012; Caliari and Harley 2013). The expression levels of the MMP genes are 
shown relative to the normalized scaffold contraction for each group, at each time point, in order 
to better elucidate the interplay of cell-mediated contraction forces and cell-mediated remodeling 
(Gotoh, Hamada et al. 1997; Lo, Marchuk et al. 2004; Jones, Corps et al. 2006; Clegg, Strassburg 
et al. 2007). 
Statistical Analysis 
One-way analysis of variance (ANOVA) was performed on all data sets within each group to 
examine differences with time. Two-way ANOVAs (independent factors: crosslinking density, Tf) 
were applied to data sets for each time point. For scaffold contraction, significant changes from 
the day 0 time point were determined by Dunnett’s post-hoc test. Statistical significance for all 
other measurements were determined by Tukey-HSD post-hoc tests. Significance was set at p < 
0.05. Cell metabolic activity (n=6), scaffold diameter (n=6), and gene expression (n=3) were 
analyzed at each time point. For MMP gene expression, relative to normalized scaffold diameter, 
linear or exponential regression models were used to fit the data and corresponding R2 values (n = 




Tenocyte viability in CG scaffolds 
Tenocytes remained viable in all scaffold variants across the fourteen day experiment. While the 
metabolic activity of the tenocyte-seeded scaffolds was consistent for all scaffold groups at day 1 
after seeding, by day 14, significant expansion in overall metabolic activity and cell number was 
observed. Here, cell number and construct metabolic activity increased significantly (p < 0.01) 
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with crosslinking density, with the largest increases in cell number and metabolic activity seen for 
the most strongly crosslinked (EDC:NHS:COOH 5:2:1) variants (Figure 2.1A, 2.1B). A 
significant effect of both crosslinking density (p < 0.001) and scaffold pore size (Tf, p < 0.001) 
was observed on tenocyte mediated scaffold contraction (Figure 2.1C). Scaffolds crosslinked at 
the lightest (1:1:5) density started showing signs of contraction as early as day 1, Then, they  
showed significantly (p < 0.01) greater contraction (smaller, normalized diameter) than scaffolds 
crosslinked at higher densities on all following days. Scaffolds crosslinked at a middle (5:2:5) 
density began to show signs on contraction by day 4, and on all following days, they were 
significantly more contracted than the scaffolds crosslinked at the highest (5:2:1) density. These 
scaffolds at the highest crosslinking density exhibited little-to-no contraction throughout the 14-
day experiment. For crosslinking densities that yielded significant contraction (1:1:5, 5:2:5), there 
was also a significant (p < 0.01) effect of scaffold pore size on contraction. Scaffolds with larger 
pore sizes (higher Tf) showed greater contraction when compared to scaffolds with the same 
crosslinking density but smaller pore sizes. 
Tenocyte gene expression within CG scaffolds 
Subsequently, we examined the gene expression profiles of the cells remaining in each construct 
after 14 days in culture. Three distinct sub-sets of genes were examined: structural proteins 
associated with tendon ECM (COL1A2, COL3A1, COMP, DCN; Figure 2.2); genes associated 
with tendon phenotype (SCXB, TNC; Figure 2.3); and genes associated with matrix remodeling 
(MMP1, MMP3, MMP13; Figure 2.4). 
Structural protein gene expression 
Gene expression levels of COL1A1, COL3A3, COMP, and DNC showed some global changes in 
expression for earlier time points (days 1, 4, and 7; Figures 2.5, 2.6). By day 4, the scaffolds least 
 27 
resistant to contraction (1:1:5 crosslinking density) showed significant increases in COL3A1, 
COMP, and DCN. The scaffolds moderately able to resist contraction (5:2:5 crosslinking density) 
showed significantly higher expression of all four structural protein markers. Scaffolds most 
resistant to contraction (5:2:1 crosslinking density) only showed increased expression of DCN. 
More interestingly, we examined changes in structural genes at day 14, at which point significant 
cell-mediated contraction had occurred (Figure 2.2). Notably, scaffolds most resistant to 
contraction (5:2:1 crosslinking density; -40°C and -60°C Tf) showed significantly higher 
expression of COL1A2 compared to scaffolds with lower crosslinking densities and the same Tf 
(Figure 2.2). While not always significant, an overall change in expression profiles for all genes 
were observed, with crosslinking groups less resistant to contraction (1:1:5, 5:2:5) showing a 
decrease in expression with decreasing pore size; while the crosslinking groups most resistant to 
contraction (5:2:1) showed an increase in expression with decreasing pore size. Finally, while there 
were no significant differences in expression of DCN, the scaffold with the smallest pores, most 
resistant to contraction (-60°C Tf; 5:2:1 crosslinking) showed significantly higher expression of 
COMP than all other scaffold groups at day 14 (Figure 2.2).  
Tendon phenotype gene expression 
Expression of the transcription factor SCXB increased initially in all scaffold variants (through day 
4). However, significant cell-mediated contraction began to affect the expression profile for 
subsequent days for the scaffold groups least resistant to contraction (1:1:5 and 5:2:5 crosslinking 
density), while the scaffold group resistant to contraction (5:2:1 crosslinking density) maintained 
the elevated SCXB expression through days 14 (Figure 2.7). Comparing scaffold pore size and 
crosslinking at day 14, we observed the scaffold variant most resistant to contraction (5:2:1 
crosslinking density, -60°C Tf) showed significantly higher expression of SCXB than all other 
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groups. Further, scaffolds with reduced resistance to contraction (1:1:5 crosslinking density, -40° 
Tf) showed significantly lower expression of SCXB than all other groups (Figure 2.3). TNC 
expression followed a similar trend to SCXB, with all groups showing increasing expression 
though day 7 (Figure 2.7). While not significant by day 14, an increasing trend in TNC expression 
was observed for scaffolds most resistant to contraction (5:2:1 crosslinking density; -40 and -60°C 
Tf).  
MMP gene Expression 
All three MMP genes examined (MMP1, MMP3, and MMP13) showed similar trends regarding 
expression between groups over time (Figure 2.8). In general, MMP expression levels increased 
with each time point and were significantly higher in the scaffolds least resistant to contraction 
(warmer Tf, lower crosslinking densities). We subsequently examined MMP expression profiles 
against the normalized (versus starting diameter) diameter of each scaffold, collapsing the effect 
of time, pore size, and crosslinking density onto a single plot (Figure 2.4). With the exception of 
day 1, at which point minimal contraction had taken place (R2 = 0.25), we observed very strong 
correlation between increasing MMP expression profiles and increased scaffold contraction. This 
correlation resulted in R2 ≥ 0.84 for day 14 results. MMP1 and MMP3 showed effectively linear 
increases in expression with scaffold crosslinking and time, while MMP13 showed an exponential 
increase in expression with time. Scaffolds least resistant to contraction (1:1:5 density, -10°C Tf) 
showed more than a 600 fold increase in MMP13 over the course of 14 days (Figure 2.4C). 
 
2.5 Discussion 
Biomaterial scaffold mechanical properties, at both the macro and micro-scales, have been widely 
reported to influence cellular behaviors such as adhesion, migration, proliferation, and 
differentiation (Pelham and Wang 1997; Freyman, Yannas et al. 2001; Grinnell, Ho et al. 2003; 
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Engler, Bacakova et al. 2004; Peyton and Putnam 2005; Yeung, Georges et al. 2005; Zaman, 
Trapani et al. 2006). The motivation for this work is the significant de-differentiation often 
observed with tenocytes when cultured in vitro, as well as the observation that structural alignment 
in two-dimensions and application of tensile strain may reduce this de-differentiation (Taylor, 
Vaughan-Thomas et al. 2009). Future tendon tissue engineering efforts require the expansion of 
primary tenocytes in order to address large injuries, necessitating approaches that use three-
dimensional biomaterial constructs for cell culture and eventual in vivo implantation. If a 
microstructurally-aligned material is unable to maintain a high degree of anisotropy, due to 
contractile forces, the microstructural cues that guide cell-fate decisions will be significantly 
altered as the cells remodel the local microenvironment.  
Here, we describe the production and analysis of a series of anisotropic CG scaffolds fabricated at 
different Tf and a range of crosslinking densities for the in vitro culture of primary equine 
tenocytes. Our group recently described an approach where the relative density of a series of CG 
scaffolds was varied in order to prevent TC-mediated contraction, resulting in reduced scaffold 
contraction. Maintenance of the aligned structural cues, provided by the scaffold and resultant, 
increased maintenance of TC-associated gene expression profiles for cells within the scaffold 
(Caliari, Weisgerber et al. 2012). However, changes in the relative density of the scaffold result in 
changes in scaffold pore size as well as in the mechanical properties of the scaffold. This is at the 
scale of the overall construct and at the level of an individual cell within the scaffold. This 
observation therefore motivated our effort here to generate a wider library of CG scaffolds to more 
specifically examine the effect of scaffold architecture on resultant TC-mediated contraction and 
phenotypic stability. 
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Low-density open-cell foams such as the CG scaffold demonstrate a unique set of structure-
mechanic relationships (Gibson, Ashby et al. 2010). For these materials, it is essential to consider 
the mechanical property at the scale of the overall construct (bulk properties), as well as at the 
level of the individual fibers (termed struts) that make up the scaffold architecture and to which 
individual cells attach. The bulk mechanical properties of the scaffold critically depend on the 
crosslinking density and relative density (1 – porosity), not pore size, of the scaffold. For example, 
the elastic modulus of the bulk scaffold (E*) depends on the crosslinking density of the collagen 
(defining Es, the modulus of the individual strut) along with the relative density (ρ*/ρs) of the 
scaffold: E* ~ Es∙(ρ*/ρs)
2 (Harley, Leung et al. 2007). However, the modulus is insensitive to 
scaffold pore size (Gibson and Ashby 1997; Harley, Leung et al. 2007). Cell-mediated contraction 
is mediated not by the bulk elastic properties, but rather the mechanical properties of the individual 
struts to which they attach. Previous studies have shown that contractile cells possess the ability 
to generate sufficient contractile forces to buckle individual struts and deform the local pore 
structure around them (Freyman, Yannas et al. 2001). These local contractions, when compounded 
throughout the entire scaffold, result in a macroscopic deformation of the overall scaffold. 
Furthermore, the magnitude of contractile forces generated by individual cells can be estimated 
via the flexural rigidity of the strut, depending on crosslinking density (Es) and the length and 
thickness of the strut (Harley, Freyman et al. 2007). Here, increasing the pore size for a series of 
scaffolds with a set relative density increases the length of individual struts (Harley, Leung et al. 
2007). Therefore, selective modification to both scaffold crosslinking and pore size provides a 
wider platform to consider the influence of local strut mechanical properties, resistance to TC-
mediated contraction, and subsequent maintenance of tenogenic gene expression profiles within 
the scaffold.  
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For this project, we employed a previously defined set of scaffold fabrication techniques, altering 
the freezing temperature during lyophilization to generate a series of anisotropic scaffolds within 
decreasing pore size (-10°C, -40°C, -60°C; 243, 152, and 55 µm pore size) (Caliari and Harley 
2011). We subsequently employed a series of three discrete carbodiimide crosslinking densities 
(1:1:5, 5:2:5, 5:2:1) that span a 3.6-fold increase in stiffness (Harley, Leung et al. 2007). TC-
mediated contraction, metabolic activity and cell number, and resultant changes in gene expression 
profiles for a diverse set of tendon-associated structural proteins, tenocyte markers, and matrix-
remodeling genes were then traced across the full set of 9 experimental scaffold groups. Here, we 
observed scaffold pore size and crosslinking density were able to elicit differential responses 
during long-term cell culture.  
In general, an increase in the number and metabolic activity of primary equine tenocytes was 
observed with culture time. However, we noted a significant effect of both crosslinking density 
and scaffold pore size on cell-mediated contraction of the scaffolds (Figure 2.1A). Increasing 
scaffold crosslinking density resulted in reduced cell-mediated contraction; however, we also 
noted a significant effect of pore size on contraction, with scaffolds containing smaller pores more 
able to resist cellular contractile forces over time (Figure 2.1C). The loss of structural stability via 
contraction has a significant, negative effect on cell metabolic activity due with time, likely due to 
reduced biotransport through the denser scaffold. This finding is consistent with previous findings 
showing reduced scaffold permeability with the application of compressive strain (Weisgerber, 
Kelkhoff et al. 2013). While we observed a significant reduction in metabolic activity and cell 
number after 14 days of culture in scaffolds that exhibited significant contraction (Figure 2.1A, 
2.1B), it was important to also establish the effect on the phenotype of the resultant cells. 
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We subsequently examined the effects of cell-mediated contraction on the maintenance of a 
healthy tendon-like phenotype via transcript levels of ECM proteins associated with native tendon 
(COL1A2, COL3A1, COMP, DCN) (Lui, Rui et al. 2011), as well as transcription factors and 
matricellular markers of tenocytes (SCXB, TNC) (Blitz, Viukov et al. 2009; Pryce, Watson et al. 
2009; Doroski, Levenston et al. 2010; Schweitzer, Zelzer et al. 2010) (Figures 2.2-2.3). Lastly, 
we also examined a series of matrix metalloproteinases (MMP1, MMP3, MMP13) important for 
cell migration, wound healing, and matrix remodeling, but also those that showed reduced 
expression levels, indicative of healthy tendon (Gotoh, Hamada et al. 1997; Jones, Corps et al. 
2006; Clegg, Strassburg et al. 2007). Transcript levels at each time point were normalized against 
expression levels of tenocytes in scaffolds with a -10°C Tf and 5:2:1 crosslinking density to 
compare to previous studies investigating the influence of the CG scaffold microenvironment on 
the transcriptomic stability of tenocytes (Caliari and Harley 2011; Caliari, Weisgerber et al. 2012; 
Caliari and Harley 2013). Importantly, by day 14, COL1A2, COL3A1, COMP, and DCN all 
showed decreased expression in scaffolds with reduced crosslinking density (1:1:5 and 5:2:5) and 
scaffolds with the largest pore size (least resistant to contraction). Expression levels were increased 
in scaffolds most resistant to contraction (Tf -60; 5:2:1 crosslinking density). Expression of SCXB 
was significantly higher in scaffolds most resistant to contraction (Tf -60; 5:2:1 crosslinking 
density), while TNC expression follows a similar, but not significant, trend. Heightened MMP1, 
MMP3, and MMP13 expression all followed nearly identical and dramatic trends. By plotting the 
results, not as a function of scaffold pore size or crosslinking density, but rather versus overall 
resistance to TC-mediated contraction, these data collapse onto clear trends of reduced TC-
associated markers with increasing cell-mediated contraction (Figure 2.4).  
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While earlier results suggested reduced TC-associated markers with increasing scaffold 
contraction results in changes in overall scaffold relative density(Caliari, Weisgerber et al. 2012), 
changes in relative density masked our ability to determine whether the stiffness of the scaffold 
strut versus the flexural rigidity of the strut was the primary design consideration that could be 
used in subsequent biomaterial variants. Here, by selectively modifying scaffold pore size and 
crosslinking density, we are able to independently tune strut length versus strut stiffness. We found 
that the overall ability to resist contraction was the best predictor of maintenance of tenocyte-
associated gene expression profiles. However, examining the effect of pore size versus 
crosslinking in more detail, we noted that crosslinking density provides a primary means to resist 
TC-mediated contraction. For lower crosslinking densities (1:1:5, 5:2:5) where significant 
contraction was observed, the poorest response was seen in the smallest pore size variants. Likely 
due to the significant contraction, not only destroying the aligned structure signals provided by the 
pore, but also significantly reducing biotransport. However, in the highest crosslinking density 
(5:2:1) where limited contraction was observed, the scaffold with the smallest pore size, more 
resistant to contraction, demonstrated the highest level of TC-associated genes. Together, these 
results suggest that while scaffold ability to resist TC-mediated contraction forces play a 
significant role in regulating tenocyte gene expression, scaffold crosslinking, not necessarily 
changes in pore size, provides the primary means to optimize culture conditions for expansion and 
maintenance of primary tenocytes.  
2.6 Conclusions 
This work describes the evaluation of the ability for a series of anisotropic CG scaffolds to promote 
the expansion of primary tenocytes in vitro. In general, equine tenocytes showed increased 
proliferation and metabolic activity, as well as less cell-mediated contraction in scaffolds with 
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higher crosslinking densities and smaller pore sizes. Gene expression analysis showed scaffolds 
most resistant of cell-mediated contraction were able to maintain a tendon-like-phenotype over the 
course of the experiment. Importantly, the high expression levels of MMPs 1, 3, and 13 in scaffolds 
that showed more contraction indicate a high degree of scaffold remodeling and loss of tendon-
like phenotype. This suggests that the structural stability of biomaterials for tissue engineering 
applications is of particular importance when considering clinical translation.   
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2.7 Table 
Table 2.1 PCR primer sequences. 
Transcript Sequence Reference 
COL1A2 
 
Forward: 5’- GCACATGCCGTGACTTGAGA -3’ 
Reverse: 5’- CATCCATAGTGCATCCTTGATTAGG -3’ 
(Taylor, 
Vaughan-




Forward: 5’- GTCCACCTGAGGAACTGTCT--3’  
Reverse: 5’- TGATCAGGACCACCAACATCA-3’ 
(Taylor, 
Vaughan-




Forward: 5’- GGTGCGGCTGCTATGGAA -3’ 
Reverse: 5’- CCAGCTCAGGGCCCTCAT -3’ 
(Taylor, 
Vaughan-




Forward: 5’- CATCCAGGTTGTCTACCTTCATAACA-3’ 
Reverse: 5’- CCAGGTGGGCAGAAGTCATT -3’ 
(Taylor, 
Vaughan-
Thomas et al. 
2009) 
SCXB Forward: 5’- TCTGCCTCAGCAACCAGAGA -3’ 
Reverse: 5’- TCCGAATCGCCGTCTTTC-3’ 
(Taylor, 
Vaughan-
Thomas et al. 
2009) 
TNC Forward: 5’- GGGCGGCCTGGAAATG -3’ 
Reverse: 5’- CAGGCTCTAACTCCTGGATGATG-3’ 
(Taylor, 
Vaughan-
Thomas et al. 
2009) 
MMP1 Forward: 5’- GGTGAAGGAAGGTCAAGTTCTGAT -3’ 
Reverse: 5’- AGTCTTCTACTTTGGAAAAGAGCTTCT -3’ 
(Garvican, 
Vaughan-
Thomas et al. 
2008) 
MMP3 Forward: 5’- GCACATGCCGTGACTTGAGA-3’ 
Reverse: 5’- CCTATGGAAGGTGACTCCATGTG -3’ 
(Garvican, 
Vaughan-
Thomas et al. 
2008) 
MMP13 Forward: 5’- CTGGAGCTGGGCACCTACTG -3’ 
Reverse: 5’- ATTTGCCTGAGTCATTATGAACAAGAT-3’ 
(Garvican, 
Vaughan-
Thomas et al. 
2008) 
GAPDH Forward: 5’- GCATCGTGGAGGGACTCA -3’ 
Reverse: 5’- GCCACATCTTCCCAGAGG-3’ 
(Taylor, 
Vaughan-





Figure 2.1 Tenocyte viability and contraction of CG scaffolds. (A) Metabolic activity of 
tenocytes at days 1 and 14 for all nine CG scaffold groups. (B) Normalized number of cells 
(relative to number initially seeded) at day 14 for all nine CG scaffold groups. (C) Scaffold 
contraction, normalized to the initial scaffold diameter, at days 1, 4, 7, and 14 for all nine CG 
scaffold groups. Data expressed as mean ± SEM (n=6). ˅ : significantly (p < 0.01) lower than initial 
scaffold diameter. †: significantly (p < 0.01) different than scaffolds of same pore size with lowest 
(1:1:5) crosslinking density. ‡: significantly (p < 0.01) different than scaffolds of same pore size 
with middle (5:2:5) crosslinking density. *: significantly (p < 0.01) different from scaffolds of 
same crosslinking density with largest pore size (-10°C Tf). #: significantly (p < 0.01) different 
from scaffolds of same crosslinking density with middle pore size (-40°C Tf). 
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Figure 2.2 Structural protein gene expression. Expression levels of (A) COL1A2, (B) COL3A1, 
(C) COMP, and (D) DCN after 14 days in all 9 scaffold groups. Data expressed as mean ± SEM 
(n=3). †: significantly (p < 0.01) different than scaffolds of same pore size with lowest (1:1:5) 
crosslinking density. ‡: significantly (p < 0.01) different than scaffolds of same pore size with 
middle (5:2:5) crosslinking density. *: significantly (p < 0.01) different from scaffolds of same 
crosslinking density with largest pore size (-10°C Tf). #: significantly (p < 0.01) different from 




Figure 2.3 Tendon phenotype gene expression. Expression levels of (A) SCXB and (B) TNC 
after 14 days in all 9 scaffold groups. Data expressed as mean ± SEM (n=3). †: significantly (p < 
0.01) different than scaffolds of same pore size with lowest (1:1:5) crosslinking density. ‡: 
significantly (p < 0.01) different than scaffolds of same pore size with middle (5:2:5) crosslinking 
density. *: significantly (p < 0.01) different from scaffolds of same crosslinking density with 
largest pore size (-10°C Tf). #: significantly (p < 0.01) different from scaffolds of same crosslinking 




Figure 2.4. MMP gene expression. (A) MMP 1, (B) MMP3, and (C) MMP13 expression levels 
at days 1, 4, 7, and 14 relative to normalized scaffold diameter for all 9 scaffold groups. Data 
expressed as mean ± SEM (n=3). The degree of correlation (R2) was between gene expression and 
scaffold contraction was determined as a function of experimental time point (day 1, 4, 7, and 14).  
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Figure 2.5: Structural protein gene expression (1). Expression levels of (A) COL1A2 and (B) 
COL3A1 in all 9 scaffold groups at days 1, 4, 7, and 14. Data expressed as mean ± SEM (n=3). †: 
significantly (p < 0.01) different than scaffolds of same pore size with lowest (1:1:5) crosslinking 
density. ‡: significantly (p < 0.01) different than scaffolds of same pore size with middle (5:2:5) 
crosslinking density. *: significantly (p < 0.01) different from scaffolds of same crosslinking 
density with largest pore size (-10°C Tf). #: significantly (p < 0.01) different from scaffolds of 
same crosslinking density with middle pore size (-40°C Tf). ˅: significantly (p < 0.01) lower than 
expression at previous time point within group. ^: significantly (p < 0.01) than expression at 
previous time point within group.  
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Figure 2.6: Structural protein gene expression (2). Expression levels of (A) COMP, and (B) 
DCN in all 9 scaffold groups at days 1, 4, 7, and 14. Data expressed as mean ± SEM (n=3). †: 
significantly (p < 0.01) different than scaffolds of same pore size with lowest (1:1:5) crosslinking 
density. ‡: significantly (p < 0.01) different than scaffolds of same pore size with middle (5:2:5) 
crosslinking density. *: significantly (p < 0.01) different from scaffolds of same crosslinking 
density with largest pore size (-10°C Tf). #: significantly (p < 0.01) different from scaffolds of 
same crosslinking density with middle pore size (-40°C Tf). ˅: significantly (p < 0.01) lower than 
expression at previous time point within group. ^: significantly (p < 0.01) than expression at 
previous time point within group.  
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Figure 2.7: Tendon phenotype gene expression. Expression levels of (A) SCXB and (B) TNC in 
all 9 scaffold groups at days 1, 4, 7, and 14. Data expressed as mean ± SEM (n=3). †: significantly 
(p < 0.01) different than scaffolds of same pore size with lowest (1:1:5) crosslinking density. ‡: 
significantly (p < 0.01) different than scaffolds of same pore size with middle (5:2:5) crosslinking 
density. *: significantly (p < 0.01) different from scaffolds of same crosslinking density with 
largest pore size (-10°C Tf). #: significantly (p < 0.01) different from scaffolds of same crosslinking 
density with middle pore size (-40°C Tf). ˅: significantly (p < 0.01) lower than expression at 
previous time point within group. ^: significantly (p < 0.01) than expression at previous time point 
within group.  
 43 
 
Figure 2.8: MMP gene expression. Expression levels of (A) MMP1, (B) MMP3, and (C) MMP13 
in all 9 scaffold groups at days 1, 4, 7, and 14. Data expressed as mean ± SEM (n=3). †: 
significantly (p < 0.01) different than scaffolds of same pore size with lowest (1:1:5) crosslinking 
density. ‡: significantly (p < 0.01) different than scaffolds of same pore size with middle (5:2:5) 
crosslinking density. *: significantly (p < 0.01) different from scaffolds of same crosslinking 
density with largest pore size (-10°C Tf). #: significantly (p < 0.01) different from scaffolds of 
same crosslinking density with middle pore size (-40°C Tf). ˅: significantly (p < 0.01) lower than 
expression at previous time point within group. ^: significantly (p < 0.01) than expression at 
previous time point within group.   
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CHAPTER 3: CYCLIC TENSILE STRAIN ENHANCES HUMAN MESENCHYMAL 
STEM CELL Smad 2/3 ACTIVATION AND TENOGENIC DIFFERENTIATION IN 
ANISOTROPIC COLLAGEN-GLYCOSAMINOGLYCAN SCAFFOLDS3 
3.1 Chapter overview 
In this chapter, the influence of intermittent cyclic tensile strain on the tenogenic differentiation 
potential of MSCs in aligned CG scaffolds is explored using a custom bioreactor system. The 
initial work focused on the design and fabrication of a bioreactor that is suitable for the use with 
porous 3D materials. Then, the immediate impact of cyclic tensile strain on MSC-scaffold 
interactions and mechanotransduction pathway activation were evaluated in order to validate an 
appropriate loading paradigm for extended culture. The validated loading paradigm was then 
applied over the course of a 7-day experiment and the resulting impact on cellular activity, 
tenogenic differentiation, and Smad pathway activation are assessed.  
3.2 Introduction 
Tendon and ligament injuries pose a significant challenge for medical professionals, affecting a 
wide range of individuals, from athletes to the elderly, with more than 32 million occurrences 
every year in the US alone (James, Kesturu et al. 2008; Liu, Ramanath et al. 2008; Xu and Murrell 
2008; Breidenbach, Gilday et al. 2013). While not all injuries require surgical intervention, many 
classes of these injuries, such as rotator cuff and Achilles tendon tears, account for more than 
100,000 surgeries per year in the US (Vitale, Vitale et al. 2007; Pedowitz and Kirwan 2013) and 
can show wide ranges of re-failure rates based on patient demographics (Galatz, Sandell et al. 
2006). Tendon and ligament defects generally display poor intrinsic healing properties, requiring 
                                                 
 
3 This chapter has been adapted from the following publication: 
Grier, W. G., A. S. Moy, et al. (2017). "Cyclic tensile strain enhances human mesenchymal stem cell Smad 2/3 
activation and tenogenic differentiation in anisotropic collagen-glycosaminoglycan scaffolds." European cells & 
materials 33: 227-239. 
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surgical intervention.  These result in fibrous scar tissue formation with misaligned extracellular 
matrix (ECM) and inferior mechanical properties, leading to high rates of injury recurrence (James, 
Kesturu et al. 2008; Liu, Ramanath et al. 2008; Xu and Murrell 2008). As a result, tissue 
engineering solutions, particularly those that are able to address the geometrically aligned and 
mechanically dynamic nature of these tissues, are becoming researched at an increasing rate in 
order to address the shortcomings of current surgical procedures and to improve outcomes from 
injury. 
Collagen-glycosaminoglycan (CG) scaffolds have been used in a wide variety of tissue 
engineering applications for skin, peripheral nerve, and cartilage tissue engineering, as well as 3D 
environments for in vitro studies of cell-matrix interactions (cell, migration and contraction) 
behavior (Yannas, Lee et al. 1989; Schulz Torres, M. Freyman et al. 2000; Harley, Spilker et al. 
2004; O'Brien, Harley et al. 2005; Farrell, O'Brien et al. 2006; Harley, Freyman et al. 2007; Harley, 
Kim et al. 2008). We have recently developed a fabrication method to produce anisotropic CG 
scaffolds composed of an aligned ellipsoidal pore structure for applications in tendon repair 
(Caliari and Harley 2011). The anisotropic scaffold microstructure promotes cell alignment along 
the long axis of the ellipsoidal pores (Caliari and Harley 2011), resists tenocyte-mediated 
contraction and loss of tenogenic gene expression profiles (Caliari, Weisgerber et al. 2012; Grier, 
Iyoha et al. 2017), and promotes mesenchymal stem cell (MSC) elongation and differentiation 
towards a tenogenic phenotype in the absence of applied cyclic strain or exogenous growth (Caliari 
and Harley 2011; Caliari and Harley 2014). While promising, these initial findings suggested the 
need to improve the structural mechanics of the materials. By incorporating structural 
reinforcement elements, one can make the scaffold more mechanically robust for in vivo 
applications (Mozdzen, Rodgers et al. 2016; Mozdzen, Vucetic et al. 2017). As a result, there is a 
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specific need to identify culture conditions to enhance tenogenic differentiation and promote 
extracellular matrix remodeling in order to ensure the scaffold would remain structurally 
competent and fully integrate into a wound repair site.  
Mechanical stimulation has shown significant value in musculoskeletal tissue engineering 
applications. Matrix mechanical cues have shown to be important tools for altering stem cell 
differentiation profiles (Engler, Bacakova et al. 2004; Janmey and McCulloch 2007; Hao, Zhang 
et al. 2013). Of particular interest to tendon applications, mechanical force has been shown to be 
a critical element during development in the recruitment of scleraxis-expressing cells to the 
tendon-bone-junction enthesis (Schweitzer, Zelzer et al. 2010; Chen, Yin et al. 2012) as well as to 
promote rehabilitative healing of the enthesis after injury (Thomopoulos, Zampiakis et al. 2008; 
Galloway, Lalley et al. 2013). In addition to playing a role in development, mechanotransduction 
pathways activated through microstructural cues and applied mechanical stimulation can influence 
stem cell activation and differentiation. Substrate alignment and stiffness can activate canonical 
RhoA/ROCK1 and FAK pathways to promote MSC differentiation towards musculoskeletal 
lineages (Sarasa-Renedo, Tunç-Civelek et al. 2006; Xu, Song et al. 2011; Allen, Cooke et al. 2012; 
Xu, Song et al. 2012; Andalib, Lee et al. 2013; Kanazawa, Furumatsu et al. 2014). As a result of 
this increased focus on mechanical cues, bioreactors capable of providing mechanical strain to 
cell-seeded biomaterials are of particular interest in recent tendon and ligament tissue engineering 
applications. Here, applied cyclic tensile strain can promote the phosphorylation of ERK 1/2 via 
RhoA activation (Laboureau, Dubertret et al. 2004) and the upregulation of procollagen mRNA 
(Papakrivopoulou, Lindahl et al. 2004). As a result, many studies have focused on identifying 
strain profiles to prolong ERK 1/2 activation to promote cell-mediated ECM biosynthesis (Paxton, 
Hagerty et al. 2012). The p38 mitogen-activated protein kinase pathway inhibits ERK 1/2 
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activation (Papakrivopoulou, Lindahl et al. 2004; Weinbaum, Schmidt et al. 2013), suggesting an 
alternate target for promoting ECM biosynthesis. In the related area of biomaterial for ligament 
repair, Paxton et al. demonstrated that MSCs in fibrin hydrogels showed increased ERK 1/2 
activation when exposed to an intermittent cyclic tensile strain paradigm where the constructs were 
subjected to 10% strain at 1 Hz for just 10 minutes every 6 hours (Paxton, Hagerty et al. 2012). 
Maximal re-activation and sustained activation of ERK 1/2 required 6 hour periods of rest after 
the initial application of strain, thought to be a mediated by residual phosphorylated p38 inhibiting 
ERK 1/2 re-phosphorylation.  
The Smad 2/3 and Smad 1/5/8 pathways play a crucial role in the development of musculoskeletal 
tissues, primarily through regulating the action of the TGF-β and BMP family of growth factors 
on cell differentiation and activity (Miyazono 2000; Shi and Massague 2003; Maeda, Sakabe et al. 
2011; Allen, Cooke et al. 2012). Activation of Smad 1/5/8 by BMP-2 plays an important role in 
MSC osteogenic differentiation while the activation of Smad 2/3 by TGF-β plays a critical role in 
tendon and ligament development (Towler and Gelberman 2006; Maeda, Sakabe et al. 2011; Shen, 
Gelberman et al. 2013). Recent work by Berthet et al. also showed activated Smad 3 binds to the 
Scleraxis (SCXB) and Mohawk (MKX) transcriptional regulators during tendon matrix 
development (Berthet, Chen et al. 2013). Efforts by the Alliston lab also reported that crosstalk 
between mechanical stimuli and growth factor supplementation could both activate Smad 1/5/8 as 
well as drive a feedback loop driven by subsequent endogenous growth factor production to 
enhance musculoskeletal differentiation (Allen, Cooke et al. 2012). And while the vast majority of 
this body of work has primarily employed 2D culture environment, it motivates new efforts to 
define linkages between the mechanical microenvironment of the cell, smad activation and 
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endogenous growth factor production, as well as subsequent stem cell differentiation and tissue 
development.  
Here we describe the development of a bioreactor system to facilitate the culture and analysis of 
MSC-seeded collagen-GAG scaffolds under physiological levels of cyclic tensile strain (CTS). 
Based on a design previously described by Levenston et al. (Vanderploeg, Wilson et al. 2008; 
Doroski, Levenston et al. 2010), this bioreactor allows parallel culture of 24 distinct biomaterial 
constructs in individually isolated wells. Many early bioreactor systems employed clamps to grip 
and pull on the ends of cell-seeded materials (Bosworth, Rathbone et al. 2014), though many 
clamping approaches require the ends of the substrate to be crushed or significantly deformed to 
prevent slippage, which is not suitable for extended culture of porous biomaterial scaffolds. As a 
result, recent efforts have focused on the use of yarn or textile style biomaterials that show less 
deformation from clamps or can be looped or tied around loading posts (Paxton, Hagerty et al. 
2012; Bosworth, Rathbone et al. 2014). Unfortunately, neither of these approaches lend themselves 
to use with porous biomaterials. Temenoff et al. recently described a potentially translatable 
approach where a hydrogel substrate was infiltrated into porous polymeric end blocks that could 
be securely griped within a bioreactor (Doroski, Levenston et al. 2010). Here, we used 
Polydimethylsiloxane (PDMS) to infiltrate both the ends of the CG scaffolds as well as porous, 
polymeric end blocks to facilitate immobilization of the porous CG scaffold within the bioreactor. 
We report the effect of cyclic tensile strain on activation of MSC mechanotransduction pathways 




3.3 Materials and Methods 
All materials were purchased from Sigma-Aldrich (St Louis, MO) unless otherwise specified. 
Fabrication of collagen-GAG scaffolds 
Type 1 microfibrillar collagen from bovine tendon (Collagen Matrix Inc. Oakland, NJ) and 
chondroitin sulfate from shark cartilage (Sigma-Aldrich, St. Louis, MO) were homogenized in 
0.05M acetic acid at a ratio of collagen to glycosaminoglycan at 11.25:1 (Yannas, Lee et al. 1989; 
Madaghiele, Sannino et al. 2008). Anisotropic scaffolds were fabricated via lyophilization using a 
previously described directional solidification approach (O'Brien, Harley et al. 2004; Caliari and 
Harley 2011). Briefly, degassed CG suspension was pipetted into wells (6mm diameter, 30mm 
deep) within in a polytetrafluoroethylene (PTFE) mold with a copper bottom that was then placed 
on a pre-cooled (-10oC) freeze-dryer shelf (VirTis, Gardner, NY). The mismatch in thermal 
conductivity between the PTFE body and copper base of the mold promotes unidirectional heat 
transfer through the more conductive copper (Caliari and Harley 2011). The CG suspension was 
frozen at -10°C for 2h, and then sublimated at 0°C and 200mTorr to remove the ice crystals, 
resulting in a dry porous scaffold. Following lyophilization, scaffolds crosslinked via 
dehydrothermal (DHT) crosslinking in a 105°C oven (Welch, Niles, IL) under vacuum (<25torr) 
for 24 hours and then stored in a desiccator until use.  
Bioreactor design 
Inspired by a previous design from the Levenston lab (Doroski, Levenston et al. 2010), the cyclic 
tensile strain bioreactor system consisted of a sliding rake system that was controlled by a linear 
motor actuator and controller (Fig. 3.1A) (Pololu Corp. Las Vegas, NV). The motor was controlled 
using a custom C# program. A total of 24 modular wells were constructed with a static loading 
post at one end. The modular nature of the wells allows for easy adaptation to various scaffold 
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sizes and geometries. For static controls, a separate set of wells of identical geometry with two 
posts at a fixed distance was constructed. The ends of dry CG scaffolds were embedded into hollow 
end blocks fabricated via additive manufacturing that could be affixed to the static and loading 
posts within the bioreactor. In order to measure scaffold strain as a function of bioreactor settings, 
dry scaffolds were marked with black India Ink (Dick Blick Art Materials, Galesburg, IL) (Fig. 
3.1B). Video was then taken while the bioreactor was in motion using a Canon EOS-5D Mark II 
SLR 21.1MP Digital Camera (Canon, Tokyo, Japan). Individual frames were then converted to 
grayscale image sequences and imported into ImageJ where the distance between each mark was 
then measured using the Object Tracker plugin. Overall strain was calculated by normalizing the 
distance between each point to the initial length and then averaging across the entire scaffold (Fig. 
3.1C). Due to tolerances required to insert the scaffolds into the bioreactor, a discrepancy in 
applied system strain (movement of the sliding rake system) and resultant scaffold deformation 
was observed. Throughout the experiment, we will refer to the magnitude of applied strain as the 
movement of the sliding rake system. 
Embedding scaffolds into loading blocks 
Hollow end blocks were fabricated from acetyl-butyl-styrene (ABS) using a Makerbot Replicator 
2X 3D printer (MakerBot Industries, Brooklyn, NY). One side of the end blocks was designed to 
fit over the loading posts of the bioreactor system (5 mm dia.) while the other end was open to 
allow for the ends of the scaffolds to be inserted (6 x 6 mm). End blocks were filled with a 5:1 
solution of polydimethylsiloxane (PDMS): catalyst (Hisco Inc. Houston, TX). After allowing the 
PDMS to cure at 37°C for 45 minutes, 5 mm of one end of 25mm long CG scaffolds was inserted 
into the PDMS in the end block, then allowed to cure overnight at 37°C. This was then repeated 
with the opposite side of the scaffold, resulting in a 15 mm gauge length (Fig 3.1B). 
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Scaffold crosslinking 
After embedding, scaffolds were immersed in 200-proof ethanol for 6 hours, followed by washing 
with phosphate-buffered saline (PBS) overnight. The scaffolds were then crosslinked via 
carbodiimide chemistry. Scaffolds were soaked in a solution of 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 
(NHS) at a molar ratio of 5:2:1 EDC:NHS:COOH in PBS for 2hr at room temperature (Olde 
Damink, Dijkstra et al. 1996; Harley, Leung et al. 2007). After crosslinking, the scaffolds were 
washed twice in sterile PBS before seeding. 
Critical point drying and SEM analysis 
Scaffold microstructure was examined after carbodiimide crosslinking. First, each scaffold was 
dehydrated using a series of washes with ethanol from 10% to 100% concentration followed by 
subjection to critical point drying (CPD) using a Samdri-PVT-3D (Tousimis, Rockville, MD). The 
CPDD process replaces the ethanol with liquid CO2, and held above 1072 PSI and 31°C allowing 
the CO2 to be gently removed from the system as a gas with minimal structure deformation. The 
samples were then sectioned by cutting and mounted on carbon tape before sputter coating with a 
gold/palladium mixture. Imaging was then carried out with a Philips XL30 ESEM-FEG (FEI 
Company, Hillsboro, OR) at 5 kV with a secondary electron detector.  
Human mesenchymal stem cell culture 
Human bone marrow-derived MSCs were purchased from Lonza (Walkersville, MD). Cells from 
multiple lots originating from separate donors were combined to account for any donor-specific 
responses. The MSCs were cultured in a complete MSC growth medium, consisting of low-glucose 
Dulbecco’s Modified Eagle Medium with 10 vol% MSC fetal bovine serum and 1 vol% antibiotic-
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antimitotic (Thermo Fisher, Waltham, MA), at 37°C and 5% CO2, fed twice a week, and used at 
passage 6 for all experiments. 
Culture of MSC-seeded CG scaffolds 
CG scaffolds embedded in end blocks (6 mm diameter, 15 mm gauge length) were seeded with 
MSCs using a previously validated static seeding method (O'Brien, Harley et al. 2005). Briefly, 
scaffolds were partially dried with Kimwipes and seeded with 3.0×105 MSCs per 60 μL media 
(3x20 μL drops along scaffold length) in the individual wells of the bioreactor system. Cells were 
allowed to attach for 1 hour before submerging in media; constructs were given an additional 24 
hours before application of CTS to ensure cell attachment. Cell-seeded scaffolds in the CTS groups 
were subjected to continuous cyclic tensile strain (10% strain at 1 Hz) for 10 – 120 minutes to 
demonstrate the activation of mechanotransduction pathways. For extended culture examining 
MSC differentiation, scaffolds were subjected to intermittent CTS (10% strain, 1 Hz) for 10 
minutes every 6 hours for up to 6 days using a protocol inspired by Paxton et al. (Paxton, Hagerty 
et al. 2012) to allow for sufficient cellular refractory period to ensure prolonged effects. Cell-
seeded scaffolds were cultured at 37°C and 5% CO2 and fed twice a week with complete MSC 
growth medium. For static controls, scaffolds were placed into a separate set of wells of identical 
geometry to the bioreactor but which contained two posts at a fixed distance equal to that of the 
bioreactor at rest. During the experiment, scaffolds were collected for further analysis immediately 
after the conclusion of a strain cycle by physically separating them from the end blocks by cutting.  
Protein Extraction, gel electrophoresis, and immunoblotting  
Following stretch, scaffolds were briefly washed in warm phosphate-buffered saline, blotted dry, 
and then submerged in RIPA buffer with 1/100 dilutions of protease and phosphatase II and III 
inhibitor cocktails and kept on ice for 30 minutes with regular agitation. Total protein 
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concentration was determined by the BCA assay kit (Pierce). For gel electrophoresis, 10 µg of 
protein from each sample was solubilized in an equal volume Laemmli sample buffer and heated 
to 90°C for 10 minutes. Total lysates were separated by tris-glycine gel electrophoresis on 4-20% 
gradient gels using a constant 150V for 90 minutes. Following electrophoresis, a semi-dry transfer 
was used to transfer proteins to a nitrocellulose membrane (GE Healthcare) at 15 V for 15 min. 
Membranes were then blocked for 1 hour in 5% milk in Tris-buffered-saline + 0.1% Tween 
(TBST). Membranes were incubated overnight at 4°C with the appropriate primary antibody in 
5% bovine serum albumin in TBST. The membrane was then washed three times in TBST before 
incubation for 1 hour at room temperature with HRP-linked goat anti-rabbit IgG secondary 
antibody (1:5,000. Cell Signaling) in TBST. Antibody binding was then detected using 
SuperSignal West Pico or Femto Chemiluminescent Substrate (Thermo Fisher, Waltham, MA). 
After probing, membranes were stripped with OneMinute® Western Blot Stripping Buffer (GM 
Biosciences, Rockville, MD) and re-probed up to two times following the same protocol. 
Antibodies were purchased from Cell Signaling (Danvers, MA): ROCK1 (4035), FAK (3285), 
pFAK (3283), p38 (8690), p-p38 (9215), ERK 1/2 (4695), pERK 1/2 (4370), Smad 2/3 (8685), 
pSmad 2/3 (8828), Smad 1 (6944), pSmad 1/5/8 (9511), β-actin (4967). Imaging was carried out 
using an Imagequant LAS 4010 system (GE Healthcare) and ImageJ was used for band intensity 
quantification. 
Quantifying cell number and metabolic activity 
A previously described DNA quantification assay was used to determine the number of cells 
attached to the scaffold (Kim, Sah et al. 1988). Briefly, scaffolds were washed in PBS to remove 
unattached cells, placed in a papain solution to digest the scaffold and lyse the cells in order to 
expose their DNA, then incubated with a Hoechst 33258 dye (Invitrogen, Carlsbad, CA) to 
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fluorescently label double-stranded DNA. Fluorescence intensities (352/461 nm 
excitation/emission) from each sample were read using a fluorescence spectrophotometer (Tecan, 
Männedorf, Switzerland) and then compared to a standard curve created from known numbers of 
MSCs.  
The mitochondrial metabolic activity of the MSCs within each scaffold was determined through 
the use of non-destructive alamarBlue® assay as previously described (Tierney, Duffy et al. 2013). 
Cell-seeded scaffolds were incubated in the alamarBlue solution (Invitrogen, Carlsbad, CA) with 
gentle shaking for 1 h. The reduction of resazurin in the solution by metabolically active cells to 
the fluorescent by-product resorufin was measured on a fluorescent spectrophotometer. Relative 
cell metabolic activity was determined from a standard curve generated from known cell numbers 
prior to seeding the scaffolds and reported as a percentage of the total number of seeded cells. 
RNA isolation and real-time PCR 
RNA was extracted from the MSC-seeded scaffolds at days 1, 4, 7, and 14, using an RNeasy Plant 
Mini kit (Qiagen, Valencia, CA). RNA was then was reverse transcribed to cDNA in a Bio-Rad 
S1000 thermal cycler using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) as 
previously described (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012). Real-time 
PCR reactions were carried out in triplicate, using 10ng of cDNA and QuantiTect SYBR Green 
PCR kit (Qiagen, Valencia, CA) in a 7900HT Fast Real-Time PCR system (Carlsbad, CA). The 
primers used were consistent with previous studies, and were synthesized by Integrated DNA 
Technologies (Coralville, IA). The expression level of the following markers was quantified: 
collagen type I alpha 2 (COLIA2), collagen type III alpha 1 (COL3A1), cartilage oligomeric matrix 
protein (COMP), decorin (DCN), scleraxis (SCXB), tenascin-c (TCN), Mohawk homeobox (MKX), 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) which was used as a house keeping 
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gene (Table 3.1). Results were generated using the ΔΔCt method and all results were expressed as 
fold changes normalized to the expression levels of MSCs at the time of seeding the scaffolds. 
Statistical analysis 
One-way analysis of variance (ANOVA) was performed on the western blot, metabolic activity, 
cell number, and gene expression data sets (independent variable: strain condition) followed by 
Tukey-honest significant difference post hoc tests. Significance was set at p < 0.05. All statistical 
analysis was performed in R. Scaffolds from three independent experiments were analyzed at each 
time point for all metrics. Error is reported in figures as the standard error of the mean unless 
otherwise noted.  
3.4 Results 
Identifying the duration of tensile strain required to activate MSC mechanotransduction 
pathways within CG scaffolds 
We first examined whether the level of applied strain (5, 10, 15% strain) altered the activation of 
MSC mechanotransduction pathway, and found no significant difference in activation with level 
of tensile strain (data not shown). As a result, and inspired by previous studies showing optimal 
ligament cell response to 10% strain (Paxton, Hagerty et al. 2012), all subsequent studies were 
performed at 10% CTS. Initial activation of MSC mechanotransduction pathways in response to 
10% CTS at 1 Hz were monitored for up to two hours of continuous strain application. ROCK1 
expression was significantly reduced within 10 minutes of application of cyclic strain, and 
remained reduced for up to 2 hours of CTS (Fig. 3.2A). Maximal activation of ERK 1/2 was seen 
after 10 minutes of CTS stimulation, but was significantly reduced when CTS was maintained for 
longer time periods (30m – 2 h). The reduction in ERK 1/2 activation was associated with an 
increase in p38 activity starting by 30 minutes of CTS (Fig. 3.2B). In order to maximize ERK 1/2 
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activation for long-term, subsequent experiments used an intermittent strain paradigm with 10 
minutes of CTS followed by 5 hours 50 minutes rest to facilitate recovery of baseline ERK 1/2 and 
p38 expression (Paxton, Hagerty et al. 2012).  
Intermittent tensile strain alters MSC proliferation and metabolic activity 
MSC metabolic activity and cell number were monitored over the course of 6 days of culture with 
and without CTS (10% strain, 1Hz, for 10 minutes every 6 hours). While not statistically 
significant (p = 0.12), MSCs subjected to CTS trended towards increased metabolic activity during 
the first three days of culture. However, by the end of the 6 days, there was no noticeable increase 
or decrease in the metabolic activity of the cell populations with or without CTS (Fig. 3.3A). While 
there were no significant changes in total cell number in the scaffolds between days 1 and 6 within 
either the Static or CTS cultures, Static cultures showed significantly greater total number of cells 
compared to CTS at day 6 (Fig. 3.3B) (p < 0.01), suggesting the metabolic activity per cell is 
enhanced in response to CTS throughout the experiment. 
Cyclic tensile strain promotes activation of tendon-related genes 
We subsequently examined expression levels of a series of tendon-phenotype related genes TNC, 
MKX, and SCXB over the course of the experiment. The tenogenic transcription factor SCXB was 
significantly upregulated as rapidly as 24 hours (p = 0.017) in response to CTS and was found to 
be more strongly expressed in CTS culture for the remainder of the experiment (Fig. 3.4A). 
Expression levels of the transcription factor MKX and tendon-associated glycoprotein TNC showed 
little difference between CTS and static groups at days 1 and 3 (Fig. 3.4B,C). While not always 
significant, expression levels for all three genes trended towards being increased after 6 days with 
CTS when compared to expression levels at day 1 with the effect of time significant for MKX. 
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Cyclic tensile strain promotes activation of ECM biosynthesis related genes 
We subsequently examined the effect of CTS on the expression of tendon-associated matrix 
biosynthesis genes. Expression levels of the primary tendon matrix component COL1A2 was 
similarly expressed between CTS and static culture throughout the duration of the 6-day culture 
(Fig. 3.5A). However, levels of COL3A1, a critical element of tendon healing due to its ability to 
catalyze formation of rapid crosslinks to stabilize the repair site (Liu, Yang et al. 1995), increased 
significantly after days 3 and 6 with CTS. By day 6 COL3A1 expression was significantly higher 
in response to CTS versus static culture (p = 0.024) (Fig. 3.5B). DCN, a regulator of the assembly 
of collagen fibrils during tendon development (Zhang, Ezura et al. 2006), was found to increase at 
each time point in the anisotropic scaffolds, and expression was significantly higher after day 6 
with CTS. (Fig. 3.5C). CTS also promoted higher expression levels of the tendon-associated 
matrix gene COMP at all three time points, especially at day 6 (Fig. 3.5D), where expression levels 
in the static control group were almost completely lost (p < 0.001). 
Smad 2/3 pathway is activated in the presence of cyclic tensile strain 
The activation of the Smad 2/3 and Smad 1/5/8 pathways in MSCs within the CG scaffold was 
evaluated after 24 hours of CTS and again after 6 days of culture. At day 6, expression levels of 
Smad 2/3 were significantly increased for MSCs within scaffolds cultured under CTS conditions 
(Fig. 3.6A). However, activation of the Smad 1/5/8 pathway was not significantly altered by the 
application of cyclic strain at the time points examined (Fig. 3.6B).  
3.5 Discussion 
Mechanical stimulation, in the form of cyclic tensile strain, has been shown to be a critical 
regulator in the development of the tendon enthesis and in the regulation of stem cell fate decisions 
(Murchison, Price et al. 2007; Blitz, Viukov et al. 2009; Pryce, Watson et al. 2009; Schweitzer, 
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Zelzer et al. 2010). Our group has recently described an approach to fabricate CG scaffolds with 
an anisotropic pore geometry that is suitable for tendon tissue engineering applications (Caliari 
and Harley 2011). While the porous anisotropic CG scaffolds have been previously shown to 
support both the stable culture of differentiated tenocytes (Caliari, Weisgerber et al. 2012; Grier, 
Iyoha et al. 2017) as well as to induce tenogenic differentiation of MSCs (Caliari and Harley 2014), 
this work focused on the development of a custom bioreactor system to facilitate studies on 
mechanical stimulation of human MSCs in porous anisotropic CG scaffolds. Previous work using 
a variety of 2D and 3D constructs has shown that a number of protein kinases are activated in 
mesenchymal stem cells in response to tensile strain (Banes, Tsuzaki et al. 1995; Wang, Miyazu 
et al. 2001; Arnoczky, Tian et al. 2002). In particular, ERK 1/2 is believed to play an important 
role in the stretch-activated increase in collagen production (Papakrivopoulou, Lindahl et al. 2004), 
making it an important target for development of tendon repair biomaterial. To examine the effect 
of CTS on MSC response within the CG scaffold, we developed a 24-well tensile strain bioreactor 
inspired by previous work of Vanderploeg et al. (Vanderploeg, Wilson et al. 2008) that allows us 
to isolate individual samples and/or media at intermediate time-points to evaluate a range of 
different metrics. The programmable nature of the linear actuator further allows for easily tunable 
culture conditions (strain amplitude, rate, durations; refractory period), and the modular design 
enables adaptation to fit a wide range of scaffold geometries. In order to facilitate attachment of 
scaffolds within the bioreactor, a method inspired by the Temenoff lab’s procedure using end 
blocks to fix hydrogels between two posts was employed (Doroski, Levenston et al. 2010). By 
embedding the scaffold ends into hollow end blocks with PDMS, we were able to avoid scaffold 
deformation, tearing, or slippage as commonly seen with the traditional use of clamps. 
 59 
This work concentrates on initial metrics of MSC response to applied cyclic strain for up to 6 days. 
While not long enough to demonstrate extensive matrix remodeling in response to CTS, it did 
allow us to define MSC protein kinase response to applied cyclic tensile strain, with results here 
using CG scaffolds consistent with the antagonistic roles of ERK1/2 and p38 seen in 2D and 3D 
biomaterials (Banes, Tsuzaki et al. 1995; Wang, Miyazu et al. 2001; Arnoczky, Tian et al. 2002). 
Indeed, our examination of MSC response within porous collagen scaffolds within a tensile 
bioreactor showed time-resolved activation of ERK1/2 and p38 on a time scale of 10 to 30 minutes, 
consistent with previous result for Achilles tendon fibroblasts in fibrin hydrogels as reported by 
Paxton et al. (Paxton, Hagerty et al. 2012). More significantly, we showed the combination of CTS 
and an anisotropic CG scaffold is sufficient to establish critical cellular signatures of early tendon 
development in MSCs. CTS did not lead to negative effects on cell proliferation, and in fact 
increased metabolic activity per cell. Further, gene expression levels of markers of early tenogenic 
development (SCXB, TNC, MKX) as well as tendon-associated extracellular matrix proteins 
(COL3A1, COMP, DCN) were all generally elevated after 6 days in culture with mechanical 
stimulation. Indeed, the significant drop in COMP expression in static culture suggests that not 
only can CTS provide significant positive influence on remodeling associated genes, but that a 
lack of tensile stimulation has significant negative effects on cell activity and remodeling potential 
over time. This upregulation of traditional tendon markers, when taken in combination with the 
increase in metabolic activity on a per cell basis, demonstrates that CTS promotes robust 
differentiation of metabolically active MSCs towards an early tendon phenotype on aligned CG 
scaffolds.  
While previous work in our lab showed that an anisotropic microstructure was sufficient to drive 
initial tenogenic differentiation of MSCs within 7 days (Caliari and Harley 2014), the biomaterial 
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alone did not provide an adequate environment to promote robust expression of remodeling 
associated genes. With the development of this bioreactor system we show that intermittent cyclic 
tensile strain, when applied in an appropriate manner, can be used to improve MSC metabolic 
activity, enhance tenogenic differentiation, and show enhanced expression levels of key tendon-
associated ECM compounds (DCN, COMP, COL3A1). However, the lack of increases in other 
matrix remodeling genes such as COL1A2 after 7 days suggest the need for longer bioreactor 
cultures in future experiments. Findings here also suggest opportunities to continue to explore the 
canonical vs. non-canonical activation of Smad2/3. While previous efforts have largely 
concentrated on 2D cell cultures, our efforts using anisotropic CG scaffolds also demonstrate 
preferential activation of Smad 2/3 and enhanced tenogenic differentiation within 6 days of CTS, 
a finding well-aligned with previously reported responses. Cytoskeletal tension and matrix 
mechanical signals are known critical factors for Smad activation and TGF-β production (Skutek, 
van Griensven et al. 2001; Allen, Cooke et al. 2012; Rys, Monteiro et al. 2016). Further, heightened 
ERK 1/2 activity is a known element of non-canonical Smad pathway activation (Hayashida, 
Decaestecker et al. 2003). Together, this suggests that CTS applied to MSC-seeded CG scaffolds 
may drive non-canonical Smad activity via enhanced ERK 1/2 activation, leading to tenogenic 
differentiation as well as the endogenous production of TGF-β family growth factors which may 
then lead to canonical Smad2/3 activation and enhanced tenogenic differentiation. While the 
presence of such an autocatalytic feedback loop is not the subject of this project, ongoing efforts 
are now employing the bioreactor system developed and validated here to better elucidate the 
relationship between CTS, TGF-β associated growth factor signaling, Smad activation, and the 
role that these pathways play in the regulation of musculoskeletal tissue development. Such efforts 
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will also allow for a more focused approach to develop long-term culture systems to study in vitro 
scaffold remodeling and more mature tendon development.  
3.6 Conclusions 
This work demonstrates the use of a custom-designed cyclic tensile strain bioreactor to 
mechanically stimulate human MSCs in anisotropic CG scaffolds as a means to enhance 
proliferation and tenogenic differentiation. Intermittent CTS (10% applied strain, 1Hz, 10 minutes 
every 6 hours) was found to rapidly, stably upregulate mechanosensitive protein kinase activity. 
MSCs showed increased gene expression profiles of a range of tendon-related ECM proteins and 
phenotypic markers in response to CTS over the course of the experiment in the presence of applied 
CTS. Interestingly, we also found that Smad 2/3, but not Smad 1/5/8, was preferentially activated 
in MSCs exposed to extended CTS. This work demonstrates a pathway to refine mechanical 
stimulation protocols to enhance tenogenic differentiation and matrix biosynthesis for tendon 
repair applications. Given the design of the bioreactor that affords separate culture of each 
specimen, these findings also highlight significant opportunities to further define the role played 
by CTS on the endogenous production of growth factors that may further refine MSC 




Table 3.1 PCR primer sequences. 
Transcript Sequence Reference 
COL1A2 
 
Forward: 5’- TGACCTCAAGATGTGCCACT -3’ 
Reverse: 5’- ACCAGACATGCCTCTTGTCC -3’ 
(Pauly, Klatte et al. 2010) 
COL3A1 
 
Forward: 5’- GCTGGCATCAAAGGACATCG -3’  
Reverse: 5’- TGTTACCTCGAGGCCCTGGT -3’ 
(Pauly, Klatte et al. 2010) 
COMP 
 
Forward: 5’- GCAACACGGACGAGGACAAG -3’ 
Reverse: 5’- CGCCATCACTGTCCTTCTGG -3’ 




Forward: 5’- CGCCTCATCTGAGGGAGCTT -3’ 
Reverse: 5’- TACTGGACCGGGTTGCTGAA -3’ 
(Pauly, Klatte et al. 2010) 
SCXB 
 
Purchased from Qiagen (sequence unavailable) (Caliari and Harley 2014) 
MKX Forward: 5’- CGTATTGGAAGGAGATCAACG -3’ 
Reverse: 5’- GGACGACTTCTGGATGATGC -3’ 
(Lorda-Diez, Canga-
Villegas et al. 2013) 
TNC Forward: 5’- TTCACTGGAGCTGACTGTGG -3’ 
Reverse: 5’- TAGGGCAGCTCATGTCACTG -3’ 
(Pauly, Klatte et al. 2010) 
GAPDH Forward: 5’- CCATGAGAAGTATGACAACAGCC -3’ 
Reverse: 5’- CCTTCCACGATACCAAAGTTG -3’ 





Fig. 3.1 Custom cyclic strain bioreactor. (A) Custom bioreactor designed with 24 individual 
wells with static loading posts and moveable rake controlled by a programmable linear actuator. 
(B) Scaffolds (with fiduciary marks) embedded into hollow PLA end-blocks that can be attached 
on either end to the static loading post and movable rake within the bioreactor. (C) Superimposition 
of measured scaffold deformation in response to a range of system applied cyclic strain amplitudes 
(5 – 20%, all 1 Hz). Scaffold deformation is shown as mean ± SEM. (D) SEM image of aligned 




Fig. 3.2 Rapid activation of mechanotransduction pathways with applied cyclic tensile strain. 
(A) Expression of ROCK1 normalized to β-actin expression as a function strain cycle duration is 
rapidly down regulated in response to CTS (all at 10% strain, 1 Hz). (B) MSCs in CG scaffolds 
showed a sequential increase in the ratio of active (phosphorylated) to total protein for ERK 1/2 
(p/t ERK1/2) and then p38 MAPK (p/t p38), normalized to the ratio seen under static conditions, 
as a function of increasing time of applied CTS (10% applied system strain, 1 Hz). Data expressed 




Fig. 3.3 MSC viability in CG scaffolds undergoing CTS. (A) Metabolic activity of MSCs in CG 
scaffolds in either static culture or exposed to repeated cycles of CTS (10min at 10% strain and 1 
Hz) followed by 5 hours 50 minutes recovery at days 1, 3, and 6. (B) Normalized number of cells 
(relative to number initially seeded) at days 1 and 6 in both static and CTS groups. Data expressed 




Fig. 3.4 Changes on pro-tenogenic gene expression profiles in response to CTS. Expression 
levels of (A) SCXB, (B) TNC, and (C) MKX at days 1, 3, and 6 relative to cells at the time of 
seeding in both static and CTS groups. Data expressed as mean ± SEM (n = 3). b Significantly 
higher (p < 0.05) than static group at same day. a Significantly higher expression (p < 0.05) than 
day 1 within the same group. 
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Fig. 3.5 Changes in structural protein gene expression in response to CTS. Expression levels 
of (A) COL1A2, (B) COL3A1, (C) DCN, and (D) COMP at days 1, 3, and 6 relative to cells at the 
time of seeding in both static and CTS groups. Data expressed as mean ± SEM (n = 3). b 
Significantly higher (p < 0.05) than static group at same day. a Significantly higher expression (p 
< 0.05) than day 1 within the same group. c Significantly lower expression (p < 0.05) than both day 





Fig. 3.6 Differences in the activation of canonical vs. non-canonical Smad pathways for MSCs 
within the CG scaffold in response to CTS. Relative phosphorylation of (A) the non-canonical 
Smad 2/3 and (B) the canonical Smad 1/5/8 at days 1 and 6 as determined by immunoblot. Data 
expressed as mean ± SEM (n = 3). b Significantly higher (p < 0.05) than static group at same day.  
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CHAPTER 4: THE INFLUENCE OF CYCLIC TENSILE STRAIN ON MULTI-
COMPARTMENT COLLAGEN-GAG SCAFFOLDS FOR SPATIAL CONTROL OF 
MSC LINEAGE SELECTION4 
 
4.1 Chapter overview 
In chapters 2 and 3, we evaluated the use of single-compartment CG scaffolds with anisotropic 
pore structures for applications in tendon tissue engineering. Here, we apply the knowledge gained 
regarding cyclic tensile strain to multi-compartment scaffolds with distinct regions of structural 
anisotropy and mineral content designed for tendon-bone junction regeneration. The application 
of strain across a spatially-graded material results in variations in local strain profiles 
corresponding to the mechanics of each compartment. The local effects of strain in combination 
with local material properties are evaluated for alterations in the differentiation potential of MSCs 
in an effort to reproduce the organization of the native tendon-bone junction.  
 
4.2 Introduction 
The tendon-bone junction (TBJ), or enthesis, is a complex stratified region that functionally 
integrates tendon to bone to provide a smooth transition between the two dissimilar tissues (Moffat, 
Wang et al. 2009; Yang and Temenoff 2009). The aligned and elastic structure of tendon makes it 
very strong under tensional loads while the increased stiffness and mineral content of bone are 
more optimized for compressive loading. As a result, the interface between these two tissues are 
sites of high stress concentrations (Shaw and Benjamin 2007). In order to effectively dissipate 
these high stress concentrations while maintaining structural integrity, the TBJ displays opposing 
gradients in structural organization via collagen alignment and mineralization (Genin, Kent et al. 
                                                 
 
4 This chapter has been adapted from the following publication: 
Grier, W.K. M.D. Ramsey et al. (submitted). "The influence of cyclic tensile strain on multi-compartment collagen-
GAG scaffolds for tendon-bone junction regeneration." 
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2009; Lu and Thomopoulos 2013). Nevertheless, certain TBJs, such as in the rotator cuff, are prone 
to a variety of chronic and acute injuries. Unfortunately, the intricate nature of the enthesis is not 
naturally regenerated following surgical repair, which is characterized by the formation of 
disorganized scar tissue, resulting in high rates of recurrence (Lu and Thomopoulos 2013; Font 
Tellado, Balmayor et al. 2015). Improved techniques for the regeneration of the full spectrum of 
tendon-to-bone need to be developed with the future potential for the regeneration of a functional 
interface.  
Tissue engineering is an attractive strategy to improve on current standards for tissue interface 
regeneration. The extracellular matrix (ECM) environment in which a cell resides has been shown 
to be critical for tissue development by influencing cell proliferation, morphology, adhesion, and 
differentiation (Engler, Bacakova et al. 2004; Dalby, Gadegaard et al. 2014). Thus, many groups 
have developed biomaterial systems that mimic components of the native ECM across various 
orthopedic interfaces. The Gibson Group has previously developed a layered scaffold with distinct 
regions of mineral content and porous microstructure for osteochondral repair. (Harley, Lynn et 
al. 2010; Harley, Lynn et al. 2010; Lynn, Best et al. 2010).  A number of groups have developed 
polymeric biomaterial systems specifically for the tendon-bone interface with either gradients of 
mineral content (Lipner, Liu et al. 2014), or multiphase materials with separate regions for tendon, 
bone, and interface regeneration (Spalazzi, Dagher et al. 2008; Font Tellado, Bonani et al. 2017).   
Collagen-glycosaminoglycan (CG) materials are composed of natural ECM components and have 
shown great promise as tissue engineering scaffolds. Initially developed for a clinical dermal 
regeneration template, porous CG scaffolds are fabricated by freeze-drying acidic suspensions of 
type I collagen and glycosaminoglycans (Yannas, Lee et al. 1989). CG scaffolds have since been 
developed for a wide range of applications, including nerve (Chamberlain, Yannas et al. 2000), 
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cartilage (Vickers, Gotterbarm et al. 2010), and tendon (Caliari and Harley 2011; Caliari, 
Weisgerber et al. 2012). Calcium phosphate-mineralized variants have also been employed for 
bone applications (Harley, Lynn et al. 2010; Lee, Pereira et al. 2015; Ren, Bischoff et al. 2015; 
Weisgerber, Caliari et al. 2015; Ren, Tu et al. 2016; Ren, Weisgerber et al. 2016). By combining 
directional solidification and liquid cy-synthesis techniques we have previously developed a multi-
compartment CG scaffold with distinct regions of structural anisotropy and mineral content  with 
a continuous interface for TBJ regeneration (Caliari, Weisgerber et al. 2015). This material system 
was shown to promote the initial signs of spatially-selective tenogenic and osteogenic 
differentiation of human mesenchymal stem cells (MSCs), indicating that would be a promising 
candidate for future studies to regenerate the full spectrum from tendon to bone. 
While CGCaP scaffold variants alone have been shown to be sufficient for the robust regeneration 
of bone tissue (Ren, Bischoff et al. 2015), structural anisotropy can only drive an initial tenogenic 
response from MSCs. Generally, soluble growth factors have been required in order to induce a 
strong tenogenic response (Caliari and Harley 2014; Holladay, Abbah et al. 2014; Jiang, Gao et al. 
2016). Growth factors present complications for clinical applications due to their prohibitive cost, 
dosage requirements, and off-target effects (Lyons, Gleeson et al. 2014; Quinlan, Thompson et al. 
2015). As an alternative, many groups have explored the use of alternate treatment strategies, such 
as the application of low-amplitude cyclic tensile strain (CTS), in order to reproduce the unique 
mechanical environment of tendons for a more robust differentiation profile (Doroski, Levenston 
et al. 2010; Paxton, Hagerty et al. 2012; Bosworth, Rathbone et al. 2014; Govoni, Muscari et al. 
2016).  
Mechanical force has been shown to be important during the development of the TBJ (Schweitzer, 
Zelzer et al. 2010; Chen, Yin et al. 2012), as well as to promote rehabilitative healing of the 
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enthesis after injury (Thomopoulos, Zampiakis et al. 2008; Galloway, Lalley et al. 2013). Exposure 
to mechanical strain has been shown to lead to the phosphorylation of ERK 1/2 mitogen-activated 
protein kinase (MAPK) pathway via the activation of RhoA (Laboureau, Dubertret et al. 2004). 
The increased activity of ERK 1/2 has been shown to lead to the upregulation of procollagen 
mRNA (Papakrivopoulou, Lindahl et al. 2004). As a result, a number of tissue regeneration studies 
have focused on identifying strain paradigms to maximize ERK 1/2 activation in order to promote 
cell-mediated ECM deposition and remodeling (Paxton, Hagerty et al. 2012). The p38 MAPK 
pathway is known to inhibit ERK 1/2 activation after extended exposure to strain 
(Papakrivopoulou, Lindahl et al. 2004; Weinbaum, Schmidt et al. 2013), suggesting the need to 
use an intermittent strain paradigm to best promote ECM biosynthesis. Paxton et al. have 
previously demonstrated that tendon fibroblasts seeded in fibrin hydrogels showed increased ERK 
1/2 activation when exposed to an intermittent cyclic tensile strain paradigm (10% strain at 1 Hz 
for just 10 minutes every 6 hours) for ligament engineering applications (Paxton, Hagerty et al. 
2012). We have recently reported on the use of a CTS bioreactor system with a similar strain 
paradigm to promote increased tenogenic differentiation through the activation of growth factor-
associated pathways and upregulation of tendon-specific gene markers of MSCs on anisotropic 
CG scaffolds (Grier, Moy et al. 2017).   
Here, we integrate our previous work in multi-compartment CG biomaterials and CTS bioreactor 
systems to show that the application of an intermittent strain paradigm can elicit compartment-
specific cellular responses. The discrepancy in stiffness between the anisotropic and mineralized 
compartments results in the total scaffold strain being primarily distributed over the softer non-
mineralized region. Thus, it is expected that the effects of the CTS will be more pronounced in the 
regions with higher local strain. Additionally, the application of a dynamic loading profile may 
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lead to the preliminary development of an enthesis phenotype at the interface between the two 
compartments. We report the combined effects of cyclic tensile strain and scaffold microstructure 
and composition on spatially-selective MSC proliferation, mechanotransduction pathway 
activation, and differentiation in extended in vitro culture.  
4.3 Materials and Methods 
All materials were purchased from Sigma-Aldrich (St Louis, MO) unless otherwise specified. 
Preparation of collagen suspensions 
Two types of collagen suspensions were prepared. The first CG suspension consisted of 1 w/v% 
type 1 microfibrillar collagen from bovine tendon (Collagen Matrix Inc. Oakland, NJ) and heparin 
from porcine intestinal mucosa (Sigma-Aldrich, St. Louis, MO) were homogenized in 0.05M 
acetic acid at a ratio of collagen to glycosaminoglycan at 11.25:1 (Yannas, Lee et al. 1989; 
Madaghiele, Sannino et al. 2008). Next, a collagen-glycosaminoglycan-calcium phosphate 
(CGCaP) suspension was made by adding calcium salts (Ca(OH)2, Ca(NO3)2∙4H2O) to the 
collagen and heparin and by substituting phosphoric acid as the solvent (Harley, Lynn et al. 2010; 
Lynn, Best et al. 2010).  Both suspensions were homogenized at 12000 rpm and 4°C to prevent 
collagen denaturation as previously described (Yannas, Lee et al. 1989; O'Brien, Harley et al. 
2004). Following homogenization suspensions were stored overnight at 4°C and degassed prior to 
use.  
Multi-compartment scaffold fabrication via freeze-drying 
Multi-compartment scaffolds were fabricated by combining a previously described directional 
solidification approach (O'Brien, Harley et al. 2004; Caliari and Harley 2011) with a liquid-phase 
co-synthesis method (Harley, Lynn et al. 2010). First, degassed CG suspension was pipetted into 
wells (6mm diameter, 30mm deep) within in a polytetrafluoroethylene (PTFE) mold with a copper 
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bottom. Then, CGCaP suspension was carefully layered on top of the CG suspension in the mold 
in a 1:1 volume ratio (Fig. 4.1A). The mold was then placed on a freeze-dryer shelf (VirTis, 
Gardiner, NY) precooled to -10°C and maintained at this temperature for 2 h to complete freezing. 
The mismatch in thermal conductivity between the PTFE body and copper base of the mold 
promotes unidirectional heat transfer through the more conductive copper (Caliari and Harley 
2011). Following the freezing step, the frozen suspensions were then sublimated at 0°C and 
200mTorr to remove the ice crystals, resulting in a dry porous scaffold with a distinct mineralized 
CGCaP and aniostropically-aligned CG compartments with a continuous interfacial region (Fig. 
4.1B). Following lyophilization, a guide was used to trim the ends of each scaffold equidistant 
from the interface to a total length of 25 mm. The scaffolds were then stored in a desiccator until 
use. 
Embedding scaffolds into loading blocks 
As previously described (Grier, Moy et al. 2017), hollow end blocks were fabricated from acetyl-
butyl-styrene (ABS) using a Makerbot Replicator 2X 3D printer (MakerBot Industries, Brooklyn, 
NY). One side of the end blocks was designed to fit over the loading posts of the bioreactor system 
(5 mm dia.) while the other end was open to allow for the ends of the scaffolds to be inserted (6 x 
6 mm). End blocks were filled with a 5:1 solution of polydimethylsiloxane (PDMS): catalyst 
(Hisco Inc. Houston, TX). After allowing the PDMS to cure at 37°C for 45 minutes, 5 mm of one 
end of 25mm long CG scaffolds was inserted into the PDMS in the end block, then allowed to cure 
overnight at 37°C. This was then repeated with the opposite side of the scaffold, resulting in a 15 
mm gauge length. A group of 6 scaffolds was set aside and marked with black India Ink (Dick 
Blick Art Materials, Galesburg, IL) to be used for strain analysis. 
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Scaffold hydration and crosslinking 
Scaffolds were immersed in 200-proof ethanol for 6 hours, followed by washing with phosphate-
buffered saline (PBS) overnight. The scaffolds were then crosslinked via carbodiimide chemistry. 
Scaffolds were soaked in a solution of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) at a molar ratio of 5:2:1 
EDC:NHS:COOH in PBS for 2 hours at room temperature (Olde Damink, Dijkstra et al. 1996; 
Harley, Leung et al. 2007). After crosslinking, the scaffolds were washed twice in sterile PBS. 
Scaffolds designated for cell-seeding were soaked in complete MSC growth media, consisting of 
low-glucose Dulbecco’s Modified Eagle Medium with 10 vol% MSC fetal bovine serum and 1 
vol% antibiotic-antimitotic (Thermo Fisher, Waltham, MA), for 72 hours prior to seeding. 
Critical point drying and SEM analysis 
Scaffold microstructure was examined after crosslinking. First, each scaffold was dehydrated using 
a series of brief washes with ethanol from 10% to 100% concentration followed by subjection to 
critical point drying (CPD) using a Samdri-PVT-3D (Tousimis, Rockville, MD). The CPD process 
first replaces the ethanol with liquid CO2, and then holds the sample above 1072 PSI and 31°C 
allowing the CO2 to be gently removed from the system as a gas, minimizing any structural 
deformation. The samples were then sectioned and mounted on carbon tape prior to sputter coating 
with a gold/palladium mixture. Imaging was then carried out with a Philips XL30 ESEM-FEG 
(FEI Company, Hillsboro, OR) at 5 kV with a secondary electron detector.  
Bioreactor design 
The cyclic tensile strain bioreactor used in this study was previously described for use with 
monolithic anisotropic CG scaffolds for tendon regeneration (Grier, Moy et al. 2017). Inspired by 
a previous design from the Levenston lab (Doroski, Levenston et al. 2010), the main system 
 76 
consists of 24 loading and 24 stationary wells, a moveable rake, and a linear actuator and controller 
that are integrated with a custom C# program (Fig. 4.2A) (Pololu Corp. Las Vegas, NV). One end 
block on each scaffold was placed over the stationary loading post in each well while the other end 
block was interfaced with the rake. The high stiffness of the end blocks compared to the hydrated 
scaffolds allowed for the strain to be completely distributed along the length of the scaffold (Grier, 
Moy et al. 2017). For static controls, a separate set of wells with identical geometry to the 
bioreactor was constructed. These wells contained two posts at a fixed distance equal to that of the 
bioreactor at rest (Fig. 4.2B). In order to measure local scaffold strain as a function of bioreactor 
settings, the scaffolds that had been marked with India Ink were placed into the system. Video was 
then taken while the bioreactor was set to a 5% system strain at 1 Hz using a Canon EOS-5D Mark 
II SLR 21.1MP Digital Camera (Canon, Tokyo, Japan). Individual frames were then converted to 
grayscale image sequences and imported into ImageJ where the distance between each mark was 
then measured using the Object Tracker plugin. Overall strain was calculated by normalizing the 
distance between each point to the initial length and then averaging across the entire scaffold. 
Groups of points within each compartment were analyzed in order to determine compartment 
specific strain (Fig. 4.2C). Due to tolerances required to insert the scaffolds into the bioreactor, a 
discrepancy in applied system strain (movement of the sliding rake system) and resultant scaffold 
deformation was observed. A system setting of 5% strain translated to a 3.44 ± 0.05% overall strain 
with 5.69 ± 0.04% and 1.90 ± 0.11% strain in the CG and CGCaP compartments, respectively. 
Throughout the experiment, we will refer to the magnitude of applied strain as the movement of 




Human mesenchymal stem cell culture 
Human bone marrow-derived MSCs were purchased from Lonza (Walkersville, MD). Cells from 
multiple lots originating from separate donors were combined to account for any donor-specific 
responses. The MSCs were cultured in a complete MSC growth medium, at 37°C and 5% CO2, 
fed twice a week, and used at passage 6 for all experiments. 
Culture of MSC-seeded CG scaffolds 
CG scaffolds embedded in end blocks (6 mm diameter, 15 mm gauge length) were seeded with 
MSCs using a previously validated static seeding method (O'Brien, Harley et al. 2005). Briefly, 
scaffolds were partially dried with Kimwipes and seeded with 3.0×105 MSCs per 60 μL media 
(3x20 μL drops along scaffold length) in the individual wells of the bioreactor and static well 
systems. Cells were allowed to attach for 2 hours before submerging in media; constructs were 
given an additional 24 hours before application of CTS to ensure cell attachment. Cell-seeded 
scaffolds in the CTS groups were subjected to continuous cyclic tensile strain (5% overall strain 
at 1 Hz) for 10 minutes every 6 hours, for up to 6 days, using a protocol inspired by Paxton et al. 
(Paxton, Hagerty et al. 2012; Grier, Moy et al. 2017), to allow for sufficient cellular refractory 
period to ensure prolonged effects. Cell-seeded scaffolds were cultured at 37°C and 5% CO2 and 
fed twice a week with complete MSC growth medium. During the experiment, scaffolds were 
collected for further analysis at designated times, or immediately after the conclusion of a strain 
cycle, by physically separating them from the end blocks by cutting with a razor blade. A cutting 
guide was then used to cut the scaffolds into three sections for compartment-specific analysis, one 
each from the CG compartment, CGCaP compartment, and the middle third of the scaffold 
containing the interface.  
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Protein Extraction, gel electrophoresis, and immunoblotting  
Following stretch cycles, scaffold sections were briefly washed in warm phosphate-buffered 
saline, blotted dry, and then submerged in RIPA buffer with 1/100 dilutions of protease and 
phosphatase II and III inhibitor cocktails. The scaffold sections were then kept on ice for 30 
minutes with regular agitation. Total protein concentration was determined by the BCA assay kit 
(Pierce). For gel electrophoresis, 10 µg of protein from each sample was solubilized in an equal 
volume Laemmli sample buffer and heated to 90°C for 10 minutes. Total lysates were separated 
by tris-glycine gel electrophoresis on 4-20% gradient gels using a constant 150V for 90 minutes. 
Following electrophoresis, a semi-dry transfer was used to transfer proteins to a nitrocellulose 
membrane (GE Healthcare) at 15 V for 15 minutes. Membranes were then blocked for 1 hour in 
5% milk in Tris-buffered-saline + 0.1% Tween (TBST). Membranes were incubated overnight at 
4°C with the appropriate primary antibody in 5% bovine serum albumin in TBST. The membrane 
was then washed three times in TBST before incubation for 1 hour at room temperature with HRP-
linked goat anti-rabbit IgG secondary antibody (1:5,000. Cell Signaling) in TBST. Antibody 
binding was then detected using SuperSignal West Pico or Femto Chemiluminescent Substrate 
(Thermo Fisher, Waltham, MA). After probing, membranes were stripped with OneMinute® 
Western Blot Stripping Buffer (GM Biosciences, Rockville, MD) and re-probed up to two times, 
following the same protocol. Antibodies were purchased from Cell Signaling (Danvers, MA): p38 
(8690), p-p38 (9215), ERK 1/2 (4695), pERK 1/2 (4370), Smad 2/3 (8685), pSmad 2/3 (8828), 
Smad 1 (6944), pSmad 1/5/8 (9511), β-actin (4967). Imaging was carried out using an Imagequant 




Quantifying cell number and metabolic activity 
The mitochondrial metabolic activity of the MSCs within each scaffold section was determined 
through the use of non-destructive alamarBlue® assay as previously described (Tierney, Duffy et 
al. 2013). Cell-seeded sections were incubated in the alamarBlue solution (Invitrogen, Carlsbad, 
CA) with gentle shaking for 1 hour. The reduction of resazurin in the solution by metabolically 
active cells to the fluorescent by-product resorufin was measured on a fluorescent 
spectrophotometer. Relative cell metabolic activity was determined from a standard curve 
generated from known cell numbers prior to seeding the scaffolds and reported as a percentage of 
the total number of seeded cells. 
RNA isolation and real-time PCR 
RNA was extracted from the MSC-seeded scaffold sections at days 1, 3, and 6 using an RNeasy 
Plant Mini kit (Qiagen, Valencia, CA). RNA was then was reverse transcribed to cDNA in a Bio-
Rad S1000 thermal cycler using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) 
as previously described (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012). Real-time 
PCR reactions were carried out in triplicate, using 10ng of cDNA and QuantiTect SYBR Green 
PCR kit (Qiagen, Valencia, CA) in a 7900HT Fast Real-Time PCR system (Carlsbad, CA). The 
primers used were consistent with previous studies, and were synthesized by Integrated DNA 
Technologies (Coralville, IA). The expression level of the following markers was quantified: 
collagen type III alpha 1 (COL3A1), cartilage oligomeric matrix protein (COMP), scleraxis 
(SCXB), Mohawk homeobox (MKX), aggrecan (ACAN), SRY Box 9 (SOX9), alkaline 
phosphatase (ALP), bone sialoprotein (BSP), osteopontin (OP), runt-related transcription factor 2 
(RUNX2), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which was used as a house 
keeping gene (Table 4.1). Results were generated using the ΔΔCt method, and all results were 
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expressed as fold changes normalized to the expression levels of MSCs at the time of seeding the 
scaffolds. 
Statistical analysis 
Two-way analysis of variance (ANOVA) was performed on the western blot, metabolic activity, 
and gene expression data sets to evaluate the effects of scaffold compartment and strain conditions 
(independent variables: scaffold compartment, strain condition). One-way ANOVA was 
performed within each group to evaluate temporal effects (independent variable: time). ANOVA 
was followed by Tukey-honest significant difference post hoc tests. Significance was set at p < 
0.05. A minimum of three independent scaffolds were analyzed at each time point for all metrics. 
Error is reported in figures as the standard error of the mean unless otherwise noted. All statistical 
analysis was performed in Microsoft Excel using the Real Statistics Resource Pack.  
4.4 Results 
The effects of intermittent cyclic tensile strain on compartment-specific cellular metabolic activity. 
MSC metabolic activity was monitored in each scaffold compartment over the course of 6 days of 
culture with and without CTS (5% total strain, 1 Hz, for 10 minutes every 6 hours) (Fig. 4.3). In 
general, higher levels of cellular metabolic activity were observed in the CG compartment 
compared to the CGCaP compartment, and within the CG compartment, metabolic activity was 
higher with CTS compared to static conditions. Initially, cells in the CG compartment subjected 
to CTS show significantly higher metabolic activity (p < 0.05) compared to all other groups. By 
day 3, cells in the static CG show higher activity compared to day 1 (p < 0.05), and cells in both 
CG compartments, with and without CTS, are significantly more active than in the CGCaP 
compartments (p < 0.05). At the end of the culture on day 6, cells in the static CG compartment 
and CGCaP compartment with CTS display an increased metabolic activity in comparison to day 
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1 (p < 0.05). However, the cells in the CG compartment with CTS show increased metabolic 
activity levels compared to both days 1 and 3 as well as all other groups on day 6 (p < 0.05). 
Mechanotransduction pathway activation 
Samples were analyzed immediately prior to and at the conclusion of the first (0-10 minutes) and 
second (360-370 minutes) strain cycles in culture in order to evaluate compartment-specific 
mechanotransduction pathway activation as a result of the intermittent CTS paradigm. While not 
significant, ERK 1/2 activation tended to be higher in the CGCaP compartment compared to the 
CG compartment at all timepoints (p = 0.18) (Fig. 4.4A). Additionally, immediately after the 
second strain cycle, ERK 1/2 activation is significantly upregulated in the CGCaP compartment (p 
< 0.05).  The activation of p38 MAPK displays an inverse trend compared to ERK 1/2 with slightly 
lower activation levels in the CGCaP compartment compared to the CG compartment, and 
significantly reduced activation in the CGCaP compartment after the second strain cycle (p < 0.05) 
(Fig. 4.4B). 
Smad pathway activation 
The compartment-specific activation of the Smad 2/3 and Smad 1/5/8 pathways was evaluated 
after 1 and 3 days in culture.  While not significant, the activation of Smad 1/5/8 tended to be 
higher in the CGCaP compartment compared to the CG compartment and with strain compared to 
static condition (Fig. 4.5A). The activation of Smad 2/3 on the other hand did not show much 
effect of strain condition or compartment on day 1, but did trend higher in the CG compartment 




The impact of CTS on compartment-specific gene expression 
The gene expression profiles for the cells in each scaffold section were examined throughout the 
6-day culture. Three sub-sets of genes were examined: tendon-related genes (COL3A1, COMP, 
SCX, MKX, Fig. 4.6); osteogenic-related genes (ALP, BSP, OP, RUNX2, Fig. 4.7); and 
fibrocartilage-related genes that are relevant to the TBJ (ACAN, SOX9, Fig. 4.8).  
Tendon-specific gene expression 
After 1 day of culture, gene expression levels of COMP, SCX, and MKX were generally highest in 
the CG and interface compartments with strain while there was negligible impact of strain on the 
expression of COL1A1 (Fig. 4.9).  Interestingly, many of differences between groups were not 
noticeable on day 3. The most relevant comparisons were made at the end of the study, on day 6, 
between the two main compartments of the scaffolds with and without CTS (Fig. 4.6).  A 
significant decrease in COL1A1 expression is observed in the CGCaP compartment when exposed 
to CTS, compared to the CG compartment with or without CTS (p < 0.05).  The expression levels 
for both COMP and SCX are significantly upregulated in the CG compartment with CTS, 
compared to the same compartment under static conditions, and the CGCaP compartment, 
regardless of strain conditions (p < 0.05). Finally, MKX expression, while still relatively low, is 
significantly higher in the CG compartment with CTS compared to the CGCaP compartment under 
static conditions (p < 0.05).  
Osteogenic gene expression 
In general, CTS had a much smaller impact on osteogenic genes compared to the tenogenic 
markers over the full course of the experiment (Fig 4.10).  On the final day of the study, ALP 
expression was significantly higher in the interface region under static conditions compared the 
other groups (p < 0.05). There was no significant impact of CTS, nor scaffold compartment, on 
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the expression levels of BSP. Expression levels for OP were higher in the CGCaP compartment 
with CTS, on day 1, compared to all groups under static conditions, while the interface region in 
static culture showed significantly lower expression than all other groups and conditions (p < 0.05). 
On days 3 and 6, this trend reversed, and the groups exposed to CTS showed lower expression 
levels of OP compared to those in static culture (p < 0.05). RUNX2 expression levels were higher 
in the CGCaP compartment with CTS compared to the same compartment in static culture on day 
1 (p < 0.05) but lower in the static CGCaP compartment compared to the other groups under static 
conditions on day 6 (p < 0.05). Most importantly, we examined the differences between the CGCaP 
compartment, with and without CTS, at the conclusion of the study (Fig. 4.7). Here, it can be seen 
that there is a minor downregulation of OP expression in the CGCaP compartment with CTS (p < 
0.05). Otherwise, there is no significant impact of CTS on osteogenic gene expression within the 
CGCaP compartment.  
Interface gene expression 
The expression levels of both ACAN and SOX9, while variable, were generally higher in groups 
exposed to CTS compared to those in static culture (Fig. 4.8). All groups in static culture showed 
significantly lower expression of ACAN compared to the interfacial region on day 1 and both the 
interface and CG compartment on day 3 (p < 0.05). SOX9 expression was also significantly higher 
in the interface on day 6 and both the interface and CGCaP compartment on day 1 compared to all 
three compartments under static conditions (p < 0.05).  
4.5 Discussion 
The application of low-amplitude cyclic tensile strain is known to be an important regulator in the 
development of the native tendon and enthesis, as well as for the regulation of a number of stem 
cell fate decisions (Murchison, Price et al. 2007; Blitz, Viukov et al. 2009; Pryce, Watson et al. 
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2009; Schweitzer, Zelzer et al. 2010). Our group has recently described the development of a multi-
compartment CG scaffold material system with distinct regions of structural anisotropy and 
mineral content for tendon-bone-junction engineering (Caliari, Weisgerber et al. 2015). While this 
work was able to demonstrate the ability to tailor material properties in order influence stem cell 
fate in a spatially-dependent manner, there is a distinct need to drive a more robust tenogenic 
response in the structurally anisotropic region of the scaffold for more complete tissue 
development. Separately, we have also described the use of a custom bioreactor system in 
conjunction with monolithic anisotropic CG scaffolds which showed a more robust upregulation 
of tenogenic markers and activation of mechanotransduction and TGF-β growth factor pathways 
known to be vital in the development of native tendon (Grier, Moy et al. 2017). This work focused 
on the integration of these two technologies to demonstrate the use of CTS within a multi-
compartment CG scaffold for spatially-selective augmentation of tenogenic development for the 
regeneration of the full tendon-bone-junction.  
The primary focus on this work was to examine how the application of CTS within a multi-
compartment material may impact the initial determinants of tenogenic and osteogenic 
differentiation in a spatially-dependent manner.  While the timeframe of the work did not allow 
for the demonstration of extensive matrix remodeling and de novo tissue development, it has 
allowed us to show that MSCs seeded on a spatially graded material with gradations in 
microstructural alignment, mineral content, and bulk mechanics, will display disparate responses 
to tensile stimulation depending on the location within the material. Specifically, the cells within 
the CG compartment displayed responses that were consistent with our previous work in single-
compartment CG scaffolds (Grier, Moy et al. 2017). When exposed to CTS on an anisotropic CG 
material, MSCs exhibited higher cellular metabolic activity, increased expression levels of 
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tenogenic markers COMP, SCX, and MKX, and generally increased activation of the Smad 2/3 
pathway.  
Additionally, it was important to evaluate the effect of CTS on cells within the CGCaP 
compartment of the scaffold. This compartment is about 20-fold stiffer than the CG compartment 
and thus subject to minimal levels of local strain (Weisgerber, Kelkhoff et al. 2013). With that 
being said, the very low amplitude strain that was observed along with fluid flow in dynamic 
culture could have implications on MSC responses. Indeed, previous work has shown that both 
CTS (Jiang, Wang et al. 2016) and shear flow (Yourek, McCormick et al. 2010) could be drivers 
of osteogenic differentiation of MSCs. In this case, there was little-to-no impact of CTS on MSCs 
within the CGCaP compartment. This was not altogether surprising. As we have previously shown, 
the CGCaP material alone is sufficient to drive a robust osteogenic response.  MSCs seeded on 
CGCaP scaffolds show increased mineral deposition and matrix remodeling along with 
upregulation of osteogenic markers BSP, OP, and osteocalcin (Lee, Pereira et al. 2015; 
Weisgerber, Caliari et al. 2015). This increase in osteogenic activity has been demonstrated to be 
a result of the innate activation of the Smad 1/5/8 pathway in MSCs seeded on the CGCaP material 
(Ren, Bischoff et al. 2015; Ren, Tu et al. 2016). Any potential impact of the comparatively low 
amplitude strain that was observed in this stiffer compartment was likely overshadowed by the 
response to the material properties. 
While not the primary goal of this study, the evaluation of fibrocartilaginous markers at the 
intersection of the two compartments does provide intriguing insight for future studies. When 
evaluating the expression levels of ACAN and SOX9 across each scaffold, a clear trend of increased 
expression when exposed to CTS was observed. This trend was especially apparent for SOX9 in 
the middle third of each scaffold which contained the interface between the two materials. This is 
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promising for next generation approaches to specifically regenerate the tendon enthesis. Previous 
work from Spalazzi et al. demonstrated the use of used a tri-culture system on a tri-phasic material 
with osteoblasts, chondrocytes, and fibroblasts seeded on bone, interface, and tendon specific 
regions (Spalazzi, Dagher et al. 2008). He et al. also developed a similar tri-lineage co-culture with 
MSCs seeded between osteoblasts and fibroblasts on a uniform silk scaffold for the development 
of a partially mineralized fibrocartilaginous interfacial zone (He, Ng et al. 2012). Recently, Liu et 
al. investigated the use of decellularized tendon matrix treated with ultrasound in order to influence 
rabbit MSCs towards an fibrocartilaginous-like state (Liu, Yang et al.).  While these previous 
works do show the potential for these multipotent MSCs to develop into enthesis tissue, there has 
yet to be any in depth evaluation of a full tendon-bone-junction model that incorporates a 
physiologically relevant and competent enthesis. In this case, the combination of CTS along with 
the unique material properties at the intersection of two distinct, but continuous compartments, 
may be sufficient to drive that initial fibrocartilaginous response. 
In order to comprehensively evaluate the impact of CTS on multi-compartment scaffolds for TBJ 
regeneration, we plan to address three critical components. First, a better understanding of the 
interplay between CTS and compartment-specific Smad activation should be explored. We have 
demonstrated Smad 2/3 activation on CG scaffolds after exposure to CTS, but the mechanism of 
this activation is not yet understood. There are two possible modes of Smad activation. Canonical 
activation could result from the endogenous production of TGF-β growth factors after initial 
differentiation. Non-canonical methods of activation could also play a role as 
mechanotransduction pathways like ERK 1/2 and p38 have been shown to influence Smad activity 
(Ren, Weisgerber et al. 2016). It is also possible that the initial non-canonical activation of Smad 
2/3 by mechanical stimulation could drive an autocatalytic cycle of differentiation and endogenous 
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growth factor production resulting in more robust Smad activation and MSC differentiation as 
postulated by Allen et al. (Allen, Cooke et al. 2012). There is also a need for extended studies to 
evaluate long-term matrix remodeling and de novo tissue development. We have shown that this 
scaffold model is capable of driving spatially-distinct initial tenogenic and osteogenic responses, 
but the long-term effects of this treatment have yet to be verified. A final consideration needs to 
be for the specific development of a function enthesis zone between the tendon and bone. This 
requires higher resolution methods to evaluate cellular activity and gene expression at the narrow 
region, which is generally less than 1 mm, between the bulk of the two compartments (Weisgerber, 
Kelkhoff et al. 2013; Caliari, Weisgerber et al. 2015). 
4.6 Conclusions 
This work demonstrated the use of multi-compartment scaffolds, with distinct but continuous 
regions of structural anisotropy and mineral content, in combination with intermittent cyclic tensile 
strain to drive spatially-controlled MSC responses for the regeneration of the tendon-bone-
junction.  The strain paradigm (5% strain, 1 Hz, for 10 minutes every 6 hours) was found to have 
very little effect on the osteogenic capacity of MSCs in the stiffer, mineralized CGCaP region of 
the scaffold, while there was significant upgregulation of tenogenic markers and cellular metabolic 
activity in the anisotropic non-mineral CG region when subjected to CTS. These results provide 
the basis for future work to define the role of the interplay between cellular local microenvironment 




Table 4.1 PCR primer sequences. 
Transcript Sequence Reference 
COL3A1 
 
Forward: 5’- GCTGGCATCAAAGGACATCG -3’  
Reverse: 5’- TGTTACCTCGAGGCCCTGGT -3’ 
(Pauly, Klatte et al. 2010) 
COMP 
 
Forward: 5’- GCAACACGGACGAGGACAAG -3’ 
Reverse: 5’- CGCCATCACTGTCCTTCTGG -3’ 




Purchased from Qiagen (sequence unavailable) (Caliari and Harley 2014) 
MKX Forward: 5’- CGTATTGGAAGGAGATCAACG -3’ 
Reverse: 5’- GGACGACTTCTGGATGATGC -3’ 
(Lorda-Diez, Canga-
Villegas et al. 2013) 
ACAN Forward: 5’- TGCATTCCACGAAGCTAACCTT -3’ 
Reverse: 5’- GACGCCTCGCCTTCTTGAA -3’ 
(Zhou, Xu et al. 2011) 
SOX9 Forward: 5’- AGCGAACGCACATCAAGAC -3’ 
Reverse: 5’- GCTGTAGTGTGGGAGGTTGAA -3’ 
(Zhou, Xu et al. 2011) 
ALP Forward: 5’- AGCACTCCCACTTCATCTGGAA -3’ 
Reverse: 5’- GAGACCCAATAGGTAGTCCACATTG -3’ 
(Zhou, Xu et al. 2011) 
BSP Forward: 5’- TGCCTTGAGCCTGCTTCC -3’ 
Reverse: 5’- GCAAAATTAAAGCAGTCTTCATTTTG -3’ 
(Frank, Heim et al. 2002) 
OP Forward: 5’- CTCAGGCCAGTTGCAGCC -3’ 
Reverse: 5’- CAAAAGCAAATCACTGCAATTCTC -3’ 
(Frank, Heim et al. 2002) 
RUNX2 Forward: 5’- AGAAGGCACAGACAGAAGCTTGA -3’ 
Reverse: 5’- AGGAATGCGCCCTAAATCACT -3’ 
(Zhou, Xu et al. 2011) 
GAPDH Forward: 5’- CCATGAGAAGTATGACAACAGCC -3’ 
Reverse: 5’- CCTTCCACGATACCAAAGTTG -3’ 






Figure 4.1 CG scaffold fabrication. (A) Schematic of scaffold mold with layered collagen 
suspensions. (B) Scanning electron micrographs of individual multi-compartment CG scaffold 




Fig. 4.2 Custom cyclic strain bioreactor. (A) Custom bioreactor designed with 24 individual 
wells with static loading posts and moveable rake controlled by a programmable linear actuator. 
(B) Static well system for control cultures run in parallel to bioreactor. (C) Compartment-specific 
measured scaffold deformation in response to cyclic tensile strain (5%, at 1 Hz). Scaffold 




Fig. 4.3 MSC metabolic activity in multi-compartment scaffolds undergoing CTS. 
Compartment-specific metabolic activity of MSCs in CG scaffolds in either static culture or 
exposed to repeated cycles of CTS (10min at 5% strain and 1 Hz) followed by 5 hours 50 minutes 
recovery at days 1, 3, and 6. Data expressed as mean ± SEM (n = 6). * Significantly higher (p < 
0.05) than indicated groups at same day. ^ Significantly higher (p < 0.05) than same group on day 




Fig. 4.4 Compartment-specific mechanotransduction pathway activation with CTS. Relative 
levels of phosphorylated : total (A) ERK 1/2 and (B) p38 MAPK in each compartment of CG 
scaffolds with and without CTS as determined by immunoblot immediately prior to and following 




Fig. 4.5 Compartment-specific Smad pathway activation with CTS. Relative levels of 
phosphorylated : total (A) Smad 1/5/8 and (B) Smad 2/3 in each compartment of CG scaffolds 
with and without CTS as determined by immunoblot on days 1 and 3. Data expressed as mean ± 




Fig. 4.6 Changes in pro-tenogenic gene expression in response to CTS. Compartment-specific 
expression levels of COL1A1, COMP, SCX, and MKX with and without CTS on day 6. Data 




Fig. 4.7 Changes in pro-osteogenic gene expression in response to CTS. CGCaP compartment-
specific expression levels of ALP, BSP, OP, and RUNX2 with and without CTS on day 6. Data 




Fig. 4.8 Changes in pro-chondrogenic gene expression in response to CTS. Compartment-
specific expression levels of (A) ACAN and (B) SOX9 with and without CTS on days 1,3, and 6. 




Fig. 4.9 Changes in pro-tenogenic gene expression in response to CTS. Compartment-specific 
expression levels of (A) COL1A1, COMP, (C) SCX, and (D) MKX with and without CTS on days 




Fig. 4.10 Changes in pro-osteogenic gene expression in response to CTS. Compartment-
specific expression levels of (A) ALP, (B) BSP, (C) OP, and (D) RUNX2 with and without CTS 
on days 1, 3, and 6. Data expressed as mean ± SEM (n = 6). *: p < 0.05. 
  
 99 
CHAPTER 5: INCORPORATION OF β-CYCLODEXTRIN INTO COLLAGEN-GAG 
SCAFFOLDS FOR THE SELECTIVE SEQUESTRATION AND PRESENTATION OF 
GROWTH FACTORS TO GUIDE MSC FATE5 
 
5.1 Chapter overview 
The preceding three chapters focused on the development of biomaterials and culture systems for 
specific tissue engineering applications. In this chapter, a novel method for the incorporation and 
presentation of growth factors in CG scaffolds to direct stem cell responses. Β-cyclodextrin is 
incorporated into CG slurry prior to lyophilization allowing for the passive pull-down of growth 
factors from solution and subsequent controlled release via guest-host interactions. The effects of 
growth factor release from the scaffolds is then evaluated on MSC responses through cellular 
metabolic activity, proliferation, the activation of growth factor signaling pathways, and 
differentiation. 
5.2 Introduction 
Collagen-glycosaminoglycan (CG) materials are composed of natural extracellular matrix (ECM) 
components and have shown great promise as tissue engineering scaffolds. Initially developed for 
skin regeneration applications, these porous CG scaffolds are produced by the lyophilization of an 
acidic suspension of type I collagen and glycosaminoglycans (Yannas, Lee et al. 1989). One of the 
major advantages of CG scaffolds is the ease in which the microstructure, composition, or 
bioactivity can be adapted to meet the functional demands of a wide variety of tissue engineering 
applications. For instance, the freezing kinetics can be manipulated to produce anisotropic 
scaffolds composed of aligned tracks of ellipsoidal pores for tendon repair applications (Caliari 
                                                 
 
5 This chapter has been adapted from the following publication: 
Grier, W.K. M.D. Ramsey et al. (submitted). "Incorporation of β-cyclodextrin into collagen-GAG scaffolds for the 
selective sequestration and presentation of growth factors to guide MSC fate." 
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and Harley 2011; Caliari, Weisgerber et al. 2012; Caliari and Harley 2013). Calcium phosphate 
nanocrystallites have be incorporated during lyophilization to enhance mesenchymal stem cell 
(MSC) osteogenic differentiation and bone regeneration (Harley, Lynn et al. 2010; Quinlan, 
Lopez-Noriega et al. 2015; Ren, Bischoff et al. 2015; Weisgerber, Caliari et al. 2015; Ren, Tu et 
al. 2016; Ren, Weisgerber et al. 2016). These structural modifications have also shown to bias 
MSC differentiation down chondrogenic versus osteogenic lineages in the presence of mixed 
media supplementation (Caliari and Harley 2014). The desire to promote increasingly specific cell 
behaviors (e.g., proliferation, MSC lineage specification) has motivated efforts to incorporate 
design elements that alter the bioavailability of growth factors within the scaffolds network itself. 
In addition to covalent immobilization of growth factors to the scaffold via carbodiimide (Banks, 
Mozdzen et al. 2014) and benzophenone (Martin, Caliari et al. 2011) crosslinking chemistries,  
growth factors have also been covalently bound to polymeric reinforcing cages fabricated by 3D 
printing that can be incorporated into the scaffold during Lyophilization to generate a composite 
with enhanced mechanical and biomolecular properties (Mozdzen, Vucetic et al. 2017). However, 
while covalent immobilization offers benefits in the form of extended bioavailability, this process 
is only applicable to biomolecular signals that do not require receptor internalization. Exciting 
opportunities therefore exist in the space of non-covalent presentation of biomolecular signals. 
Temporal control over growth factor bioavailability is also possible via incorporation of gene 
delivery motifs (e.g., polyethylenimine-DNA complexes) into the scaffold network (Tierney, 
Duffy et al. 2013; Hortensius, Becraft et al. 2015). Recently, Hortensius et al. adapted charge-
based transient sequestration concepts previously demonstrated in heparin-modified hydrogels 
(Sakiyama-Elbert and Hubbell 2000) and 2D culture surfaces (Hudalla, Kouris et al. 2011), and 
showed the glycosaminoglycan content of the CG scaffold itself could be manipulated to 
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transiently sequester and release growth factors from the media (Hortensius and Harley 2013; 
Hortensius, Ebens et al. 2016). However, the complexity of the glycosaminoglycan components 
to the CG scaffolds motivates efforts here to examine alternative chemistries to transiently 
sequester activity-inducing growth factors within the CG scaffold network.  
A promising method for the selective incorporation of growth factors into biomaterial constructs 
is the use of supramolecular interactions such as those found in cyclodextrins. These six, seven, 
and eight member D-glucopyranose rings (-cyclodextrin, -cyclodextrin, and -cyclodextrin 
respectively) (Mura 2014; Radu, Parteni et al. 2016) are more commonly used in pharmaceutical 
applications to increase drug solubility. Cylcodextrins are known for their ability to form 
cyclodextrin inclusion complexes (CDIC), where guest-host interactions enable the adsorption of 
hydrophobic guest molecules into the central cavity (Fig. 5.1 A) (Bibby, Davies et al. 2000).  
Cyclodextrin chemistries have been demonstrated as a means to generate dynamic, adaptable 
hydrogel environments (Liu, Zhang et al. 2011; Machín, Isasi et al. 2012; Liu, Zhang et al. 2013; 
Osman, Soliman et al. 2015; Rodell, Highley et al. 2016). Cyclodextrins into porous biomaterials 
as a means to alter the release of drug molecules (Prabaharan and Jayakumar 2009; 
Soheilmoghaddam, Sharifzadeh et al. 2014). While cyclodextrins have been shown to have a 
strong affinity for various growth factors (Yuen, Folkman et al. 1990), the ability for these 
molecules to regulate growth factor sequestration and display within porous scaffold-based 
biomaterial has not been deeply exploited.  
Here, we describe the incorporation of β-cyclodextrin into a CG scaffold variant under 
development for musculoskeletal repair applications (Fig. 5.1 B). We hypothesized that 
incorporation of cyclodextrin into the CG scaffold network would facilitate the formation of 
CDICs with exogenously added soluble growth factors, leading to growth factor sequestration and 
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enhanced activity on MSCs within the scaffold. We examine sequestration and subsequent release 
of a model growth factor, transforming growth factor-beta 1 (TGF-1), within the scaffold 
network. We then examine the capacity for cyclodextrin modified CG scaffolds (CGcyclo) to 
enhance the activity of the chondrogenic growth factor TGF-1 or the osteogenic growth factor 
bone morphogenetic protein-2 (BMP-2) to influence MSC fate. We examine MSC osteo-chondral 
lineage specification via activation of activation of the Smad 1/5/8 and Smad 2/3 pathways as well 
as changes in gene expression profiles.  
5.3 Materials and Methods 
All materials and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
specified.  
Scaffold fabrication  
Type I collagen from bovine Achilles tendon and chondroitin sulphate from shark cartilage were 
homogenized in 0.05 M acetic acid at a ratio of collagen to glycosaminoglycan of 11.25:1(Yannas, 
Lee et al. 1989; Madaghiele, Sannino et al. 2008). For the cyclodextrin scaffolds, two variants 
were produced, CGcyclo 1x and 5x were prepared by adding 3.70 μg/mL 18.52 μg/mL of β-
cyclodextrin in deionized water directly to the CG slurry. Briefly, 200 µL of degassed CG 
suspension was pipetted into wells (6 mm diameter, 7 mm deep), within a polysulfone mold that 
was subsequently placed on a freeze-dryer shelf (VirTis, Gardner, NY). The CG suspension was 
frozen at -10°C for 2 hours and then sublimated at 0°C and 200 mTorr to remove the ice crystals, 
resulting in a dry porous scaffold.  
Scaffolds were removed from the molds and cut laterally in half using a 3D printed guide 
(MakerBot Industries, Brooklyn, NY). Scaffolds were then hydrated by immersion in 200 proof 
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ethanol overnight followed by a 24 hour rinse in sterile phosphate-buffered saline (PBS) replacing 
the PBS three times. Each scaffold was then crosslinked using carbodiimide chemistry by 
immersion in a solution of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) 
and N-hydroxysulfosuccinimide (NHS) for 2 hours at room temperature in a 5:2:1 molar ratio 
(EDC:NHS:COOH) in sterile PBS with gentle shaking. After crosslinking, the scaffolds were 
washed twice with sterile PBS and stored at 4°C.  
SEM imaging of the scaffold microstructure 
Critical point drying (CPD) was used to prepare hydrated and cell-seeded scaffolds for SEM 
imaging. CPD was performed using a Samdri-PVT-3D (Tousimis, Rockville, MD), where the 
aqueous media in the scaffold was sequentially replaced with ethanol and then liquid CO2. Liquid 
CO2 was allowed to infiltrate the scaffolds and was then held above 6.895 kPa and 31°C in order 
to remove the CO2 as a gas with minimal structural deformation. Samples were then mounted on 
carbon tape, sputter coated with a gold/palladium mixture, and imaged with a Philips XL30 ESEM-
FEG (FEI Company, Hillsboro, OR) at 5 kV with a secondary electron detector.  
Biomolecule sequestration and release 
The ability for the conventional CG or CGcylco scaffolds to sequester and release a model 
biomolecule, TGF-β1, was compared via ELISA. Briefly, scaffolds were incubated in 5ng/mL 
recombinant TGF-β1 (ProSpec-Tany, Ness-Ziona, Israel) in sterile PBS with 1% bovine serum 
albumin (BSA) for 1 hour on a gentle shaker; solution without scaffolds were used as controls. 
Following incubation, scaffolds were removed from the TBF-β1 solution, and the amount of TGF-
β1 remaining in the media was determined via DuoSet® ELISA (R&D Systems, Minneapolis, MN) 
in order to calculate the fraction of TGF-β1 sequestered by the scaffold variants themselves 
(Hortensius and Harley 2013). Some structural deficiencies of the CGcylo 5x scaffolds were 
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noticed at this point, likely due to the dilution of the CG slurry, so only the CGcylo 1x variants 
were used after this point.  
The elution of TGF-β1 from the CG and CGcyclo 1x scaffold variants was subsequently traced 
over 72 hours. Briefly, after incubating the scaffolds in 5ng/mL TGF-β1, scaffolds were transferred 
to pure PBS and maintained in the incubator (37oC, 5% CO2) for 72 hours. Samples of the media 
were removed after 1, 6, 24, and 72 hours for analysis of TGF-β1 released by the scaffold via 
DuoSet® ELISA. Results are reported as the fraction of the total TGF-β1 that each scaffold was 
exposed to that was subsequently retained by the scaffold at each time point. 
Human mesenchymal stem cell culture and scaffold seeding  
Human bone marrow-derived mesenchymal stem cells were purchased from Lonza (Walkersville, 
MD). Cells from multiple lots, originating from separate donors, were combined to account for 
any donor-specific responses. The MSCs were cultured at 37°C and 5% CO2 in a complete MSC 
growth medium, consisting of low-glucose DMEM with 10 vol% MSC fetal bovine serum and 1 
vol% antibiotic-antimitotic (Thermo Fisher, Waltham, MA), fed every three days and used at 
passage 6.  
Selected CG and CGcyclo scaffolds were incubated in 5 ng/mL human recombinant BMP-2 
(ProSpec-Tany, Ness-Ziona, Israel) or human recombinant TGF-β1 (ProSpec-Tany, Ness-Ziona, 
Israel) for 1 hour in sterile PBS in the same manner as previously described. The scaffolds were 
then moved into 5% FBS MSC Media for 2 hours as cells were lifted and centrifuged in preparation 
for seeding using a previously established static method (O'Brien, Harley et al. 2005). Scaffolds 
were partially dried with Kimwipes and seeded with 1.0 × 105 MSCs per 24 μL medium (1, 10 μL 
drop on opposite sides of the scaffold) in six well plates, with six scaffolds per well. Cells were 
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allowed to attach for 1 hour before submerging in 6 mL of low-serum MSC media, containing 5% 
FBS, per well. Cell-seeded scaffolds were cultured at 37°C and 5% CO2 and fed every three days 
with the low-serum media. 
Cell number and metabolic activity assays 
DNA quantification was performed using a previously described method to determine the number 
of cells present on each scaffold (Kim, Sah et al. 1988; Grier, Moy et al. 2017). Briefly, scaffolds 
to be terminated were washed three times in warmed, sterile PBS to remove dead and unbound 
cells and placed in papain solution (2.4 mg/mL PBS) for digestion of the scaffold overnight at 
60°C. Lysates were then incubated with Hoechst 33258 dye (Invitrogen, Carlsbad, CA) to 
fluorescently label double-stranded DNA. Fluorescent intensity (352/461 nm excitation/emission) 
from each sample was read using a fluorescent spectrophotometer (Tecan Infinite F200 Pro, 
Männedorf, Switzerland) and translated in cell counts through a standard curve of known MSC 
numbers. 
Mitochondrial metabolic activity of the MSCs bound to each scaffold was quantified using the 
non-destructive alamarBlue® assay as previously described (Tierney, Duffy et al. 2013). Cell-
seeded scaffolds were incubated in 0.75 mL of alamarBlue (Invitrogen, Carlsbad, CA) (1:20 5% 
FBS MSC Media) and incubated at 37°C for 90 minutes on a gentle shaker. The reduction of 
resazurin to resorufin by metabolically active cells was quantified on a fluorescent 
spectrophotometer through differential absorbance. Relative cell metabolic activity was 
determined from a standard curve generated with known MSC concentrations and reported as a 
fraction of initial seeding cell count. 
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Protein isolation, SDS-PAGE, and immunoblotting 
Upon reaching each time point, (day 1, 3, 6) scaffolds to be terminated were washed three times 
in warmed, sterile PBS to remove dead and unbound cells. The scaffolds were then blotted briefly 
and placed in a cold 1:100 dilution each of protease inhibitor cocktail, phosphatase inhibitor 
cocktail II and phosphatase inhibitor cocktail III in RIPA buffer and placed back on ice for thirty 
minutes with agitation. The scaffolds were then removed and lysates were frozen (Caliari, 
Weisgerber et al. 2015). Protein concentrations were quantified with the Pierce BCA Protein Assay 
Kit (Thermo Fisher, Waltham, MA) and prepared for gel electrophoresis by diluting 10 μg of 
protein from each sample with an equal volume of Laemmli buffer. Samples were heated at 90°C 
for 10 min and loaded into 4-20% polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA) in 
duplicate for both Smad 2/3 and 1/5/8 imaging. The gel electrophoresis was run at 150V for 90 
minutes in 1 L of tris-glycine running buffer (25mM NaCl, 192mM glycine, 0.1% SDS, pH~8.3 
in DI water) and immediately tank transferred onto nitrocellulose membranes (GE Healthcare, 
Little Chalfont, UK) at 300mV for 2 hours in 1 L of Towbin’s transfer buffer (2.5M Tris base, 
19.2mM glycine, 20% methanol in DI water). The nitrocellulose membranes were then cut and 
blocked in 5% milk in tris-buffered-saline + 0.1% tween 20 (TBST). Membranes were incubated 
in primary antibody at 4°C overnight in 5% BSA in TBST, washed three times in TBST, incubated 
in secondary antibody at RT for 1 hour, washed and imaged using the SuperSignal West Pico or 
Femto Chemiluminescent Substrate (Thermo Fisher, Waltham, MA) and an ImageQuant LAS 
4010 system (GE Healthcare, Little Chalfont, UK). Primary antibodies were purchased from Cell 
Signaling (Danvers, MA): pSmad 2/3 (8828), Smad 2/3 (8685), pSmad 1/5/8 (9511), Smad 1 
(6944), -actin (4967). Secondary antibody used was HRP-linked goat anti-rabbit IgG (1:5000 in 
TBST). Membranes were stripped using the OneMinute® Western Blot Stripping Buffer (GM 
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Biosciences, Rockville, MD) and re-imaged two additional times, repeating the above procedure. 
ImageJ was used for band intensity quantification. Results were reported as the ratio of 
phosphorylated to total protein for each pathway. 
RNA isolation and target gene expression characterization  
RNA was extracted from the MSC-seeded scaffolds at D1, D3, D6 using an RNeasy Plant MiniKit 
(Qiagen, Valencia, CA) and frozen. The isolated RNA was then reverse transcribed to cDNA in a 
Bio-Rad S1000 thermal cycler, using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, 
CA) (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012). Real-time PCR reactions were 
carried out in triplicate, using 10 ng of cDNA and QuantiTect SYBR Green PCR kit (Qiagen, 
Valencia, CA) in a 7900HT Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA). 
The primers used were consistent with previous studies and were synthesized by Integrated DNA 
Technologies (Coralville, IA). The expression level of the following markers was quantified: 
proteoglycan aggrecan (ACAN), cartilage oligomeric matrix protein (COMP), SRY-Box9 (SOX9), 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which was used as a house keeping 
gene (Table 5.1). Results were generated using the ΔΔCt method and expressed as fold changes, 
normalized to the expression levels of MSCs at the time of seeding, D0. 
Statistical analysis 
One-way analysis of variance (ANOVA) was performed on the two ELISA experiments (initial 
sequestration and elution), and two-way ANOVA was performed on western blot, metabolic 
activity, cell number and gene expression data sets (independent variables: -cyclodextrin loading 
and growth factor incubation), followed by Tukey-honest significant difference post hoc tests. 
Significance was set at p < 0.05. For cell experiments, scaffolds at each time point were analyzed 
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for all metrics, however, no statistical analyses was performed between time points. Error is 
reported in figures as the standard error of the mean, unless otherwise noted.  
5.4 Results 
Scaffold morphology 
Scaffold morphology was examined by SEM after carbodiimide crosslinking and subsequent CPD. 
The CG scaffolds showed a distinct porous morphology, consistent with our previous studies (Fig. 
5.2A). Closer examination shows that the characteristic banding pattern of the collagen is 
maintained through the fabrication and SEM preparation processes (Fig. 5.2B).  Additional images 
were acquired 72 hours after MSC seeding, which show cells spreading out along the struts of the 
CG scaffolds (Fig. 5.2C).  
-cyclodextrin Incorporated Scaffolds Bind TGF-1 More Efficiently and Exhibit Decreased 
Elution Profiles 
First, the binding equilibrium of -cyclodextrin was examined in CGcylco 1x and 5x scaffolds 
relative to CG scaffolds. CG scaffolds sequestered 28.98% of the TGF-1 from solution while the 
1x and 5x CGcylco groups sequestered 43.55% and 48.27% of the TGF-1, respectively (Fig. 
5.3A). Due to there being only a minimal difference between the 1x and 5x -cyclodextrin groups’ 
binding kinetics, and structural deficiencies in the 5x group due to dilution of the initial CG slurry, 
the 5x group was eliminated from future experiments.  
The binding equilibrium was then further explored through characterization of the elution profile 
of TGF-1 from blank and CGcylco 1x scaffolds. After just 1 hour, the CG scaffolds eluted 
significantly more bound growth factor than the CGcylco scaffolds (p < 0.05). At the end of 72 
hours, just 1.38% of the TGF-1 was retained in the CG scaffolds, while the CGcyclo scaffolds 
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retained 15.92%, resulting in a more than a 10-fold increase in TGF-1 retention over 72 hours 
(Fig. 5.3B).     
TGF-1--cyclodextrin inclusion complexes increase metabolic activity and proliferation 
After establishing the binding efficacy of CGcyclo scaffolds, the growth factor’s presentation and 
effect on MSC response was explored. Specifically, the effect of TGF-1 on cell number, 
metabolic activity and protein expression was examined. TGF-1 had no effect on cellular 
proliferation (Fig. 5.4A) with all four experimental groups increasing from D1 to D3 and 
essentially remaining constant to D6. Conversely, there was a significant upregulation in cellular 
metabolic activity in the CGcyclo group with TGF-1 at all three time points (p < 0.05). 
Accounting for this equal cell count between all four groups, the distinct upregulation of cellular 
metabolic activity can be attributed to the complexed growth factor within the CGcyclo scaffolds 
(Fig. 5.4B).  
BMP-2--cyclodextrin inclusion complexes increase metabolic activity and proliferation 
In parallel with TGF-1, the effect of BMP-2 on cell number and metabolic activity was also 
examined. It was found that BMP-2 has minor effects on cellular proliferation (Fig. 5.5A).  Slightly 
lower cell numbers on the CGcyclo scaffolds with BMP-2 compared to the CG scaffolds with no 
BMP-2 on day 1, while this trend was reversed on day 6. While significant, (p < 0.05) the 
magnitudes of these changes are small compared to the significantly lower metabolic activity 
observed in the CGcylco scaffolds with BMP-2 compared to the three other groups at all time 




TGF-1--cyclodextrin inclusion complexes activate the Smad 2/3 pathway  
The effect of TGF-1 inclusion into CGcyclo scaffolds on the activation of the Smad 2/3 and Smad 
1/5/8 pathways was evaluated by SDS-PAGE and western blot on days 1 and 3. Samples showed 
an increased activation of the Smad 2/3 pathway on day 3 when exposed to TGF-1 (Fig. 5.6A). 
The increased activation of Smad 2/3 was significantly higher in the CGcyclo group with TGF-1 
compared to both the CG and CGcyclo groups without growth factor. (p < 0.05). The Smad 1/5/8 
pathway was also examined to determine the non-targeted MSC cellular response to TGF-1. No 
significant effects of the incorporation of β-cyclodextrin or TGF-1 were observed on the 
activation of Smad 1/5/8 (Fig. 5.6B). 
BMP-2--cyclodextrin inclusion complexes activate the Smad 1/5/8 pathway  
The effect of BMP-2 inclusion into CGcyclo scaffolds on the activation of the Smad 2/3 and Smad 
1/5/8 pathways was also evaluated on days 1 and 3. Interestingly, significant upregulation of Smad 
2/3 activation was seen in the CGcyclo scaffolds with BMP-2 compared to the other three groups 
on day 1 (Fig. 5.7A) (p < 0.05). Additionally, while not significant, there was a general trend of 
increased activation of the Smad 1/5/8 pathway in the CGcyclo group with BMP-2 compared to 
the other three groups (Fig. 5.7B).  
TGF-1--cyclodextrin inclusion complexes increase tenogenic gene expression 
The resultant effect of TGF-1 inclusion into CGclyco scaffolds on MSC chondrogenic gene 
expression was evaluated on days 1, 3 and 6 (Fig. 5.8A-C). While the expression levels for ACAN 
were quite low, large increases in expression of COMP and SOX9 were observed in the CGcyclo 
group with TGF-1. The expression levels for ACAN were considerably lower throughout the 
experiment and were found to be significantly downregulated in both the CG and CGcyclo groups 
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with TGF-1 on day 6 (p < 0.05). Conversely, expression levels for COMP were significantly 
higher in the groups with TGF-1 compared to the unsupplemented CG and CGcyclo groups on 
days 1 and 3, while the CGcyclo group with TGF-1 was significantly higher than all three other 
groups on day 6 (p < 0.05).  By day 6, the expression levels of SOX9 were significantly higher in 
just the CGcyclo group with TGF-1 compared to all three other groups (p < 0.05). 
5.5 Discussion 
Previous research from our group has shown that porous CG scaffolds serve as robust supports for 
both the stable culture of MSCs and their subsequent differentiation to tendon, cartilage, and 
osteogenic phenotypes (Caliari and Harley 2014; Caliari, Gonnerman et al. 2015; Caliari, 
Weisgerber et al. 2015; Grier, Moy et al. 2017). Here, the focus was shifted to accelerating this 
differentiation through the more efficient loading and display of growth factors into the CG 
scaffolds through -cyclodextrin sequestration. As previously stated, the driving force for -
cyclodextrin sequestration is hydrophobic interactions. Therefore, it is crucial that the host 
molecule contains hydrophobic moieties to interact with the interior of -cyclodextrin. 
Examination of TGF-1 reveals exposed hydrophobic regions through -strands -8 and -9 that 
form the ‘bow-tie’ link of its two arm domains and through an extended loop connecting α1 and 
α2 helices rich in proline and aromatic residues (Shi, Zhu et al. 2011). It is this region, directly 
surrounding the α1 helix, that most likely binds the interior of -cyclodextrin, as it is more exposed 
on the tip of the molecule and most extensively hydrophobic in character. BMP-2 has been found 
to contain hydrophobic residues throughout the molecule and in particular local density at the 
bottom of the growth factor’s central cleft (Scheufler, Sebald et al. 1999). The fundamental 
mechanism for -cyclodextrin sequestration is applicable to the two growth factors, as it is also 
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known that BMPR-II:BMP-2 complex interactions are dominantly hydrophobic in nature, proven 
through residue mutations, and TGF- receptor:ligand complexes result from a combination of 
hydrophobic and electrostatic interactions (Yin, Fu et al. 2008; Hinck 2012).  
Elucidating the sequestration mechanism for each growth factor to -cyclodextrin clarifies the 
results of the work presented. The additional TGF-1 initially bound by the CGcyclo scaffolds 
compared to the CG scaffold can be wholly attributed to -cyclodextrin incorporation. Not only 
was more TGF-1sequestered by the CGcyclo scaffolds, but the TGF-1 that was sequestered was 
also retained over a longer period. The controlled release of the TGF-1from the CGcyclo 
scaffolds makes them an ideal candidate for the control of MSC fate as we have shown here. 
Bone morphogenetic proteins (BMPs) belong to the larger transforming growth factor β (TGF-β) 
superfamily, which regulate a wide array of cellular functions including cell migration, adhesion, 
division, and differentiation throughout the human life span (Massague and Chen 2000). Cell 
metabolic activity and Smad pathway activation, traditionally associated with TGF-β1 and BMP-
2 signaling, was consequently employed as the metrics for increased growth factor loading. 
Previous work has shown that the minimum effective concentrations for TGF-1 and BMP-2 are 
0.02 – 2.0 ng/mL and ~20 ng/mL respectively (Zhang and Laiho 2003; Lysdahl, Baatrup et al. 
2014). This difference in threshold concentration can help to explain the data observed in Fig. 5.4-
5.7 and the lower activity of BMP-2 compared to TGF-β1 in this study.  
TGF-1 was found to increase cellular metabolic activity, Smad 2/3 pathway activation, and the 
expression of chondrogenic markers COMP and SOX9. This is consistent with previous work 
where TGF-1 has been found to stimulate proliferation and self-renewal of MSCs and inhibit 
differentiation into osteogenic lineages through Smad 3 signaling (Guo and Wang 2009). TGF-1 
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has also been found to co-stimulate Smad 2/3 through phosphorylation which collectively 
associates into a larger transcription factor complex (Massague and Wotton 2000; Xin, Li et al. 
2013).  Phosphorylated Smad 2/3 has then been shown to stimulate tenogenic lineages in 
conjunction with COMP, ACAN, and SOX9 expression (Caliari and Harley 2014; Grier, Moy et al. 
2017; Grier, Iyoha et al. 2017).  
Conversely, BMP-2 was found to lead to a slight drop in cellular metabolic activity and 
simultaneously generally increase Smad 1/5/8 phosphorylation. The BMP II receptor-mediated 
phosphorylation of Smad 1/5/8 allows the activated isoforms to associate with Smad 4, translocate 
to the nucleus, and stimulate transcription of target genes related to bone deposition, making the 
1/5/8 signaling pathway critical in MSC osteogenic signaling (Soltanoff, Yang et al. 2009; Chen, 
Uludag et al. 2012; Beederman, Lamplot et al. 2013). The upregulation of one such target gene, 
runt-related transcription factor 2 (RUNX2), has been found to lead to the subsequent expression 
of alkaline phosphatase (ALP) and osteocalcin (OC), genes critical for bone formation (Lysdahl, 
Baatrup et al. 2014). The activation of the Smad 1/5/8 osteogenic pathway strongly correlates with 
the metabolic activity data presented in Fig. 5.4, as mature osteocytes rarely divided compared to 
the more immature MSCs (Malaval, Liu et al. 1999; Westhrin, Xie et al. 2015). 
5.6 Conclusions 
The work presented demonstrates the ability for β-cyclodextrins to efficiently bind growth factors 
from solution prior to cell-seeding through CDIC formation as a means to accelerate MSC 
differentiation with lineage guidance dependent on growth factor bound. This mechanism can 
effectively lower the in vitro concentration of growth factors needed to induce cellular responses 
and can be potentially utilized for a variety of growth factors, cell types and applications in the 
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hope of driving down patient related costs. This work establishes a new method for the successful 
incorporation and display of growth factors within CG scaffolds which, in combination with 
previously developed methods, has the potential to allow for more intricate designs for the 




Table 5.1 PCR primer sequences. 
Transcript Sequence Reference 
ACAN Forward: 5’- TGCATTCCACGAAGCTAACCTT -3’ 
Reverse: 5’- GACGCCTCGCCTTCTTGAA -3’ 
(Zhou, Xu et al. 2011) 
COMP 
 
Forward: 5’- GCAACACGGACGAGGACAAG -3’ 
Reverse: 5’- CGCCATCACTGTCCTTCTGG -3’ 
(Klatte-Schulz, Pauly et al. 
2013) 
SOX9 Forward: 5’- AGCGAACGCACATCAAGAC -3’ 
Reverse: 5’- GCTGTAGTGTGGGAGGTTGAA -3’ 
(Zhou, Xu et al. 2011) 
GAPDH Forward: 5’- CCATGAGAAGTATGACAACAGCC -3’ 
Reverse: 5’- CCTTCCACGATACCAAAGTTG -3’ 





Figure 5.1 β-cyclodextrin guest-host interactions and incorporation into CG scaffolds. (A) 
Seven-membered ring structure of β-cyclodextrin and the spontaneous process of forming 
inclusion complexes. (B) Representation of β-cyclodextrin incorporation into CG scaffold 




Figure 5.2 CG scaffold microstructure. (A) Cross-section of the porous CG scaffolds. Scale bar: 
100µm (B) High-magnification image of the individual collagen fiber banding. Scale bar: 1 µm 
(C) hMSC spreading along scaffold surface. Scale bar: 40 µm. 
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Figure 5.3 TGF-β1 pull-down and controlled release from CG scaffolds with β-cyclodextrin. 
(A) The incorporation of β-cyclodextrin into CG scaffolds in both 1x and 5x concentrations 
resulted in increased pull-down of TGF-β1 from solution. (B) β-cyclodextrin scaffolds showed 




Figure 5.4 MSC viability in CG scaffolds exposed to TGF-β1. (A) Number of cells and B) 
normalized metabolic activity in blank and β-cyclodextrin scaffolds with and without TGF-β1 on 




Figure 5.5 MSC viability in CG scaffolds exposed to BMP-2. (A) Number of cells and (B) 
normalized metabolic activity in blank and β-cyclodextrin scaffolds with and without BMP-2 on 




Figure 5.6 Smad pathway activation in CG scaffolds exposed to TGF-β1. Relative levels of 
phosphorylated : total (A) Smad 2/3 and (B) Smad 1/5/8 in scaffolds with and without TGF-β1 as 
determined by immunoblot on days 1 and 3 after seeding. Data expressed as mean ± SEM (n = 3). 
*: p < 0.05. 
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Figure 5.7 Smad pathway activation in CG scaffolds exposed to BMP-2. Relative levels of 
phosphorylated : total (A) Smad 2/3 and (B) Smad 1/5/8 in scaffolds with and without BMP-2 as 
determined by immunoblot on days 1 and 3 after seeding. Data expressed as mean ± SEM (n = 
3). *: p < 0.05. 
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Figure 5.8 Changes in pro-chondrogenic gene expression in response to TGF-β1. Expression 
levels of (A) ACAN, (B) COMP, and (C) SOX9 with and without TGF-β1 exposure on days 1, 3, 
and 6. Data expressed as mean ± SEM (n = 6). *: p < 0.05. 
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK 
 
6.1 Conclusions 
In this work, we sought to develop new biomaterial and culture methods to promote spatial-
controlled differentiation of mesenchymal stem cells (MSCs) for tendon-bone junction (TBJ) 
regeneration applications. We described the development of a collagen-GAG (CG) scaffold system 
and methods to alter scaffold microstructure and composition in an effort to mimic components of 
the natural tissue extracellular matrix (ECM) environment to influence MSC differentiation.  
Chapter 2 describes the evaluation of scaffold microstructure and mechanics and resultant impacts 
of tenocyte viability and gene expression profiles for a series of anisotropic CG scaffolds with 
variable pore size and strut stiffness, as a function of crosslinking density. Equine tenocytes 
demonstrated considerably less cell-mediated contraction of the more mechanically robust 
scaffolds with smaller pore sizes (Tf = -60°C) and highest crosslinking density (5:2:1 
EDC:NHS:COOH). The tenocytes seeded in these scaffolds that were able to resist contraction 
showed increased proliferation, metabolic activity, and expression levels of traditional tenogenic 
ECM and phenotypic markers. This is likely due to the fact that the cell-mediated contraction 
resulted in constricted pore diameter, limiting nutrient biotransport. Interestingly, the expression 
levels of matrix metalloproteinases MMP 1, MMP3, and MMP 13 were all significantly 
upregulated in scaffolds that exhibited the most cell-mediated contraction, a likely indicator of 
cellular remodeling of the scaffold structure due to losses in contact guidance cues. This work 
suggests that the scaffold microstructural properties and mechanics are critical design parameters 
for tendon tissue engineering and the maintenance and development of cellular behavior of long-
term culture.  
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Chapter 3 utilized the optimized anisotropic CG scaffold identified in Chapter 2, in conjunction 
with a custom bioreactor system to evaluate the potential to use cyclic tensile strain (CTS), as a 
method to drive tenogenic differentiation of MSCs. The custom bioreactor system was designed 
with individual wells for sampling and to be adaptable for a wide variety of scaffold geometries 
and loading paradigms. Additionally, a novel method to embed the ends of porous CG scaffolds 
into hollow end blocks was developed to enable the loading of scaffolds into the bioreactor without 
the use of clamps, which can result in crushing or tearing of the scaffold or slippage. The initial 
effects of CTS on cell-material interactions and mechanotransduction pathways was evaluated and 
validated that MSCs within our system follow a standard pattern of ERK 1/2 and p38 activation, 
which led to the development of an intermittent CTS paradigm to promote increased ERK 1/2 
activation and resultant collagen production. When exposed to CTS over a 6-day culture period, 
MSCs showed enhanced tenogenic differentiation as evidenced by increased expression of markers 
like, COL3AI, COMP, SCX, TNC, and MKX. By day 6, the application of CTS also resulted in 
increased activation of the Smad 2/3 pathway, evidence of endogenous TGF-β production which 
could drive long-term tissue development. Improved understanding of cell-material interactions 
and responses to CTS here motivated the next generation of work leveraging mechanical 
stimulation as a means to drive spatially-dependent MSC responses on a graded material. 
Chapter 4 then expanded on the work presented in Chapter 3 and investigated the application of 
CTS on a multi-compartment CG scaffold with continuous, but distinct, regions of mineral content 
and structural anisotropy, for TBJ regeneration. The variations in mechanical properties across the 
scaffold compartments resulted in the strain amplitude being primarily localized to the non-
mineralized anisotropic compartment of the scaffold. We found that the localization of strain to 
the CG compartment drove a preferential tenogenic response in that compartment, as evidenced 
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by expression levels of COL3A1, COMP, SCX, and MKX. There were minimal negative effects of 
CTS on the expression of osteogenic differentiation markers ALP, BSP, and RUNX2 in MSCs 
within the mineralized compartment. These results were supported by evidence of preferential 
activation of the Smad 2/3 and Smad 1/5/8 pathways in the anisotropic and mineralized 
compartments, respectively.  Interestingly, sections of each scaffold that contained the interfacial 
zone, along with regions of each compartment, were evaluate for expression levels of 
fibrocartilaginous interface markers ACAN and SOX9. These interface-specific genes were 
generally upregulated with strain and there was some evidence of preferential upregulation 
specifically in the interfacial region of the scaffold. The low resolution of the sampling techniques 
used does not allow us to draw any specific conclusions as to how CTS may enhance interface 
development within a graded biomaterial, but it does motivate future work specifically focused on 
this region.  
While Chapters 2-4 focused on the development of instructive biomaterial cues and cellular 
interactions with dynamic culture systems, Chapter 5 investigated the potential to alter biomaterial 
composition for the control of growth factor presentation.  Scaffolds with incorporated β-
cyclodextrin showed increased pull-down of growth factors, like TGF-β, from solution, followed 
by controlled release over a number of days. When seeded with MSCs, the β-cyclodextrin scaffolds 
that had previously been loaded with TGF-β, promoted increased cellular metabolic activity, 
heightened activity of Smad 2/3, and higher expression of chondrogenic gene markers COMP and 
SOX9. Loading β-cyclodextrin scaffolds with BMP-2 resulted in similar results regarding the 
osteogenic differentiation of MSCs. Cells exposed to extended release of BMP-2 showed lower 
metabolic activity levels, evidence of osteogenic differentiation, and generally increased activation 
of Smad 1/5/8. This work provides a new method to selectively sequester and present growth 
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factors within a biomaterial without the need to chemically modify the scaffold or growth factor. 
This technology could easily be applied to spatially-graded materials produced by liquid-phase co-
synthesis to control the spatial distribution of growth factors with CG scaffolds.   
6.2 Future Directions 
This thesis provides a foundation for understanding biomaterial design and culture 
supplementation strategies for the regeneration of complex, structurally heterogeneous, orthopedic 
interfaces, such as the TBJ. Importantly, this work highlights many key challenges associated with 
developing comprehensive tissue engineering solution, including: 
• Understanding long-term culture dynamics and de novo tissue formation or regeneration 
of structurally competent tissue structures.  
• Developing higher resolution techniques to evaluate fibrocartilaginous interface 
regeneration on a physiologically-relevant sub-millimeter scale through gene expression 
analysis, cell-matrix interactions, and tissue formation. 
• Structural reinforcement of the scaffold structure in order to withstand physiological 
loading paradigms in order to avoid failure after implantation. 
• Evaluation of scaffold performance and healing properties in in vivo preclinical animal 
models. 
Long-term culture dynamics 
The work presented in this thesis was primarily limited to shorter-duration experiments, up to 6 
days of culture, and examined early signs of stem cell differentiation. However, tissue 
development and healing generally occur over a timespan of weeks to months. It will be important 
to evaluate how and if this initial MSC differentiation can translate into robust tissue development, 
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ECM deposition and organization, and augmented mechanical properties over an extended 
timeline. This will be important for developing in vitro culture systems to produce engineered 
tissue constructs or for understanding the long-term development of implanted biomaterials.  
Techniques for interface regeneration 
As suggested in Chapter 4, MSCs on spatially-graded CG scaffolds that are exposed to CTS do 
begin to show initial signs of fibrocartilaginous interface development. This is a particular area of 
focus that must be explored more thoroughly. Unfortunately, the sub-millimeter scale of the native 
TBJ limits the available tools to fully and consistently analyze the dynamics in this narrow regime. 
Emerging statistical and analytical techniques to evaluate gene expression in samples, with small 
numbers of cells, are becoming more accessible and could be applied in such a situation. 
Additionally, it may be prudent to engineer biomaterials with a defined interfacial zone. One may 
look to design materials with localized distributions of growth factor presentation using a method 
such as the β-cyclodextrin incorporation discussed in Chapter 5. Alternatively, a distinct 
fibrocartilage compartment could be incorporated into a CG scaffold. One idea would be to 
engineer a hydrogel interface that is distributed between the mineralized and anisotropic 
compartments of the materials used in Chapter 4. While hydrogels lack many of the mechanical 
properties that are ideal for many orthopedic applications, a number of emerging technologies now 
exists to print hydrogels with intricate designs and display of factors. Such a hydrogel could be 
integrated into the scaffold interface to promote fibrocartilage development and relying on the 




Scaffold structural reinforcement 
One of the main drawbacks of CG scaffolds is an inability for the scaffold material to match the 
mechanical properties of native tendon tissue. Tendons are dynamic and strong tissues which 
undergo consistently high levels of strain in vivo. The potential for the scaffold to tear or pull out 
of a defect after implantation is a serious concern before beginning preclinical trials. We have 
previously demonstrated the use of membrane core-shell composites to improve the mechanical 
properties of aligned CG scaffolds as well as in incorporation of 3D printed polymer materials to 
bear high levels of load within a larger composite construct. This type of material could be 
engineered to work with a multi-compartment material and to promote the spatial distribution of 
mechanical cues that were seen in Chapter 4.  
Animal models 
A key step forward for clinical translation of the materials and methods developed in this thesis 
will be the initialization of animal trials to evaluate their in vivo efficacy. Preliminary mouse 
ectopic models have already been conducted to assess graft durability and capacity to support 
cellular infiltration ad growth. Eventually, there will be a need for these scaffolds to be implanted 
into load-bearing wound models. There are early plans to implant miniaturized versions of the 
multi-compartment scaffolds into either rat or rabbit rotator cuff injury models. 
Concluding thoughts 
This suite of technologies represents a path towards the development of biomaterials and 
techniques to control stem cell fate in a spatially-dependent manner for the regeneration of 
orthopedic interfaces such as the TBJ. The biomaterial systems applied in this thesis still require 
further development and must be validated through rigorous animal testing before clinical use. 
This work has helped to answer fundamental questions regarding the influence of material 
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properties and dynamic culture conditions on MSC differentiation which will inform future studies 
relating the regeneration of the TBJ and other complex orthopedic tissues and the design of 
platforms to better understand physiological and pathological states. 
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APPENDIX A: SCAFFOLD FABRICATION AND CHARACTERIZATION 
PROTOCOLS 
A.1 CG suspension preparation protocol 
 
Reference: (Yannas, Lee et al. 1989; O'Brien, Harley et al. 2004) 
 
Reagents 
• Collagen from bovine Achilles tendon (Sigma-Aldrich C9879); store at 4oC 
• Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich C4384); store at 4oC 
• Glacial acetic acid (Sigma-Aldrich 71251) 
• Ethylene glycol (VWR BDH1125-4LP) 
• Deionized water 
 
Supplies and equipment 
• Recirculating chiller (Fisher Isotemp Model 900) 
• Rotor-stator (IKA 0593400) 
• Disperser (IKA 3565001) 
• Jacketed beaker (Ace Glass 5340-115) 
• Freeze-dryer (VirTis Genesis) 
• Dual range balance (Mettler Toledo XS105) 
• Beakers 




*This procedure describes how to make 300 mL of 0.5% CG suspension. Scale collagen and GAG 
content appropriately to create different volumes of suspension. 
 
1) Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making sure 
that the cooling coils are completely immersed in the liquid. Set the recirculating chiller to 4oC. 
 
2) Attach recirculating chiller to jacketed beaker and give 20-30 min for temperature to equilibrate 
to 4oC. Maintaining this temperature is important, as it will prevent the collagen from denaturing 
during the blending process. 
 
3) Prepare a 0.05 M solution of acetic acid by adding 0.87 mL of glacial acetic acid to 300 mL of 
deionized water. 
 
4) Weigh 1.5 g of collagen and add to the jacketed beaker.  
 
5) Pour 250 mL of the 0.05 M acetic acid into the jacketed beaker. 
 
6) Assemble the rotor-stator and attach it to the disperser. Lower the rotor-stator into the 
suspension. The rotor-stator should be vertical and centered in the beaker. 
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7) Blend the suspension at 15,000 rpm for 90 min at 4oC. The height of the rotor-stator may need 
to be adjusted during the blending process: If the rotor-stator is positioned too high, the holes on 
its side will be visible; if it is too low, the suspension will bubble excessively. Periodically check 
to see if the rotor-stator is clogged with collagen; remove clogs with a spatula as needed. 
 
8) Add 50 mL of 0.05 M acetic acid to a 50 mL centrifuge tube. Weigh out 0.133 g of chondroitin 
sulfate (GAG) and add to the centrifuge tube. Keep GAG solution in the refrigerator (4oC) until 
next step. 
 
9) Mix the GAG solution well and add it drop-wise with a transfer pipet to the collagen suspension 
while it is being mixed at 15,000 rpm at 4oC. It may be necessary to stop and unclog the rotor-
stator with a spatula during this process.  
 
10) Once all of the GAG solution has been added, blend at 15,000 rpm for 90 min at 4oC. 
Periodically check to ensure the rotor-stator is lowered to the correct depth, as the suspension will 
gradually become less viscous and creep up the sides of the jacketed beaker. Periodically check to 
see if the rotor-stator is clogged; remove clogs with a spatula as needed. 
 
11) Store the suspension for 18-22 h at 4C. 
 
12) Degas the suspension in the freeze-dryer to remove any air bubbles prior to use. Make sure to 
run the ‘Degas’ program and let the condenser temperature reach < -50C to prevent liquid from 
entering the vacuum pump. Degas suspension in a Parafilm-covered beaker until solution boils. 
Note that higher density suspensions typically have more trapped bubbles so adjust the degassing 
volume accordingly. 
 
13) Store the suspension at 4oC. Periodically check the CG suspension; if not homogenous, re-
blend at 15,000 rpm for 30 min at 4oC. 
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A.2 CGCaP suspension preparation protocol 
 
Reference: (Harley, Lynn et al. 2010; Lynn, Best et al. 2010), Process Record No. PR OM-004 
Preparation of Mineralized Slurry, BioUetikon and OrthoMimetics, Process Record No. PR OM-




• Collagen from bovine Achilles tendon (Sigma-Aldrich C9879); store at 4oC 
• Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich C4384); store at 4oC 
• 0.1456M phosphoric acid / 0.037M calcium hydroxide buffer solution 
o 5.904 mL 85% phosphoric acid (Sigma-Aldrich P5811) 
o 570 mL deionized water 
o 1.644 g calcium hydroxide (Sigma-Aldrich 31219) 
o Add acid to water, then calcium hydroxide. Bring volume to 600 mL and adjust pH 
to 2.0-2.4. Solution is good for 3 months. 
• Calcium hydroxide (Sigma-Aldrich, 31219) 
• Calcium Nitrate Tetrahydrate (Sigma-Aldrich, 31218) 
• Ethylene glycol (VWR BDH1125-4LP) 
• Deionized water 
 
Supplies and equipment 
• Recirculating chiller (Fisher Isotemp Model 900) 
• Rotor-stator (IKA 0593400) 
• Disperser (IKA 3565001) 
• Jacketed beaker (Ace Glass 5340-115) 
• Freeze-dryer (VirTis Genesis) 
• Dual range balance (Mettler Toledo XS105) 
• pH meter 
• Beakers 
• Transfer pipets 




*This procedure describes how to make 300 mL of 40 wt% CGCaP suspension. 
 
1) Setup the jacketed vessel, setting the water temperature to 4C. 
 
2) Add 5.7966 g collagen to the jacketed vessel. Then add 242.12mL of phosphate acid / calcium 
hydroxide buffer to the collagen. Set the blender to 15,000 rpm for 30 min, so that the collagen is 
submerged prior to hydration. Allow the collagen to hydrate for 18-22 h in the cooled jacketed 
vessel at 4C. This mixture will become very viscous and difficult to blend. 
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3) Measure out 2.515 g of chondroitin sulfate and add it to 42.94mL of phosphate acid / calcium 
hydroxide buffer in a beaker. Then mix the buffer and the chondroitin (GAG solution), using a 
magnetic stirring bar, until fully dissolved. 
 
4) Measure out 1.92 g calcium hydroxide and 1.17 g calcium nitrate tetrahydrate and place both in 
a 50 mL centrifuge tube. Add 15 mL of deionized water to the tube using a pipette. Then mix 
(vortex/shake) the solution to suspend the salts in the water. 
 
5) Set the blender to 15,000 rpm and blend the hydrated collagen made in step 2 for 60 min. 
 
6) Add the GAG solution prepared in step 3 to the hydrated collagen solution prepared in step 2 in 
8 mL steps while mixing at 15,000 rpm. In between each 8 mL step, take care to prevent any 
clumping of the collagen/GAG with a spatula. With the additional volume, the slurry will mix 
better. 
 
7) Blend this GAG / hydrated collagen solution at 15,000 rpm for 30 min. 
 
8) Blend the collagen / GAG mixture at 200-800 rpm while adding the salts to maximize 
dispersion. Using a pipette, add the salt solution at a rate of 8mL/min to the collagen / GAG 
mixture, allowing time for blending after each volume. Then blend the slurry at 15,000 rpm for 30 
min. 
 
9) Stores the slurry for 18-22 h at 2-8C before use. Periodically check the CG suspension; if not 
homogenous, re-blend at 15,000 rpm for 30 min at 4oC. 
  
 135 
A.3 CG β-cyclodextrin suspension preparation protocol 
 
Reference: (Yannas, Lee et al. 1989; O'Brien, Harley et al. 2004) 
 
Reagents 
• Collagen from bovine Achilles tendon (Sigma-Aldrich C9879); store at 4oC 
• Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich C4384); store at 4oC 
• Glacial acetic acid (Sigma-Aldrich 71251) 
• β-cyclodextrin (Sigma-Aldrich C4805) 
• 1M NaOH 
• Ethylene glycol (VWR BDH1125-4LP) 
• Deionized water 
 
Supplies and equipment 
• Recirculating chiller (Fisher Isotemp Model 900) 
• Rotor-stator (IKA 0593400) 
• Disperser (IKA 3565001) 
• Jacketed beaker (Ace Glass 5340-115) 
• Freeze-dryer (VirTis Genesis) 
• Dual range balance (Mettler Toledo XS105) 
• Beakers 




*This procedure describes how to make 150 mL of 1% CG suspension with 3.7 μg/mL β-
cyclodextrin. Scale collagen, GAG, and β-cyclodextrin content appropriately to create different 
volumes of suspension. 
 
1) Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making sure 
that the cooling coils are completely immersed in the liquid. Set the recirculating chiller to 4oC. 
 
2) Attach recirculating chiller to jacketed beaker and give 20-30 min for temperature to equilibrate 
to 4oC. Maintaining this temperature is important, as it will prevent the collagen from denaturing 
during the blending process. 
 
3) Prepare a 0.05 M solution of acetic acid by adding 0.435 mL of glacial acetic acid to 150 mL 
of deionized water. 
 
4) Weigh 1.5 g of collagen and add to the jacketed beaker.  
 
5) Pour 135 mL of the 0.05 M acetic acid into the jacketed beaker. 
 
6) Assemble the rotor-stator and attach it to the disperser. Lower the rotor-stator into the 
suspension. The rotor-stator should be vertical and centered in the beaker. 
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7) Blend the suspension at 15,000 rpm for 90 min at 4oC. The height of the rotor-stator may need 
to be adjusted during the blending process: If the rotor-stator is positioned too high, the holes on 
its side will be visible; if it is too low, the suspension will bubble excessively. Periodically check 
to see if the rotor-stator is clogged with collagen; remove clogs with a spatula as needed. 
 
8) Add 15 mL of 0.05 M acetic acid to a 50 mL centrifuge tube. Weigh out 0.133 g of chondroitin 
sulfate (GAG) and add to the centrifuge tube. Keep GAG solution in the refrigerator (4oC) until 
next step. 
 
9) Mix the GAG solution well and add it drop-wise with a transfer pipet to the collagen suspension 
while it is being mixed at 15,000 rpm at 4oC. It may be necessary to stop and unclog the rotor-
stator with a spatula during this process.  
 
10) Prepare a solution of 10 mg/mL β-cyclodextrin in 1 M NaOH. 
 
11) Add 11.1 μL β-cyclodextrin to CG slurry. 
 
12) blend at 15,000 rpm for 15 min at 4oC. Periodically check to ensure the rotor-stator is lowered 
to the correct depth, as the suspension will gradually become less viscous and creep up the sides 
of the jacketed beaker. Periodically check to see if the rotor-stator is clogged; remove clogs with 
a spatula as needed. 
 
13) Store the suspension for 18-22 h at 4C. 
 
14) Degas the suspension in the freeze-dryer to remove any air bubbles prior to use. Make sure to 
run the ‘Degas’ program and let the condenser temperature reach < -50C to prevent liquid from 
entering the vacuum pump. Degas suspension in a Parafilm-covered beaker until solution boils. 
Note that higher density suspensions typically have more trapped bubbles so adjust the degassing 
volume accordingly. 
 
15) Store the suspension at 4oC. Periodically check the CG suspension; if not homogenous, re-




A.4 Aligned CG scaffold fabrication protocol 
 
Reference: (Caliari and Harley 2011; Caliari, Ramirez et al. 2011) 
 
Reagents 
• CG suspension; store at 4oC 
• Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105) 
  
Supplies and equipment 
• Freeze-dryer (VirTis Genesis) 
• PTFE-copper freeze-drying mold 
• Beakers 
• Parafilm 
• Aluminum foil 
 
Procedure 
*This procedure describes the fabrication of 15 mm tall aligned scaffolds (single and multi-
compartment, with and without membrane shells). Check that oil is clean (not yellow) before and 
after each freeze-dryer run, replacing when necessary. 
 
1) Degas CG suspension in Parafilm-covered beaker by pulling vacuum inside freeze-dryer to 
remove all air bubbles. Make sure the condenser is at least -50°C or cooler before degassing. 
 
2) Begin to cool freeze-dryer shelves by running 'Tf = xx C shelf cool' program where xx is the 
desired freezing temperature (-10, -40, or -60°C). 
 
3) If making scaffold-membrane composites, cut membranes to size, roll, and place in PTFE-
copper freeze-drying mold holes. 
 
4) Pipette 970 L (8 mm diameter holes) or 540 L (6 mm diameter holes) of suspension into each 
hole in PTFE-copper freeze-drying mold. For scaffold-membrane composites, allow suspension 
to hydrate membranes for 15-30 min at 4°C.  
 
5) For multi-compartment scaffold fabrication, carefully pipet the first suspension (e.g. CG 
suspension, 360 µL) into mold wells. Then, add the second suspension (e.g. CGCaP suspension, 
180 µL) carefully on top of the first suspension, taking care not to mix the two layers. Following 
pipetting, place entire mold on Kimwipe and allow to interdiffuse for 15-30 min at 4°C. 
 
6) Cancel shelf cool program and place freeze-dryer mold on the pre-cooled shelf. Shut the freeze-
dryer door and run program 'Aligned Tf = xx' where xx is the desired freezing temperature (-10, -






Time, min Ramp/Hold Vacuum 
level, torr 
PCM 
Freezing hold -60 60 H ~600 N/A 
Drying ramp 0 60 R 0.2 150 
Drying hold 0 5 H 0.2 1 
Extra drying 0 60 H 0.2 0 
Storage ramp 20 20 R 0.2 0 
Storage hold 20 indefinite H 0.2 0 
 
PCM refers to the minimum reading difference between the Pirani and capacitance manometer 
pressure gauges that must be achieved before the program proceeds to the next step. In Pirani 
gauges, a filament in the gauge is heated so that it is at a constant temperature at a given pressure. 
As the pressure increases or decreases, the amount of gas molecule collisions with the filament 
will change accordingly. More collisions remove more heat from the filament, which lowers the 
temperature and changes the resistance of the filament. This change in resistance is converted to 
an output pressure. Pirani gauges are accurate to within around 7-8%. Capacitance manometers 
operate on the principle of a diaphragm held at a very low reference pressure (10-7 mbar) that is 
deflected by changing pressure. This deflection changes the capacitance between the diaphragm 
and an electrode. This change is converted to pressure. These gauges are extremely accurate (1%). 
These gauges will read different pressures because they operate on very different principles.  The 
capacitance manometer is more accurate because it reads pressure independent of the type of gas 
present. In contrast, the temperature of the filament in the Pirani gauge is affected by the thermal 
conductivity of the colliding gas molecules. For example, the thermal conductivity of water vapor 
is higher than that of air, so for an equal number of water vapor and air molecules colliding with 
the filament the water vapor will remove more heat, causing the Pirani gauge to read a higher 
pressure than the true pressure. Once all of the water vapor is removed the differential between the 
two gauges should read about the same, indicating that the scaffolds are dry. 
 
7) Once the program has reached the storage hold stage, the program can be cancelled and scaffolds 
can be removed from the freeze-dryer. 
 
8) Allow scaffolds to sit in mold at room temperature for at least 1 h before carefully removing 
them with forceps and placing in an aluminum foil pouch. Label pouch with name, collagen type, 




A.5  Isotropic CG scaffold fabrication protocol 
 
Reference: (O'Brien, Harley et al. 2004) 
  
Reagents 
• CG suspension; store at 4oC 
• Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105) 
 
Supplies and equipment 
• Freeze-dryer (VirTis Genesis) 
• Aluminum, polysulfone tray molds (3” x 3”)  
• Beakers 
• Parafilm 
• Aluminum foil 
 
Procedure  
*This procedure describes the fabrication of 3 mm tall scaffold sheets. Check that oil is clean 
(clear, not yellowed) before and after each freeze-dryer run, replacing when necessary. It is easiest 
to replace the oil just after a run, when the oil is still warm.  
 
1) Degas the CG suspension in a beaker (covered in Parafilm with small slits) by pulling vacuum 
inside freeze-dryer. Degas just to the boiling point to remove all air bubbles. Make sure the 
condenser is at least -50°C or cooler before degassing. 
 
2) Add 24.25 mL of CG suspension to a 3” x 3” tray mold, ensuring that the suspension reaches 
the corners. Push any bubbles or unblended collagen to the edge using tweezers.  
 
3) Open freeze- dryer door, place mold on center of shelf. Quickly close the freeze-dryer door and 
run the program ‘Tf-xx No Hold’ where xx is the desired freezing temperature (-10, -40, or -60°C). 
A typical schedule is shown below for the constant cooling fabrication method with a final freezing 




Time, min Ramp/Hold Vacuum 
level, torr 
PCM 
Freezing hold 20 5 H ~600 N/A 
Freezing ramp -10 30 R ~600 N/A 
Freezing hold -10 120 H ~600 N/A 
Drying ramp 0 10 R 0.2 150 
Drying hold 0 5 H 0.2 1 
Extra drying 0 60 H 0.2 0 
Storage ramp 20 20 R 0.2 0 
Storage hold 20 indefinite H 0.2 0 
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4) Once the program has reached the storage hold stage, the program can be cancelled and the 
array can be removed from the freeze-dryer.  
 
5) Gently remove scaffold by lifting from corner with tweezers. Place scaffold in puffed aluminum 
pouch. Label pouch with name, collagen type, collagen concentration, freeze date, freeze 
temperature, and any other relevant notes. Clean mold by rubbing with soapy water; use 0.05 M 
acetic acid to remove collagen residue. Do not use cleaning brushes.  
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A.6 DHT crosslinking protocol 
 
Reference: (Yannas, Lee et al. 1989; Harley, Leung et al. 2007) 
 
Supplies and equipment 
• Sterile air filter (Millipore SLGP033RS) 
• Vacuum oven (Welch Vacuum, Fisher 13-262-52) 
 
Procedure 
*Note: vacuum pump oil levels and integrity of vacuum fittings should be checked periodically. 
Also, change sterile air filter on 'Purge' line regularly. Remember that scaffolds containing CGCaP 
content should be oven treated as this will cause irreversible dehydration of the calcium phosphate 
phase from brushite to monetite. 
 
1) Turn on vacuum oven and set desired temperature (usually 105°C). 
 
2) Once vacuum oven has reached temperature set point, place CG scaffolds in opened aluminum 
pouches carefully inside the oven. Close the oven door.  
 
3) Completely open the 'Vacuum' valve on the lower right front face of the vacuum oven while 
completely closing the 'Purge' valve. 
 
4) Turn on the vacuum pump and make sure vacuum is pulled to a sufficiently low level (< 1 in 
Hg). Allow scaffolds to crosslink for 24 h. 
 
5) After crosslinking is complete turn off the vacuum pump, close the 'Vacuum' valve, open the 
'Purge' valve, carefully remove scaffolds from the oven, and seal the aluminum pouches. Store 
sealed scaffolds (now sterile) in desiccator until time of use.  
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A.7 EDAC crosslinking protocol 
 




• 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC, Sigma-Aldrich 
E7750); store at -20oC 
• N-hydroxysulfosuccinimide (NHS, Sigma-Aldrich H7377); store in desiccator 
• Sterile phosphate-buffered saline (PBS) 
• 100% ethanol 
 
Supplies and equipment 
• 6-well plates (Fisher 08-772-1B) 
• 50 mL centrifuge tubes (Fisher 14-432-22) 
• Syringe and syringe filter (Fisher 148232A) 
• MTS 2/4 digital microtiter shaker (IKA 3208001) 
• Dual range balance (Mettler Toledo XS105) 
• Razor blades  
 
Procedure 
* Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
 
1) Cut scaffold or membrane samples to be crosslinked using a razor blade. 
 
2) Transfer scaffold or membrane pieces to sterile centrifuge tube, remove from laminar flow hood, 
and weigh pieces on dual range balance. 
 
3) Hydrate pieces in 100% ethanol overnight. 
 
4) Rinse pieces several times in PBS and then let soak in PBS for 24 h before crosslinking. 
 
5) Determine the EDAC and NHS concentrations to be used in crosslinking solution. The sample 
calculations in this protocol are done with a 5:2:1 EDAC:NHS:COOH molar ratio where COOH 
is carboxylic acid groups in CG material based on a conversion factor of 1.2 mmol COOH per 
gram of collagen (Olde Damink, Dijkstra et al. 1996). The mass of EDAC and NHS required can 


























































































0012.0                                  (Equation D.2) 
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6) Mix the EDAC and NHS in sterile PBS. Approximately 1 mL of solution will be needed per 
scaffold piece (6-8 mm diameter, 3-5 mm thick).  
 
7) In the laminar flow hood, sterile filter the solution and add to 6-well plates. 
 
8) Add scaffolds in crosslinking solution and place well plate on shaker on bench 6. Allow 
scaffolds to crosslink under moderate shaking for 1.5 h. Crosslinking time should be increased for 
less permeable constructs such as membranes and high solids content scaffolds. 
 
9) Remove EDAC/NHS solution and rinse scaffolds in sterile PBS under moderate shaking for 10-
15 min. 
 
10) Remove first PBS wash solution and rinse scaffolds in fresh PBS under moderate shaking for 
an additional 30-45 min. Store in fresh sterile PBS at 4°C until use. 
  
 144 
A.8 CG scaffold critical point drying 
Reference: (Grier, Moy et al. 2017) 
Reagents  
• 200 proof (100%) ethanol 
• Deionized water 
• Carbon dioxide gas 
Equipment and Supplies  
• 24-well plates (Fisher 08-772-1) 
• Pasteur pipettes 
• Forceps 
• MTS 2/4 digital microtiter shaker (IKA 3208001) 
• Samdri-PVT-3D Manual Critical Point Dryer (Tousimis) 
 
Scaffold dehydration procedure  
 
1) Set up step-wise ethanol washes in a 24-well plate on the shaker. 
• 20% ethanol – 30 min 
• 50% ethanol – 30 min 
• 70% ethanol – 30 min 
• 90% ethanol – 30 min 
• 100% ethanol – over night 
 
Critical point drying protocol 
*This procedure describes how to perform manual critical point drying (CPD) on CG scaffolds. 
Automated methods are available, but are not suitable due to the retention of ethanol by the 
scaffold.  
 
1) Reserve time on critical point dryer (Samfri-PVT-3D) using calendar on Beckman ITG 
Microscopy Suite website. The training contact is Cate Wallace.  
 
2) Verify that all knobs on the CPD instrument are closed and set to the zero position (cool, bleed, 
purge, fill), flip the power switch to “on” and allow the instrument to warm up for ~3 min. 
 
3) Open the chamber and inspect the o-ring for defects or flaws. 
 
4) With a pipette, transfer ~9 mL of 100% ethanol provided at Beckman (in sieves). Note: 
withdrawal ethanol from the top of the liquid as far as possible from the sieves. 
 
5) Place the scaffold/s into the chamber and close the chamber by evenly tightening the knurled 
nuts by hand (Do Not Use Tools). 
 
6) Open the valve located on the CO2 tank. 
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7) Open the cool valve and allow the temperature in the chamber to reach 0 oC. When 0 oC is 
reached, close the cool valve. This should take ~ 60 seconds. If the cooling seems to be happening 
too fast, decrease the cool valve position. 
 
8) Slowly open the fill valve and allow CO2 into the chamber and close the valve before the liquid 
level in the chamber reaches the top. Do not completely fill the chamber at this point. Allow this 
solution to equilibrate for a few minutes while ensuring that the temperature in the chamber is 
maintained between 0 oC and 10 oC by opening the cool valve periodically as necessary. 
 
9) With the fill valve closed, open the purge/vent valve and drain the chamber to ~ half level. 
Ethanol and CO2 will discharge from the tube on the side of the instrument. 
 
10) Repeat steps 7 and 8 until the scaffolds sink to the bottom of the chamber and only solid CO2 
discharges from the tube on the side of the instrument. At this point, the ethanol has been 
completely exchanged with CO2.  
 
11) Open the fill valve and completely fill the chamber. A meniscus will pass across the sight glass 
when the chamber is full. 
 
12) With the fill valve still open, open the purge/vent valve for ~ 60 seconds to ensure all ethanol 
has been removed. 
 
13) Close all valves and turn on the heat switch. Allow the chamber to heat/pressurize and allow 
the chamber to maintain the critical point for at least 5 minutes. Refer to PVT-3D manual for 
critical point parameters. 
 
14) Leaving the heat switch on, slowly open the bleed valve to exhaust the CO2 from the chamber. 
Adjust bleed valve accordingly to maintain a pressure release rate of ~ 100 psi/min. This process 
should take 10-13 minutes. 
 
15) Once the chamber pressure reaches 0 psi, the heat switch can be turned off and samples 
removed. 
 
16) Turn off the main CO2 valve on the CO2 tank and reattach the chamber lid. 
 
17) Open, in order, the bleed valve, purge/vent valve, fill valve and cool valve to clear all 




A.9 Scanning electron micrograph imaging of CG scaffolds 
Reference: (Grier, Moy et al. 2017) 
Equipment and Supplies  
• Desk-1 TSC sputter coater (Denton Vacuum) 
• FEI Quanta FEG 450 ESEM (FEI Company) 
• Carbon tape 
• Razor blades 
• Forceps 
 
Sputter coating procedure  
 
1) Reserve time on SEM (FEI Quanta FEG 450 ESEM) using calendar on Beckman ITG 
Microscopy Suite website. The training contact is Cate Wallace 
 
2) Section scaffolds as desired and mount to sample stubs using carbon tape (provided in Beckman 
ITG Microscopy Suite ESEM room). 
 
3) Place sample stubs into Desk-1 TSC sputter coater (located in wet lab area). The training contact 
is Scott Robinson. 
 
4) Follow machine instructions located on bench to coat specimens with an Au/Pd mixture. 
 
Sample loading procedure 
*This procedure and more information can be found on the Beckman ITG Microscopy Suite 
website 
 
1) Start xT Microscope Server and log on. Click to hide the Status window. Right click the top of 
the server window, and choose Show Tiny View. 
 
2) Ensure that live video feed is being displayed to observe all stage movement. 
 
3) Click ‘Vent’ on vacuum mode on the beam control Panel to open the SEM chamber. The color 
of the chamber icon changes from green to orange. This will take about 1 min. 
 
4) Once vented, slowly pull the chamber door open, taking caution to ensure that any samples left 
in machine will not hit the pole piece or any detector. Use live video feed to visually confirm this. 
 
5) Load sample stub. 
 
6) Swing the NavCam 90 degrees to activate it.  
 
7) Wait for the stage to move under the NavCam and for the lower-left quadrant to go live. 
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8) Take a picture with the NavCam by pressing the round silver button located at the base of the 
NavCam arm. An image of your sample on the stage will appear in quad III. Wait for the light to 
blink off two times.  
 
9) Swing the NavCam back to its home position. 
 
10) Slowly push the door into the close position. Before initializing pump down, ensure the door 
is completely closed. 
 
11) Click the radio button to select necessary vacuum mode (high vacuum, low vacuum, or ESEM). 
For the Low Vacuum mode select the target Chamber Pressure and aperture cone choice before 
clicking the Pump button. Press the chamber door handle firmly for a few seconds to help seal the 
chamber at the beginning of pump-down. 
 
SEM imaging procedure 
*This procedure and more information can be found on the Beckman ITG Microscopy Suite 
website 
 
1) While pumping, double click where you want to move the stage to on the NavCam image. 
 
2) Wait until chamber pressure reaches vacuum. 
 
3) Click on Beam On. Either quad I or quad II can be used to perform SEM imaging but only quad 
I can be fed into EDS. Click on the pause button (or F6) to make that quad go live. 
 
4) Click on the Auto Contrast/Brightness (half black/half white circle) button on the software 
toolbar. 
 
5) Navigate around to find a distinguishable feature on the sample surface. Focus on your sample 
by either holding down the right mouse button and dragging the mouse to the left or right or by 
using the Coarse and Fine knobs on the MUI. 
* You can use the Reduced Area icon (or F7) to assist. Focusing at 2x to 3x the magnification 
needed for the final result will make the lower magnification sharper. 
 
6) To change the magnification, use the + and – buttons on the numpad. This will double and halve 
the magnification, respectively and will always be a rounded number. You may also use the 
magnification dial on the MUI. This will change the magnification in smaller increments, but will 
not be a rounded number. You may use the asterisk (*) button on the numpad to round the number. 
 
7) Link Z by clicking on the icon that looks like a pyramid and a halo with a red question mark in 
the middle. Working distance can be reduced if necessary by going to the navigation tab on the 
right and selecting the desired working distance. Usually you want to be at least at 10mm working 
distance, if not shorter. 
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8) You can move around the sample by double clicking on the point of interest to center it within 
the quad, or using arrows on the keyboard, or pressing the scroll wheel on the mouse and dragging 
the mouse in the direction you want to move. 
 
9) If image moves when changing focus, follow instructions to center aperture.  
 
10) Correct astigmatism by focusing as well as possible at double the magnification used for 
imaging and hold shift key and right mouse button, moving to the left or right. Repeat as needed.  
 
11) Save the desired image by clicking the Image Acquisition button on upper menu banner, or by 
selecting F2. The scan will pause after one frame scanned and a save dialog will open. You can 
also save by going to the File menu and selecting Save As. 
 
Venting chamber and unloading samples 
*This procedure and more information can be found on the Beckman ITG Microscopy Suite 
website 
 
1) Turn the beam off by pressing the Beam On button. The button should turn from yellow to grey. 
 
2) Slowly pull the chamber door open while monitoring the live video feed of the chamber. Ensure 
that the sample and stage path is clear. 
 
3) Remove sample stubs. 
 
4) Slowly push the chamber door closed and click the Pump button under the Beam Control menu 
on the right to pump the chamber back to high vacuum. 
 
5) Wait for the vacuum icon to turn green. Hit the Stop button on the server window, and wait for 
the server to fully unload (the green bar will empty out). 
 
6) Log off. 
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A.10 Embedding CG scaffolds into end blocks for bioreactor 
Reference: (Grier, Moy et al. 2017) 
Equipment and Supplies  
• Poly(dimethylsiloxane) (PDMS) 
• Dual range balance (Mettler Toledo XS105) 
• Pipet tips 
• 3D printed hollow end blocks 
• 3D printed racks and holders 
• 25mm Scaffold cutting guides 




1) Prepare PDMS for scaffold immobilization. Use a monomer: curing agent ratio of 5:1. About 
10 g of PDMS is needed per 36 end blocks. 
 
2) Place end blocks into holders. 
 
3) Using a 1000 μL micropipette tip, fill end blocks with ~200 μL of PDMS. This should fill the 
end block to slightly below the surface.  
 
4) Briefly allow PDMS to settle, add additional PDMS if needed.  
 
5) Place PDMS-loaded end blocks into 37°C incubator for 45 minutes to begin polymerization.  
 
6) While PDMS is curing, cut scaffolds to length using the 25mm cutting guide.  
 
7) After 45 minutes, remove end blocks in holders from incubator and place racks over top. 
 
8) Push scaffold ends into PDMS in the end blocks, ensuring that the scaffold stays vertically 
aligned with the rack.  
 
9) Place back into incubator overnight.  
 
10) Repeat steps 1-9 for the other end of the scaffold. 
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A.11 Ethylene oxide sterilization of CG scaffolds  
Reference: (Grier, Moy et al. 2017) 
Equipment and Supplies  
• Anprolene AN74i benchtop ethylene oxide sterilizer (Anderson Products) 
• Large anprolene ampule 
• Anprolene bag 
• Humidi-chip 
• Sterilization pouches 




1) Place all scaffolds and other items to be sterilized into sterilization pouches. Any pouches 
containing soft materials, such as scaffolds should then be places into a vented plastic container. 
 
2) Place all pouches into anprolene bag. 
 
3) Turn on sterilizer, it will run through a self-test. 
 
4) Load bag containing samples into sterilizer, place venting apparatus inside bag al of the way to 
the back.  
 
5) Place humidi-chip in plastic tube and place into bag. 
 
6) Place anprolene ampoule, wrapped in paper in clear back, inside the anprolene bag. Make sure 
that it can be access from outside the bag later on. 
 
7) Close bag around the large sleeve on the venting tube. Use hook and loop straps to seal closed. 
 
8) Press Start Cycle, the sterilizer will then vent the air from the bag. This takes about 1 min.  
 
9) Once bag is vented, locate anprolene ampoule and break top. The bag will begin to inflate. 
 
10) Close and lock sterilizer door. 
 
11) Select cycle length of either 12 or 24 hours.  
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A.12 Bioreactor operation protocol  
Reference: (Grier, Moy et al. 2017) 
Equipment and Supplies  
• Bioreactor system 
• Linear actuator JRK motor controller (Pololu) 
• Computer with Pololu JRK configuration utility 




1) Connect linear actuator on bioreactor to motor controller using the quick connect cables. 
 
2) Turn on power supply, ensure that it is set to 8V.  
 
3) Open Pololu JRK software. 
 
4) Ensure that controller has open connection to motor. 
 
5) Set target length to starting position (see standard cure for setting for various scaffold lengths). 
 
6) Close Pololu configuration utility. 
 
7) Run 10on5and50off program. 
 
8) Select desired parameters, frequency, rest time, strain amplitude.  
 
9) Click Connect. 
 
10) When removing bioreactor from incubator, click Disconnect, disconnect controller from 
bioreactor. 
 
















    public partial class MainWindow : Form 
    { 
        public MainWindow() 
        { 
            InitializeComponent(); 
        } 
 
        #region events 
        /// <summary> 
        /// When the program starts, this function is called. 
        /// It gets the serial number of the first connected Jrk, 
        /// since this is probably what you want to connect to. 
        /// </summary> 
        void MainWindow_Shown(object sender, EventArgs e) 
        { 
            var deviceList = Jrk.getConnectedDevices(); 
            if (deviceList.Count > 0) 
            { 
                SerialNumberTextBox.Text = deviceList[0].serialNumber; 
                ConnectButton.Focus(); 
            } 
            else 
            { 
                SerialNumberTextBox.Focus(); 
            } 
        } 
 
        void ConnectButton_Click(object sender, EventArgs e) 
        { 
            SerialNumberTextBox.Enabled = false; 
            Log("Connecting..."); 
            UpdateTimer.Start(); 
            StopConnectingButton.Enabled = true; 
            ConnectButton.Enabled = false; 
        } 
 
        void StopConnectingButton_Click(object sender, EventArgs e) 
        { 
            SerialNumberTextBox.Enabled = true; 
            TryToDisconnect(); 
            UpdateTimer.Stop(); 
            StopConnectingButton.Enabled = false; 
            ConnectButton.Enabled = true; 
        } 
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        #endregion 
 
        #region logging 
        void Log(Exception e) 
        { 
            Log(e.Message); 
        } 
 
        void Log(string text) 
        { 
            if (LogTextBox.Text != "") 
                LogTextBox.Text += Environment.NewLine; 
            LogTextBox.Text += DateTime.Now.ToString() + "\t" + text; 
            LogTextBox.SelectionStart = LogTextBox.Text.Length; 
            LogTextBox.ScrollToCaret(); 
        } 
        #endregion 
 
        #region the Jrk connection 
 
        Jrk jrk = null; 
 
        /// <summary> 
        /// Connects to the device if it is found in the device list. 
        /// </summary> 
        void TryToReconnect() 
        { 
            foreach (DeviceListItem d in Jrk.getConnectedDevices()) 
            { 
                if (d.serialNumber == SerialNumberTextBox.Text) 
                { 
                    jrk = new Jrk(d); 
                    Log("Connected to #" + SerialNumberTextBox.Text + "."); 
                    jrk.setTarget(MaxTargetConverted);//as soon as connect, go here ASM 
                    CycleAlreadyStarted = false; 
                    return; 
                } 
            } 
        } 
 
        void TryToDisconnect() 
        { 
            if (jrk == null) 
            { 
                Log("Connecting stopped."); 
                return; 
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            } 
 
            try 
            { 
                Log("Disconnecting..."); 
                jrk.disconnect(); 
            } 
            catch (Exception e) 
            { 
                Log(e); 
                Log("Failed to disconnect cleanly."); 
            } 
            finally 
            { 
                // do this no matter what 
                jrk = null; 
                Log("Disconnected from #" + SerialNumberTextBox.Text + "."); 
            } 
        } 
 
        int sequenceCounter = 0; 
 
        private const ushort MaxTargetConverted = 850;//scaffold length ASM; switched this from 
max to min and mm to weirdunits too 
 
        private const ushort ErrorMargin = 3; 
 
        private double ConvertFromWeirdUnitToMm(ushort value)//used different standard curve 
to calc best fit line ASM 
        { 
            return (value - 148.81) / 82.877; 
        } 
        //private ushort ConvertFromMmToWeirdUnit(double value) 
        //{ 
        //    return Convert.ToUInt16((value * 82.877) + 148.81); 
        //} 
 
        bool CycleAlreadyStarted; 
 
        /// <summary> 
        /// Steps through a simple sequence, setting the target to  
        /// 1500, 2000, and 2500 with 1 second between frames. 
        /// This function is run every 100 ms when the motion sequence 
        /// is activated. 
        /// </summary> 
        void RunSequence() 
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        { 
            double second=915.0 / UpdateTimer.Interval; 
            double workingTime = (360 - 
Convert.ToInt32(cmbRestTime.SelectedItem.ToString()))*60*second; //changed for 6 hr// 
            if (anothercounter <= workingTime) 
            { 
                #region setMinTargetConvertedStrain 
                string percentStrain = cmbStrain.SelectedItem.ToString(); 
                ushort MinTargetConverted; 
                switch (percentStrain) 
                { 
                    case "2.5": 
                        MinTargetConverted = 814; 
                        break; 
                    case "5": 
                        MinTargetConverted = 779; 
                        break; 
                    case "7.5": 
                        MinTargetConverted = 744; 
                        break; 
                    case "10": 
                        MinTargetConverted = 707; 
                        break; 
                    case "12.5": 
                        MinTargetConverted = 671; 
                        break; 
                    case "15": 
                        MinTargetConverted = 636; 
                        break; 
                    case "20": 
                        MinTargetConverted = 565; 
                        break; 
                    default: 
                        MinTargetConverted = MaxTargetConverted; 
                        break; 
                } 
                #endregion 
                ushort actualPosition = jrk.getVariables().scaledFeedback; 
                #region updateUI 
                lblMin.Text = MinTargetConverted.ToString(); 
                lblMax.Text = MaxTargetConverted.ToString(); 
                lblActual.Text = actualPosition.ToString(); 
                #endregion 
 
                if (actualPosition <= MinTargetConverted + ErrorMargin) 
jrk.setTarget(MaxTargetConverted);//I switched these bc it was moving backwards ASM 
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                else if (actualPosition >= MaxTargetConverted - ErrorMargin) 
                { 
                    if (!CycleAlreadyStarted) 
                    { 
                        jrk.setTarget(MinTargetConverted);//Go back and forth (hopefully...)ASM 
                        sequenceCounter = 0; 
                        CycleAlreadyStarted = true;//start cycle and start counting ASM 
                    } 
                } 
 
 
                sequenceCounter++; 
                if (CycleAlreadyStarted && sequenceCounter >= 
Convert.ToInt32(cmbHz.SelectedItem) * second)//don't restart cycle until 1 sec ASM 
                { 
                    sequenceCounter = 0; 
                    CycleAlreadyStarted = false; 
                        jrk.setTarget(MaxTargetConverted); 
                } 
            } 
            anothercounter++; 
           if (anothercounter >= 6*60*60*second) anothercounter = 0; //changed for 6 hr//  
            //if (anothercounter >= 6 * 60 * 60 * second) { anothercounter = 0; connect(); }// 
        } 
 
        #endregion 
 
        //ashley trying to code rest time// 




        #region updating 
 
        /// <summary> 
        /// This function will be called once every 100 ms to do an update. 
        /// </summary> 
        void UpdateTimer_Tick(object sender, EventArgs eventArgs) 
        { 
            if (jrk == null) 
            { 
 
                // Try connecting to a device. 
                try 
                { 
                    TryToReconnect(); 
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                } 
                catch (Exception e) 
                { 
                    Log(e); 
                    Log("Failed connecting to #" + SerialNumberTextBox.Text + "."); 
                    jrk = null; 
                } 
            } 
            else 
            { 
                // Update the GUI and the device. 
                try 
                { 
                    RunSequence(); 
                } 
                catch (Exception e) 
                { 
                    // If any exception occurs, log it, set jrk to null, and keep trying.. 
                    Log(e); 
                    Log("Disconnected from #" + SerialNumberTextBox.Text + "."); 
                    jrk = null; 
                } 
            } 
        } 
 
        #endregion 
 
        private void label2_Click(object sender, EventArgs e) 
        { 
 
        } 
 
        private void MainWindow_Load(object sender, EventArgs e) 
        { 
            cmbHz.SelectedIndex = 0; 
            cmbStrain.SelectedIndex = 0; 
        } 
 
        private void label3_Click(object sender, EventArgs e) 
        { 




    } 
} 
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A.13 Growth factor pulldown by CG scaffolds 
Reference: (Hortensius and Harley 2013) 
Reagents  
• Bovine serum albumin (Sigma-Aldrich A7906) 
• Sterile PBS 
• Growth factors 
o Human TGF-β1 (ProSpec CYT-716) 
o Human BMP-2 (ProSpec CYT-261) 
Equipment and Supplies  
• 24-well plates (Fisher 08-772-1) 
• Sterile filters 
• Syringes 




1) Prepare 100 mL solution of 1% BSA (weight) in PBS. 
 
2) Sterile filter BSA solution.  
 
3) Add 5 ng/mL of desired growth factor to BSA solution. 
 
4) Place 3 scaffolds (6 mm diameter4 5 mm height) per well into a 24-well plate. 
 
5) Add 1 mL of growth factor/BSA solution to each well.  
 
6) Place on shaker at room temperature for 1 hr. 
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A.14 Quantitative analysis of TGF-β pulldown by CG scaffolds 
Reference: (Hortensius and Harley 2013) 
Reagents  
• 1 N HCl 
• 1.2 N NaOH/0.5 M HEPES 
• Stop Solution - 2N H2SO4 
• PBS 
• Tween 20 
• Reagent Diluent 1 10x concentrate (R&D Systems DY997) 
• Color Reagent A (R&D Systems DY007) 
• Color Reagent B (R&D Systems DY007) 
 
Equipment and Supplies  
• Human TGF-β DuoSet ELISA Kit (R&D Systems DY240) 
• ELISA Plate sealers (R&D Systems DY992) 
• Sterile filters 
• Syringes 
• Microcentrifuge tubes 
• Fluorescence spectrophotometer (Tecan, Room 100 RAL) 
 
 
Plate set up procedure 
 
1) Prepare Wash Buffer – 0.05% Tween 20 in PBS 
 
2) Prepare Block Buffer – 5% Tween 20 in PBS – sterile filtered 
 
3) Dilute the Capture Antibody (to the working concentration stated in the product datasheet ) in 
PBS without carrier protein.  
 
4) Immediately coat a 96-well microplate with 100 µL per well of the diluted Capture Antibody.  
 
5) Seal the plate and incubate overnight at room temperature. 
 
6) Aspirate each well and wash with Wash Buffer, repeating the process two times for a total of 
three washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle. After the 
last wash, remove any remaining Wash Buffer by aspirating or by inverting the plate and blotting 
it against clean paper towels.  
 
7) Block plates by adding 300 µL Block Buffer. 
 
8) Seal plate and incubate 1 hr at room temperature 
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9) Repeat wash step in Step 6. 
 
Sample activation procedure 
 
1) Add 20 µL of 1 N HCl to 100 µL of sample. Mix well. 
 
2) Incubate 10 min at room temperature 
 
3) Add 20 µL of 1.2 N NaoH/0.5M HEPES. Mix well. 
 




1) Add 100 µL of samples or standards provided in Human TGF-β DuoSet ELISA Kit in Reagent 
Diluent per well.  
 
2) Cover with adhesive strip and incubate 2 hr at room temperature 
 
3) Repeat wash step in Part 1, Step 6. 
 
4) Add 100 µL of Detection Antibody provided in Human TGF-β DuoSet ELISA Kit, diluted in 
Reagent Diluent per well. 
 
5) Cover with adhesive strip and incubate 2 hr at room temperature. 
 
6) Repeat wash step in Part 1, Step 6. 
 
7) Prepare substrate solution – 1:1 mixture of Color Reagent A and Color Reagent B. 
 
8) Add 100 μL of Substrate Solution provided in Human TGF-β DuoSet ELISA Kit to each well. 
 
9) Cover with adhesive strip and incubate 20 min at room temperature. Avoid placing in direct 
light. 
 
10) Add 50 μL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 
 





APPENDIX B: CELL CULTURE, ASSAY, AND IMAGING PROTOCOLS 
B.1 Incubator disinfection protocol 
 
Reagents 
• Steris staphene spray (Fisher 14-415-15) 




1) Shut off the CO2 tanks and turn off the incubator. 
 
2) Prepare the sterile hood by covering the inside with bench-coat. 
 
3) Cover the chemical fume hood with fresh bench-coat. 
 
4) Disassemble all removable parts from the incubator chamber. Spray all pieces from the 
incubator inside the chemical fume hood with staphene. Spray the inside of the inside of the 
incubator with staphene. Let stand for 15 min with the incubator door cracked open ~2 in.  
 
5) Spray the inside of the incubator with 70% ethanol. Wipe off the excess staphene with paper 
towels.  
 
6) Spray all internal pieces of the incubator in the chemical fume hood with 70% ethanol and wipe 
off the excess staphene. Spray each part generously with ethanol again and place into the sterile 
hood to dry. Do not wipe anything down. Allow all parts to air dry for 15-30 min.  
 
7) Spray the inside of the incubator with 70% ethanol and allow all parts to dry for 15-30 min; do 
not wipe anything down.  
 
8) Reassemble all internal pieces of the incubator, taking care to move each piece from the sterile 
hood to the incubator as quickly as possible.  
 
9) Spray the inside of incubator again with 70% ethanol. Shut the foot and allow all parts to dry; 
do not wipe anything down.  
 
10) Turn on the incubator power and open the valves on the CO2 tanks. Allow the incubator to 










B.2 Tenocyte culture protocol 
 
Reference: (Kapoor, Caporali et al. 2010; Caliari and Harley 2011; Caliari, Ramirez et al. 2011) 
 
Reagents 
• Complete tenocyte media (500 mL); store at 4oC 
o 445 mL high glucose DMEM (Based on Fisher SH30022.FS, order from Sandy at 
SCS Media Facility); store at 4oC 
o 50 mL fetal bovine serum (Invitrogen 16140-071); store at -20oC 
o 5 mL antibiotic-antimyotic (Invitrogen 15140-122); store at -20oC 
o 25 mg ascorbic acid (Wako 014-04801) 
o Sterile filter before use 
• Trypsin-EDTA (Invitrogen 25300-062); store at -20oC  
• Trypan blue (Sigma-Aldrich T8154) 
• DMSO (Fisher D128-500) 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
 
Supplies and equipment 
• Hausser phase contrast hemacytometer (Fisher 02-671-5) 
• Tabletop centrifuge (VWR 53513-812) 
• Optical microscope (Leica Microsystems DMIL LED) 
• Water bath (37oC, Fisher 15-474-35) 
• Sterile filters 
• Sterile pipettes (5, 10, 25 mL) 
• T75 tissue culture flasks 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
 
Tenocyte thawing procedure 
 
1) Place complete tenocyte media in water bath and warm to 37oC. 
 
2) Thaw frozen cell vials in 37oC water bath for about 2 min. 
 
3) Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add complete tenocyte 
media until the cerulean effect has dissipated, then bring the volume up to 9 mL. 
 
4) Remove a 10 L cell suspension aliquot for counting. Gently re-suspend the cells in the diluted 
media and pellet the cells at 1000 rpm for 7 min. 
 
5) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 




7) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
8) Seed the cells at the required density (usually 10,000 cells/cm2). Use around 10-12 mL media 
for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
 
9) Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells twice a 
week. Cells are usually confluent after 5 days. Do not use past passage 4. 
 
Tenocyte feeding procedure 
 
1) Warm complete tenocyte media in water bath to 37oC.  
 
2) When the media is warm, wipe dry with paper towel and spray with 70% ethanol before placing 
in the sterile hood.  
 
3) Remove all old media from each T75 flask, taking care not to scrape the cells with the pipette 
tip. 
 
4) Add 12-14 mL of complete tenocyte media. Return the T75 flasks to the incubator and feed 
every twice a week. Adjust volume of media accordingly for different sized flasks. 
 
Tenocyte passaging procedure 
 
1) Warm complete tenocyte media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37oC.  
 
2) When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood.  
 
3) Remove all old media from each T75 flask, taking care not to scrape the cells with the pipette 
tip. 
 
4) Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. Adjust volumes of PBS, media, and trypsin 
accordingly for different sized flasks. 
 
5) Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
6 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 




6) Add 6 mL of complete tenocyte media to each flask to neutralize the trypsin and to flush cells 
off of the tissue culture plastic. 
 
7) Remove the trypsin, additional media, and cells from the flask and put into a conical tube.  
Remove a 10 L cell suspension aliquot for counting. Centrifuge the cells at 1000 rpm for 7 min.  
 
8) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 
9) Place a cover slip on the hemacytometer and pipette 10 L of the stain/cell suspension into the 
hemacytometer. 
 
10) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
11) Aspirate off the media supernatant and add new media to dilute cells to desired concentration. 
 
12) Seed the cells at the required density (usually 10,000-50,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
 
13) Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells every 48-
72 h. 
 
Tenocyte freezing procedure 
 
1) Grow cells to confluence and replace media the day before freezing. 
 
2) Warm complete tenocyte media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37oC.  
 
3) When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood.  
 
4) Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
 
5) Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. Adjust volumes of PBS, media , and trypsin 
accordingly for different sized flasks. 
 
6) Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
6 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 




7) Add 6 mL of complete tenocyte media to each flask to neutralize the trypsin and to flush cells 
off of the tissue culture plastic. 
 
8) Remove the trypsin, additional media, and cells from the flask and put into a conical tube.  
Remove a 10 L cell suspension aliquot for counting. Centrifuge the cells at 1000 rpm for 7 min.  
 
9) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 
10) Place a cover slip on the hemacytometer and pipette 10 L of the stain/cell suspension into the 
hemacytometer. 
 
11) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
12) Aspirate off the media supernatant and calculate volume of freezing media needed to re-
suspend 1-10 x 106 cells per mL (freezing media: 50% complete tenocyte, 40% FBS, 10% DMSO).  
 
13) Aliquot cells into 1 mL cryogenic tubes and place in -20oC freezer for 1 h. 
 
14) Place cryogenic tubes in -80oC freezer. Cells can be stored here for up to 6 months. For longer-




B.3 hMSC culture and differentiation protocol 
Reference: Protocols from Matt Wheeler group and Jennie P. Mather 
 
Reagents 
• Complete hMSC media (500 mL); store at 4oC 
o 445 mL low glucose DMEM (Based on Fisher SH30022.FS, order from Sandy at 
SCS Media Facility); store at 4oC 
o 50 mL MSC-validated fetal bovine serum (Invitrogen 12662-029); store at -20oC 
o 5 mL antibiotic-antimyotic (Invitrogen 15140-122); store at -20oC 
• Trypsin-EDTA (Invitrogen 25300-062); store at -20oC  
• Trypan blue (Sigma-Aldrich T8154) 
• DMSO (Fisher D128-500) 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
 
Supplies and equipment 
• Hausser phase contrast hemacytometer (Fisher 02-671-5) 
• Tabletop centrifuge (VWR 53513-812) 
• Optical microscope (Leica Microsystems DMIL LED) 
• Water bath (37oC, Fisher 15-474-35) 
• Sterile filters 
• Sterile pipettes (5, 10, 25 mL) 
• T75 tissue culture flasks 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
 
MSC thawing procedure 
 
1) Place complete MSC media in water bath and warm to 37oC. 
 
2) Thaw frozen cell vials in 37oC water bath for about 2 min. 
 
3) Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add complete MSC 
media until the cerulean effect has dissipated, then bring the volume up to 9 mL. 
 
4) Remove a 10 L cell suspension aliquot for counting. Gently re-suspend the cells in the diluted 
media and pellet the cells at 600 g for 5 min. 
 
5) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 




7) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
8) Seed the cells at the required density (usually 5,000-6,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
 
9) Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells twice a 
week. Cells are usually confluent after 7-9 days. Do not use past passage 6. 
 
MSC feeding procedure 
 
1) Warm complete MSC or lineage-specific induction media in water bath to 37oC.  
 
2) When the media is warm, wipe dry with paper towel and spray with 70% ethanol before placing 
in the sterile hood.  
 
3) Remove all old media from each flask or well plate, taking care not to scrape the cells with the 
pipette tip. 
 
4) Add appropriate volume of media. Return the flasks or well plates to the incubator and feed 
every twice a week. Adjust volume of media accordingly for different sized containers. 
 
MSC passaging procedure 
 
1) Warm complete MSC media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be passaged 
in water bath to 37oC.  
 
2) When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood.  
 
3) Remove all old media from each T75 flask, taking care not to scrape the cells with the pipette 
tip. 
 
4) Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. Adjust volumes of PBS, media, and trypsin 
accordingly for different sized flasks. 
 
5) Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
8 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 




6) Add 6 mL of complete MSC media to each flask to neutralize the trypsin and to flush cells off 
of the tissue culture plastic. 
 
7) Remove the trypsin, additional media, and cells from the flask and put into a conical tube.  
Remove a 10 L cell suspension aliquot for counting. Centrifuge the cells at 600 g for 5 min.  
 
8) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 
9) Place a cover slip on the hemacytometer and pipette 10 L of the stain/cell suspension into the 
hemacytometer. 
 
10) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
11) Aspirate off the media supernatant and add new media to dilute cells to desired concentration. 
 
12) Seed the cells at the required density (usually 5,000-6,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
 
13) Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells twice a 
week. 
 
MSC freezing procedure 
 
1) Grow cells to confluence and replace media the day before freezing. 
 
2) Warm complete MSC media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be passaged 
in water bath to 37oC.  
 
3) When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood.  
 
4) Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
 
5) Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. Adjust volumes of PBS, media , and trypsin 
accordingly for different sized flasks. 
 
6) Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
8 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 




7) Add 6 mL of complete tenocyte media to each flask to neutralize the trypsin and to flush cells 
off of the tissue culture plastic. 
 
8) Remove the trypsin, additional media, and cells from the flask and put into a conical tube.  
Remove a 10 L cell suspension aliquot for counting. Centrifuge the cells at 600 g for 5 min.  
 
9) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 
10) Place a cover slip on the hemacytometer and pipette 10 L of the stain/cell suspension into the 
hemacytometer. 
 
11) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
12) Aspirate off the media supernatant and calculate volume of freezing media needed to re-
suspend 1-10 x 106 cells per mL (freezing media: 50% complete MSC media, 40% FBS, 10% 
DMSO).  
 
13) Aliquot cells into 1 mL cryogenic tubes and place in -20oC freezer for 1 h. 
 
14) Place cryogenic tubes in -80oC freezer. Cells can be stored here for up to 6 months. For longer-




B.4 Cell seeding on CG scaffolds protocol 
 
Reference: (Caliari and Harley 2011; Caliari, Ramirez et al. 2011) 
 
Reagents 
• Complete media (see E.2 and E.3 protocols for cell recipes); store at 4oC 
• Trypsin-EDTA (Invitrogen 25300-062); store at -20oC 
• Trypan blue (Sigma-Aldrich T8154) 
• Human recombinant PDGF-BB (R&D Systems 220-BB-010); store at -20oC 
• Human recombinant IGF-1 (R&D Systems 291-G1-050); store at -20oC 
• Human recombinant SDF-1α (R&D Systems 350-NS-050); store at -20oC 
• Human recombinant bFGF (R&D Systems 233-FB-025); store at -20oC 
• Human recombinant GDF-5 (Peprotech 120-01); store at -20oC 
• Human recombinant GDF-6 (Peprotech 120-04); store at -20oC 
• Human recombinant GDF-7 (Peprotech 120-37); store at -20oC 
• Human recombinant BMP-2 (ProSpec CYT-261); store at -20°C  
• Human recombinant BMP-7 (ProSpec CYT-333); store at -20°C  
• Human recombinant TGF-β1 (ProSpec CYT-761); store at -20°C  
• Human recombinant TGF-β3 (ProSpec CYT-368); store at -20°C  
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 
Supplies and equipment 
• Ultra-low attachment 6-well plates (Fisher 07-200-601) 
• Hausser phase contrast hemacytometer (Fisher 02-671-5) 
• Tabletop centrifuge (VWR 53513-812) 
• Optical microscope (Leica Microsystems DMIL LED) 
• Water bath (37oC, Fisher 15-474-35) 
• Sterile pipettes (5, 10, 25 mL) 
• Kimwipes 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. For growth 




1) Warm complete media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be passaged in 
water bath to 37oC.  
 
2) Place hydrated scaffold pieces in fresh media for at least 30 min. 
 
3) Carefully remove excess media from scaffolds with a Kimwipe and place 3-4 scaffold pieces in 
each well of Ultra-low attachment 6-well plates. Do not overdry scaffolds (especially CGCaP 
scaffolds) as this will lead to reduced viability. 
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4) When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood.  
 
5) Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
 
6) Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. Adjust volumes of PBS, media, and trypsin 
accordingly for different sized flasks. 
 
7) Remove the PBS and add 3 mL of trypsin per flask. Return the flasks to the incubator for 6-8 
min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 
additional min in the incubator if they do not detach after 6 min). Slap flasks a few times to detach 
cells. 
 
8) Add 6 mL of complete tendon cell media to each flask to neutralize the trypsin and to flush cells 
off of the tissue culture plastic. 
 
9) Remove the trypsin, additional media, and cells from the flask and put into a conical tube.  
Remove a 10 L cell suspension aliquot for counting. Centrifuge the cells at appropriate speed and 
time.  
 
10) While cells are spinning down, mix the 10 L cell suspension aliquot with 10 L of Trypan 
blue. Pipette several times to mix the stain and cell suspension.  
 
11) Place a cover slip on the hemacytometer and pipette 10 L of the stain/cell suspension into the 
hemacytometer. 
 
12) Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension Volume) 
 
13) Aspirate off the media supernatant and add new media to dilute cells to desired concentration. 
For 8 mm diameter, 5 mm thick scaffold pieces dilute to 1-5 x 105 cells per 20-40 L media. 
 
14) Add 10-20 L of cell suspension to each scaffold piece. Place scaffolds in incubator for 15-30 
min. 
 
15) Remove scaffolds from incubator, flip over, add additional 10-20 L of cell suspension to the 
other side of each scaffold, and return to incubate for additional 2-3 h. 
 
16) Carefully add 6 mL complete media (or media with growth factors but without serum) to each 
well. Change media every 3 days over the course of the experiment. 
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B.5 AlamarBlue metabolic activity protocol 
 
Reference: (Tierney, Jaasma et al. 2009; Caliari and Harley 2011; Caliari, Ramirez et al. 2011) 
 
Reagents 
• Complete media (see E.2 and E.3 for recipes); store at 4oC 
• AlamarBlue (Invitrogen DAL1100); store at 4oC 
 
Supplies and equipment 
• 24-well plates (Fisher 08-772-1) 
• 96-well plates (Fisher 12-565-369) 
• MTS 2/4 digital microtiter shaker (IKA 3208001) 
• Water bath (37oC, Fisher 15-474-35) 
• Fluorescence spectrophotometer (Tecan, Room 299 RAL) 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. The volumes 
of reagents used are correct for 8 mm diameter, 5 mm thick scaffold pieces. Use identical media 
to that being used for experiment. 
 
Generating standard curve procedure 
 
1) Warm media and alamarBlue in water bath to 37oC.  
 
2) Before starting an experiment, generate a standard curve with a known number of cells. The 
standard should have at least eight sample points: one well with just media, one well with media 
and alamarBlue, and six wells with media, alamarBlue, and a different number of cells. An 
example standard setup is shown: 
 
 Well 1 Well 2 Well 3 Well 4 Well 5 Well 6 Well 7 Well 8 
Media 1000 L 900 L 895 L 890 L 885 L 880 L 860 L 840 L 
Cell 
suspension 
0 L 0 L 5 L 10 L 15 L 20 L 40 L 60 L 
AlamarBlue 0 L 100 L 100 L 100 L 100 L 100 L 100 L 100 L 
 
Well 1 is a negative control, well 2 is a background control, and the other wells are used to make 
the standard curve.  
 
3) Incubate at 37oC under gentle (~50 rpm) shaking for 1.5-5.5 h. During this time healthy cells 
convert the active ingredient in alamarBlue (resazurin) to the highly fluorescent resorufin. Longer 
incubation times are necessary for smaller cell concentrations, but make sure not to incubate cells 
too long or all of the resazurin will be reduced to resorufin.  
 
4) After incubation, pipette 100 L in triplicate from each sample well into a clear 96-well plate. 
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5) Measure fluorescence (excitation: 540 nm, emission: 580 nm) on the spectrophotometer in RAL 
299 using the program ‘AlamarBlue F200’. Remember to reserve the F200 machine on the Google 
Calendar prior to use. For each data point, adjust the fluorescence reading by subtracting the 
reading from well 2 (background control). The standard curve is created by plotting cell number 
as a function of adjusted fluorescent intensity. 
 
Quantifying metabolic activity on scaffolds procedure 
 
1) For measuring cell metabolic activity on scaffolds, pipette 900 L media into each well (one 
well for each scaffold piece plus the two control wells). Add 100 L alamarBlue to each well 
except for one negative control well. Adjust volumes for smaller/larger materials accordingly, 
keeping the 9:1 media: alamarBlue® ratio constant. 
 
2) Remove scaffolds to be assayed and rinse in sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to experimental wells and incubate at 37oC under gentle (~50 
rpm) shaking for 1.5-5.5 h. The incubation time should be identical to the time used to make the 
standard curve.  
 
3) After incubation, pipette 100 L in triplicate from each sample well into a 96-well plate. 
 
4) Measure fluorescence (excitation: 540 nm, emission: 580 nm) on the spectrophotometer in RAL 
299 using the program ‘AlamarBlue F200’. Remember to reserve the F200 machine on the Google 
Calendar prior to use. Subtract the background control from the data points and extrapolate 
adjusted fluorescent intensity on the standard curve to give metabolic activity. 
 











B.6 Hoechst DNA quantification protocol 
 
Reference: (Kim, Sah et al. 1988; Caliari and Harley 2011; Caliari, Ramirez et al. 2011) 
 
Reagents 
• Hoechst dye buffer (500 mL); store at 4oC for up to 3 months 
400 mL deionized water 
58.44 g sodium chloride (RAL storeroom) 
0.605 g Tris base (RAL storeroom) 
0.185 g disodium EDTA (Sigma-Aldrich E5134) 
Adjust pH to 7.4, bring total volume to 500 mL, sterile filter before use 
• Papain buffer (100 mL); store at 4oC 
100 mL PBS 
1 mL 0.5 M EDTA (pH = 8.0, Sigma-Aldrich EDS); store at 4oC 
79 mg cysteine-HCl (Sigma-Aldrich 00320) 
• Hoechst 33258 dye solution (1 mL); store at 4oC for up to 6 months 
1 mL sterile water 
1 mg Hoechst 33258 dye (Invitrogen H1398); store at 4oC 
• Papain from Carica papaya (Sigma-Aldrich 76218); store at -20oC 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 
Supplies and equipment 
• 96-well plates (Fisher 12-565-369) 
• Vortex (Fisher 02-215-365) 
• Water bath (60oC, Fisher 15-460-2SQ) 
• Fluorescence spectrophotometer (Tecan, Room 299 RAL) 
• Microcentrifuge tubes (1.5 mL) 
 
Generating standard curve procedure 
*Note: steps 1-2 should be performed in the laminar flow hood. 
 
1) At the beginning of each experiment, a standard curve should be generated with a known 
number of cells. To make a standard curve spanning 5 x 103 to 1.5 x 106 million cells, make up 
active papain enzyme solution by dissolving 18-20 mg papain in 15 mL papain buffer in the 60oC 
water bath. 
 
2) Spin down two aliquots of 2 million cells each. Remove supernatant and add 12 mL papain 
enzyme solution to one tube and 400 L to the other tube. Allow to digest for 24 h in the 60oC 
water bath. 
 
3) After 24 h, vortex tubes thoroughly. For the 12 mL tube, add cell lysate to labeled 
microcentrifuge tubes in 30 L intervals (starting from a blank control) up to 300 L. Bring all 
volumes to 300 L with blank papain buffer. For the 400 L tube, add cell lysate to labeled 
microcentrifuge tubes in 2 L intervals (starting from a blank control) up to 30 L. Bring all 
volumes to 30 L with blank papain buffer. 
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4) Prepare Hoechst working dye solution by adding 1 L dye solution to 10 mL Hoechst dye 
buffer. Vortex thoroughly. Add working dye solution to each tube to bring total volume to 630 L. 
Vortex thoroughly. The Hoechst dye fluorescently binds to double-stranded DNA from the lysed 
cells, allowing quantification of DNA and thus cell number. 
 
5) Pipette 200 L from each tube in triplicate into a black 96-well plate. 
 
6) Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer in RAL 
299. Use the ‘DNA F200’ program and remember to reserve the F200 machine on the Google 
Calendar prior to use. For each data point, adjust the fluorescence reading by subtracting the 
reading from the blank control. The standard curve is created by plotting cell number as a function 
of adjusted fluorescent intensity. 
 
Quantifying cell number on scaffolds procedure 
*Note: step 2 should be performed in the laminar flow hood. 
 
1) For measuring cell number on scaffolds, pipette 300 L of papain enzyme solution into 
microcentrifuge tubes (one for each scaffold plus two controls: one tube with just papain enzyme 
solution as a negative control and one tube containing a blank scaffold with no seeded cells as a 
background control).  
 
2) Remove scaffolds to be assayed and rinse in sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to microcentrifuge tubes and incubate in 60oC water bath for 
24 h. Vortex occasionally to facilitate digestion of scaffold. 
 
3) After incubation, pipette 600 L Hoechst working dye solution in microcentrifuge tubes.  
 
4) Remove samples from water bath and vortex thoroughly. Add 30 L from each tube to its 
corresponding tube containing working dye solution. Vortex thoroughly. 
 
5) Pipette 200 L from each tube in triplicate from each sample well into a 96-well plate. 
 
6) Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer in RAL 
299. Use the ‘DNA F200’ program and remember to reserve the F200 machine on the Google 
Calendar prior to use. For each data point, adjust the fluorescence reading by subtracting the 
reading from the background control. Adjusted fluorescent intensity can be extrapolated on the 
standard curve to give a cell number. 
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B.7 Scaffold contraction protocol 
References: (Spilker, Asano et al. 2001; Caliari and Harley 2011) 
 
Supplies and equipment 
• Drafting template 
 
Procedure 
* Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
 
1) On day 0, measure the diameter of the fully hydrated scaffolds before cell seeding. This can be 
done several ways: 
• Place drafting template over well plate containing scaffolds and move template until  
 finding the hole that most closely approximates the diameter of the scaffold. 
• Remove scaffolds from solution and measure using template as before. 
 
Scaffolds can be measured either in or out of solution, but the key is consistency; the same method 
should be used for all samples and time points. 
 
2) Repeat step 1 for subsequent time points in experiment. Normalize measurements to results 
from day 0. 
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B.8 RNA isolation protocol 
 
Reference: (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012) 
 
Reagents 
• RNeasy Plant Mini Kit (Qiagen 74904) 
• β-mercaptoethanol (Sigma M7522-100ML) 
• 70% ethanol (use RNase free water when making solution) 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
• RNase-free water 
• Ice 
 
Supplies and equipment 
• 2 mL RNase free non-graduated microcentrifuge tubes 
• RNase free pipette tips 






Reagent prep (before starting) 
 
1) Lysis buffer: Add 10 μL β-mercaptoethanol (14.3 M) per 1 mL of Buffer RLT supplied with 
Qiagen kit. This solution can be stored at room temperature for 1 month. 
 




*All steps are performed at room temperature. Work quickly; limit the number of samples for RNA 
extraction to 18-24 in each sitting. RNase free tips should be used throughout. 
 
1) Label one microcentrifuge tube for each sample. 
 
2) Put some ice (2nd floor RAL) in an ice bucket. 
 
3) Wash scaffolds in PBS three times, cut in half with razor blade, and then place in labeled tubes.  
 
4) Add ~ 500 µL of ice-cold lysis buffer to each tube and keep on ice for ~ 5 min, shaking tubes 
periodically to help the buffer infiltrate the scaffolds. Scale amount of lysis buffer appropriately. 
 
5) Pipette lysate into a labeled QIAShredder column. Place scaffold pieces in column as well. Spin 
at 14,000 rpm for 2.5 min.  
 
6) Add equal volume of 70% ethanol to each sample and mix by pipetting up and down. 
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7) Add half of the lysate + ethanol to labeled RNeasy column (with 2-mL collection tube). 
 
8) Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
 
9) Add the remaining lysate + ethanol to the column. 
 
10) Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
 
11) Add 700 μL Buffer RW1 to the column.  
 
12) Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
 
13) Pipet 500 μL Buffer RPE into the column. 
 
14) Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
 
15) Add another 500 μL Buffer RPE into the column. 
 
16) Centrifuge at 12,000 rpm for 2.5 min. Discard flow-through and place the column in a new 2 
mL collection tube (supplied with kit).  
 
17) Centrifuge at 12,000 rpm for 2.0 min. 
 
18) Transfer the column to a new labeled, 1.5-mL collection tube. 
 
19) Pipet 30 μL RNase-free water into the column and wait 5 min. 
 
20) Centrifuge the RNeasy column at 12,000 rpm for 1.5 min. 
 
21) Store RNA at -80°C for later use or put on ice if directly proceeding to quantification, reverse 
transcription, and RT-PCR. 
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B.9 Quantification of RNA and reverse transcription protocol 
 
Reference: (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012) 
 
Reagents 
• QuantiTect Reverse Transcription Kit (Qiagen 205313); store at -20°C although individual 
kit aliquots may be stored at 4°C once opened. 
• TE buffer (pH = 8.0) 
• DTT (100 mM stock); store at -20°C 
• RNase-free water 
• RNase H; store at -20°C 
• Ice 
 
Supplies and equipment 
• Cuvettes 
• Thermocycler (BioRad 185-2196) 
• RNase-free pipette tips 
• RNase-free PCR tubes (100 µL, CLSL stockroom) 
• Ice bucket 
• Kimwipes 
• Ambion DNase I removal kit 






1) Gather pipettes, RNase-free tips, TE buffer, cuvettes, and samples in an ice bucket. 
 
2) Proceed to the spectrophotometer in the IGB 2nd floor (shared equipment). 
 
3) Remove piece of tape covering the cuvette opening and turn the machine on. Make sure it is in 
‘RNA’ mode (button 9). 
 
4) Pipet 50 µL TE buffer into a clean cuvette and blank the machine. 
 
5) For each RNA sample, pipet 10 µL of RNA into 40 µL of TE buffer in cuvette. Lightly flick 
the cuvette several times to mix and then read absorbance. Record the A260 and A260/280 ratio 
readings. 
 
6) Empty the cuvette on a pile of Kimwipes, getting the cuvette relatively dry. Repeat step 5 for 
subsequent samples. 
 
7) RNA amount (µg) can be calculated using the following equation: 
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[𝑅𝑁𝐴] = 𝐴260 ∗ (40 
µ𝑔
𝑚𝐿
) ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗  𝑅𝑁𝐴 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)                     (Equation E.1) 
 
Normal procedure for reverse transcription with hexameric primers 
 
1) Label PCR tubes for number of reactions needed and defrost reverse transcription kit 
components on ice if needed. Keep kit components and RNA samples on ice. Turn on thermocycler 
so it can warm up. 
 
2) Calculate the amount of RNA needed for each reaction. Typically, > 10 ng of cDNA will be 
desired per well for subsequent RT-PCR experiment. 
 
3) For 10 µL reactions, add 1 µL gDNA wipeout buffer (orange tubes) to each PCR tube. 
 
4) Add RNase-free water to each PCR tube so that the total reaction volume (when RNA is added) 
will be 7 µL. If RNA quantification was low do not add water. 
 
5) Add RNA to each tube. Add up to 10 µL per tube if RNA amount is very low. 
 
6) Close tubes and place in thermocycler. Close lid with extra quarter turn of tightness. 
 
7) Run the ‘CAV1’ program. This will begin by incubating the samples at 42°C for 2 min. 
 
8) While the first step is running, prepare reaction buffer. Note that the RT buffer (green tubes) 
and the Primer Mix (purple tubes) can be combined in one tube. If you do this, place a check mark 
on the lid of the green tube. Combine 2.5 µL of RT buffer/primer mix plus 0.33-0.5 µL reverse 
transcriptase (red tubes) per sample into a single tube and vortex well. 
 
9) Pipet 2.83-3 µL of reaction buffer mix into each PCR tube once the 2 min initial incubation is 
complete. Close tubes, lid, and then press enter to skip to the next step, which is a 15 min incubation 
at 42°C followed by 95°C incubation for 3 min. 
 
10) Once the cycle is complete, place samples in a labeled box or Petri dish and put on ice if 
proceeding directly to RT-PCR, or store at -20°C (short term) or -80°C (long term). 
 
Procedure for generating gene-specific cDNA 
 
1) Label PCR tubes for number of reactions needed and defrost reverse transcription kit 
components on ice if needed. Keep kit components and RNA samples on ice. Turn on thermocycler 
so it can warm up. 
 
2) DNA removal 1: incubate 1 µL gDNA wipeout buffer (orange tubes) with up to 100 ng RNA. 
Bring total volume to 7 µL with RNase-free water. 
 
3) Run the ‘ScxGFP’ program, which begins by incubating mix at 42°C for 2 min. 
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4) DNA removal 2: add 1 µL of 10x DNase I buffer, 1 µL DNase I, and 1 µL RNase-free water to 
bring total volume to 10 µL. Incubate at RT for 15 min. 
 
5) Inactivate DNase I by adding 1 µL of EDTA solution. Heat at 65°C for 10 min. 
 
6) Add 1 µL of reverse primer (20 µM stock), 1 µL reverse transcriptase (red tubes), 1 µL DTT 
(100 mM stock), 2 µL RNase-free water, and 4 µL RT buffer (green tube WITHOUT primers 
added) to each tube to bring total volume to 20 µL. 
 
7) Set up a reverse transcriptase-free control to test for the presence of genomic DNA 
contamination. 
 
8) Incubate mix at 42°C for 15 min. 
 
9) Incubate mix at 95°C for 3 min to inactivate reverse transcriptase. 
 
10) Dilute RNase H so that 2 U are added to each reaction and then add 1 µL of the diluted RNase 
H to mix and incubate at 37°C for 20 min. 
 
11) Freeze down cDNA for later use or dilute reaction 10 times in 179 µL RNase-free water to 
perform regular PCR using primers specific to the coding sequence of the scleraxis gene and 




B.10 PCR protocol 
 
Reference: (Duffy, McFadden et al. 2011; Caliari, Weisgerber et al. 2012) 
 
Reagents 
• QuantiTect SYBR Green Kit (Qiagen  204145); store at -20°C although individual kit 
aliquots may be stored at 4°C once opened. 
• Primers (Integrated DNA Technologies) 
o Dilute to 30 µM in TE buffer (pH = 8.0) 
o Aliquot and store at -20°C or keep at 4°C 
• Ice 
• DNase removal buffer 
 
Supplies and equipment 
• Rainier multi-pipettes 
• 384-well plates (Invitrogen 4309849) 
• Plate covers (Invitrogen 4311971) 
• Sealing tool 
• Rainier pipette tips (VWR) 
• RNase-free PCR tubes (500 µL, CLSL stockroom) 
• Ice bucket 
• Vortex (Fisher 02-215-365) 
• Applied Biosystems 7900HT Fast Real-Time PCR system (Applied Biosystems) 
• Sequence Detection Systems software v2.4 (Applied Biosystems)  
 
Procedure 
*Note: keep PCR area as clean as possible and remember to wipe down area with DNase removal 
buffer following each plate prep. Remember to reserve time on the PCR system on the IGB website 
(each plate takes 1 h 55 min to run). 
 
1) Diagram plate layout and determine the amount of water, SYBR green, and primers you will 
need. Master mix 1 consists of SYBR green and primers, and is added at 5.2 µL per well for 10 
µL reactions. Master mix 2 is RNase-free water and cDNA, and is added at 4.8 µL per well for 10 
µL reactions. Make up ~ 10% excess reagent for each mix. 
 
2) Make up master mixes. Vortex each tube of master mix 1 thoroughly and pipet into wells. 
 
3) Vortex each tube of master mix 2 thoroughly and pipet into wells. 
 
4) Place cover on plate. Make sure the plate is sealed tightly on all edges with the sealing tool. 
 
5) Keep plate protected from light at 4°C until ready to analyze. 
 
6) Transport to IGB 124A and set up plate on PCR machine. Follow instructions obtained during 
training on machine, making sure to add extra stage to determining product melting point. SYBR 
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green dye non-specifically binds to all DNA, so the melting curve must be obtained to confirm the 
presence of a single product. 
 
7) Analyze results using the Sequence Detection Systems software to obtain Ct values. For 
multiple plates, make sure the threshold is set at the same number for each primer pair. Calculate 
fold changes in expression using the delta-delta Ct method.  
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B.11 Protein isolation protocol 
 
Reference: (Caliari and Harley 2014) 
 
Reagents 
• RIPA buffer (500 mL) 
o 495 mL deionized water 
o 4.38 g sodium chloride (150 mM, RAL storeroom) 
o 5 mL Triton X-100 (1%, Sigma 93443-100ML) 
o 2.5 g sodium deoxycholate (0.5%, Sigma  D6750-10G) 
o 0.5 g SDS (0.1%, Sigma L3771-25G) 
o 3.03 g Tris base (50 mM, RAL storeroom) 
o Adjust pH to 8.0 and store at 4°C 
• Protease inhibitor cocktail (Sigma P8340-1ML) 
• Phosphatase inhibitor cocktail 2 (Sigma P5726-1ML) 
• Phosphatase inhibitor cocktail 3 (Sigma P0044-1ML) 
• Ice 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 
Supplies and equipment 
• Ice bucket 
• Microcentrifuge tubes 
• Vortex (Fisher 02-215-365) 
 
Procedure 
*Note: steps 2-3 should be performed in the laminar flow hood. 
 
1) Label microcentrifuge tubes for each sample. Prepare ~ 200 µL of ice-cold RIPA buffer per 
sample and add protease and phosphatase inhibitors (100x stocks) fresh to the buffer.  
 
2) Rinse scaffold pieces in PBS to remove dead and unattached cells. Place scaffolds in empty, 
labeled microcentrifuge tubes. 
 
3) Pipet 150-200 µL complete RIPA buffer onto each scaffold piece. 
 
4) Keep scaffolds on ice for 30 min, agitating with a pipet tip occasionally to aid buffer infiltration. 
 




B.12 Western blotting protocol 
 
Reference: (Caliari and Harley 2014) 
 
Reagents 
• Running buffer (1L, 10x); store at 4°C 
o 30.3 g Tris base (0.25 M, RAL storeroom) 
o 144 g glycine (1.92 M, RAL storeroom) 
o 10 g SDS (1%, Sigma L3771-25G) 
o Bring volume to 1 L in deionized water, sterile filter 
• Running buffer: Need ~700 mL per gel (when running 1-2 gels), can re-use several times 
o 10% 10x running buffer 
o 90% deionized water 
o Final concentrations:25 mM Tris base, 192 mM glycine, 0.1% SDS. pH will be ~ 
8.3.Store at 4°C. 
• Towbin’s electrotransfer buffer (1 L, 10x); store at 4°C 
o 30.3 g Tris base (0.25 M, RAL storeroom) 
o 144 g glycine (1.92 M, RAL storeroom)  
o Bring volume to 1 L in deionized water, sterile filter 
• Transfer buffer: Need ~1 L per gel, can re-use several times 
o 20% Methanol (RAL storeroom) 
o 10% 10x Towbin’s electrotransfer buffer 
o 70% Water 
o Store at 4°C 
• TBS-T (1 L, 10x); store at 4°C 
o 24.2 g Tris base (0.2 M, RAL storeroom) 
o 80 g NaCl (RAL storeroom) 
o 10 mL Tween 20 (1% v/v, RAL storeroom) 
• TBS-T (1x); store at 4°C 
o 10% 10x TBS-T 
o 90% deionized water 
o Final concentrations:20 mM Tris base, 0.8% w/v NaCl, 0.1 % v/v Tween 20, pH 
will be ~ 7.5 
• 4x Laemlii buffer (CLSL stockroom): Need ~ 12 µL per sample 
• Blocking Buffer (TBS-T + 5% non-fat milk)  
o 100 mL TBS-T 
o 5 g non-fat milk powder 
o Mix for ~ 15 min before use 
• Ponceau S stain (Fisher Scientific, K793-500mL) 
• Ice 
• Deionized water 
• β-mercaptoethanol (Sigma M7522-100ML) 
• Stripping buffer (CLSL stockroom) 
 
Supplies and equipment 
• IGB shared equipment 
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o Glass container 
o Biorad Mini-Protein apparatus 
• Rainbow ladder (GE Healthcare, CLSL stockroom); store at -20°C 
• Microcentrifuge tubes 
• Gel-loading pipet tips 
• Nitrocellulose membrane (Fisher Scientific, RPN303E) 
• Whatman paper 
• SuperSignal West Pico Chemiluminescence substrate (ECL reagents, CLSL stockroom); 
store at 4°C 
• 10% polyacrylamide gels (CLSL stockroom); store at 4°C 
• Plastic forceps 
• Ice bucket 
• Kimwipes 




Day 1: Protein lysate gel electrophoresis, transfer, primary antibody 
 
1) Have buffers and gels ready. 
 
2) Thaw lysates on ice while walking to IGB. 
 
3) Upon arrival, turn on heating block to 95°C on Schook’s bench. 
 
4) Label microcentrifuge tubes and prepare 4x Laemlii buffer by adding 0.5 µL β-mercaptoethanol 
for every 12 µL of buffer.  
 
5) Add 37.5µL of lysate and 12.5 µL of Laemlii + β-mercaptoethanol per tube, 
 
6) Heat tubes at 95°C in heating block for 5-10 min. 
 
7) While tubes are heating, remove gels from fridge and rinse with water.  
 
8) Take strip off bottom and place it to the front of electrophoresis apparatus.  
 
9) Place a blank plastic cassette or another gel on the back side. Make sure everything is clamped 
in properly. (Red-red; black-black). 
 
10) Pour running buffer between cassettes until gel is immersed. Fill container with running buffer 
to 2-gallon mark.  
 
11) Take sample tubes. Spin down for a few seconds if you have solid pieces from 
hydrogels/scaffolds.  
 
12) Carefully load 50 µL lysate/Laemlii mix into each lane (behind plate) using gel-loading tips. 
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Don’t use first or last lane. Load 5 µL rainbow ladder to one lane for reference. 
 
13) Run at 80 V for 5-10 min until lysates become thin bands in stacking gel. This step can be run 
at RT but running at 4°C may reduce “smiley face effect.” There is a power supply available in 
the back 4°C cold room. 
 
14) Run gel at 100 V for ~ 1.5 h until all lysates (blue line) arrive at the bottom black line. Check 
progress after 1 h to make sure proteins don’t run off the gel. 
 
15) Prepare nitrocellulose membranes, filter papers, and transfer buffer ~ 15 min before gel is 
finished running. Cut membranes to match gel size. 
 
16) Kill power and rinse gel cartridge thoroughly with DI water. Carefully open gel cartridge using 
opening lever by cracking open at 4 sides marked by arrowheads. 
 
17) Remove stacking gel and rinse with water. Cut lane borders on top with green cutting tool. 
 
18) Pour transfer buffer to the glass container. Then, prepare the transfer cassette assembly by 
stacking in the following order then soak it in transfer buffer in the glass container.  
• Case (clear side)  
• Sponge 
• Whatman paper 
• Membrane 
• Gel 
• Whatman paper 
• Sponge 
• Case (black side; negative terminal) 
 
19) Use plastic forceps and/or green cutting tool to carefully maneuver the gel so that the entire 
area lays on the membrane. 
 
20) Remove air bubbles by rolling with plastic pipet and then close cassette.  
 
21) Place assembly in plastic module then into electrophoresis apparatus. Remember to match 
colors (e.g. black faces black). 
 
22) Fill apparatus completely with transfer buffer, using big beaker to transfer buffer from glass 
container to the apparatus. 
 
23) Place cooling unit (stored in far -20°C freezer) in buffer and transfer at 300 mA for 2 h at 4°C 
in far cold room. 
 
24) After 2 h, take apart assembly. Discard filter paper and gel (nothing should be left in the gel, 
indicating the transfer was successful). Nick membrane edge (top left corner) with scissors so you 
know which side the protein is on (this is the side of the membrane that faced the gel!) 
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25) Stain with Ponceau S (1x) to check protein bands. Bands may not appear. Ponceau stain can 
be re-used. Cut bands according to molecular weight of desired targets while Ponceau stain is still 
visible. Rinse with TBS-T to remove stain. 
 
26) Place membrane in mini plastic container (old microscope slide boxes) and pour in 10-15 mL 
blocking buffer. Incubate for 30 min on a shaker (~ 50 rpm). 
 
27) While waiting, prepare primary antibody solution in ~ 5mL blocking buffer. Typical dilution 
is 1:2000, but optimize for each antibody. Note that primary antibodies diluted in blocking buffer 
can be used again. Store at -20°C or at 4°C for short times (< 2 weeks).  
 
28) Incubate membranes in primary antibody solution overnight at 4°C on shaker.  
 
Day 2 Secondary antibody, read blot using ECL reagents (enhanced chemiluminescence) 
 
1) Wash membranes with TBS-T for 5 min on shaker at RT (3x). 
 
2) While waiting, prepare 5 mL secondary antibody solution (1:2500 dilution) in blocking buffer 
from fridge. Make sure you use matching (anti-rabbit; anti-mouse, etc) secondary antibody. 
 
3) Incubate in secondary antibody solution for 1 hr at RT under gentle shaking. 
 
4) Wash membranes with TBS-T for 5 min on shaker at RT (3x). 
 
5) While waiting, gather supplies for ECL detection: gloves, 15 mL conical tube, 1 mL pipette 
with tips, plastic forceps, and ECL reagents. Once membranes are finished rinsing add them to box 
of supplies. 
 
6) Go down to IGB 124A. There should already be Kimwipes and saran wrap in this room. 
 
7) Once in basement, log onto computer and start up the ImageQuant program.  
 
8) Mix ECL reagents (1:1; make ~ 2 mL per full membrane).  
 
9) Place saran wrap on a flat surface. Pick up your membrane with forceps then gently blot using 
Kimwipes. Quickly do this for all membranes and pipette mixed ECL solution onto the 
membranes.  
 
10) Wrap membranes in saran wrap and keep in drawer for 2 min. 
 
11) Take membranes from the drawer, blot, and place on clean saran wrap with forceps. 
 
12) Place membranes in the detection chamber and focus to ensure membrane is in viewing 
window. Make sure the black tray is in the chamber and set at level 2 for chemiluminescence. 
Expose for 1 min first then adjust according to the output intensity.  
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13) Save image and perform post-analysis of band intensity using Gel Image Analyzer or ImageJ. 
 
Stripping for re-probing 
 
1) It may be desirable to strip the antibodies and re-probe for another protein that is close in 
molecular weight. To do this, begin by washing the membranes in TBS-T for 5 min (1x). 
 
2) Cover membranes in stripping buffer and incubate under gentle shaking for 15 min. 
 
3) Wash membranes in TBS-T for 5 min (3x). 
 
4) Re-block membranes in blocking buffer for 30 min at RT under gentle shaking (see day 1 step 
26). Repeat steps from here to completion.  
 190 




1) Open the image file in ImageJ. 
2) If the image isn’t already in 8-bit grayscale, convert to grayscale is to go to Image>Type>8-bit. 
3) If the bands are slanted, level them by selecting Image →Rotate→Arbitrairly… 
4) Choose the rectangular selection option from the toolbar and draw a rectangle around the band 
in the first lane. Click Ctrl+1 to set the first lane. 
Note: If your rectangle is taller than it is wide, ImageJ will assume your lanes run up and down, 
but if your rectangle is wider than it is tall, Image J will assume your lanes run up and down. The 
width of the selection is fixed for all lanes. It is important to get the shape and position of the first 
lane correct prior to setting it. 
5) Place the mouse over the “1” inside the rectangle, clicking and holding down while dragging 
the box to the second lane. Click Ctrl+2 (or Analyze→Gels→Select Next Lane) 
6) Place the mouse over the next rectangle band, clicking and holding down while dragging the 
box to the next lane. Again, click Ctrl+2. Repeat for any additional lanes. 
7) Upon dragging the rectangle over the last lane, click Ctrl+3 (or Analyze→Gels→Plot Lanes). 
The plots will open in a new window. 
8) Use the straight line tool to close the bottom of the first peak. 
9) Using the plot window, scroll down to the next peak (the hand tool is good for scrolling). Use 
the straight line tool to again close off the peak. Repeat for any additional peaks. 
10) Scroll back to the top and selecting the wand tool, click inside the peak. A new window will 
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